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ABSTRACT 
 
Deepali Vijay Sawant 
 
 
 
CONTROL OF INFLAMMATION, HELPER T CELL RESPONSES AND 
REGULATORY T CELL FUNCTION BY BCL6 
 
 
 
Regulatory T (Treg) cells represent an important layer of immune-
regulation indispensible for curtailing exuberant inflammatory responses and 
maintaining self-tolerance. Treg cells have translational potential for 
autoimmunity, inflammation, transplantation and cancer. Therefore, delineating 
the molecular underpinnings underlying the development, suppressor function 
and stability of Tregs is particularly warranted. The transcriptional repressor Bcl6 
is a critical arbiter of helper T cell fate, promoting the follicular helper (Tfh) 
lineage while repressing Th1, Th2 and Th17 differentiation. Bcl6-deficient mice 
develop a spontaneous and severe Th2-type inflammatory disease including 
myocarditis and pulmonary vasculitis, suggesting a potential role for Bcl6 in Treg 
cell function. Bcl6-deficient Treg cells are competent in controlling Th1 
responses, but fail to control Th2 inflammation in an airway allergen model. 
Importantly, mice with Bcl6 deleted specifically in the Treg lineage develop 
severe myocarditis, thus highlighting a critical role for Bcl6 in Treg-mediated 
control of Th2 inflammation. Bcl6-deficient Tregs display an intrinsic increase in 
Th2 genes and microRNA-21 (miR-21) expression. MiR-21 is a novel Bcl6 gene 
target in T cells and ectopic expression of miR-21 directs Th2 differentiation in 
non-polarized T cells. MiR-21 is up-regulated in mouse models of airway 
 vii 
inflammation and also in human patients with eosinophilic esophagitis and 
asthma. Thus, miR-21 is a clinically relevant biomarker for Th2-type pathologies. 
Our results define a key function for Bcl6 in repressing Gata3 function and miR-
21 expression in Tregs, and provide greater understanding of the control of Th2 
inflammatory responses by Treg cells. 
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INTRODUCTION 
Innate and Adaptive Immunity 
Immunity is the sophisticated interplay of cells, tissues and mediators that 
underlie our response to the unfathomable array of pathogens that we are 
constantly exposed to on a daily basis. The unwavering surveillance and 
protection conferred by our immune system rarely makes us aware of the diverse 
microbial challenges that we evade. The ability to discriminate self from non-self 
and recognize subtle differences between the multitude of infections, generate 
specific effector responses while curtailing excessive damage to the host and 
retain memory for subsequent infections constitute the cardinal features of our 
immune system. The immune system is able to mediate this intricate regulation 
by the comprehensive defense mechanisms offered by the innate and adaptive 
arms of the immune system, with each arm functioning independently and in 
concert with the other to boost the overall immune outcome and provide optimal 
protection.  
The physical and chemical barriers of our body serve as the first line of 
defense in any infection. Anatomic barriers like the skin and the mucous 
membranes and physiologic barriers, which include temperature, pH, oxygen 
tension, and soluble mediators prevent microbes from entering and evading the 
body. Pathogens that overcome these defense mechanisms activate other 
components of the innate immune system. The innate immune system, also 
found in primitive forms of life, acts locally and mobilizes appropriate mediators 
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for rapid clearance of the infection, although these responses are short-lived and 
lack immunological memory.  
The cells of the innate immune system derived from the myeloid lineage 
include the tissue-resident macrophages and circulating monocytes, dendritic 
cells, granulocytes and mast cells. The monocytes that circulate into the blood 
and their mature tissue forms, i.e. the macrophages constantly patrol the tissues 
to engulf and phagocytize any invading pathogen or dispose dead cells or 
components targeted by the adaptive immune system. Macrophages also 
secrete inflammation promoting components and various signaling mediators in 
addition to their role as antigen presenting cells, thus serving as an important link 
between innate and adaptive immunity. Immature dendritic cells are also 
phagocytic in nature and can engulf particulate matter as well as extracellular 
fluid by macro-pinocytosis. However, their main function upon maturation is to 
process and present antigens on their surface for activation of the T cells that 
bear the appropriate T cell receptor (TCR) and trigger the specific adaptive 
response. The granulocytes also referred to as polymorphonuclear leukocytes 
(PMNs) are the major phagocytic cells, distinguished on the basis of their 
granular contents. Neutrophils increase in large numbers following an infection 
and they function by phagocytosis and killing mediated by the oxidative and 
antimicrobial mediators stored in their granules. Eosinophils and basophils direct 
protective responses against parasites, which are difficult to engulf by the 
macrophages or neutrophils. Excessive eosinophilic activity however is 
associated with allergic responses (Wardlaw et al., 2000). Basophils and their 
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inflammatory mediators like histamine and leukotrienes are also associated with 
allergy, and more recently, basophils have been identified as a primary source of 
the Th2 cytokine, IL-4 (Min et al., 2004). Mast cells differentiate in tissues and act 
locally to release inflammatory mediators in allergic responses and during 
parasitic worm clearance.  
The lymphoid components of the innate immune system comprise NK 
cells, NKT cells and gamma-delta T cells. NK cells are cytotoxic lymphocytes that 
lack antigen-specific receptors. They are primarily responsible for killing virus-
infected cells and tumor cells. NKT cells exhibit features intermediate of NK cells 
(cell surface expression of NK1.1) and T cells (TCRs recognize lipid antigens 
presented by CD1d molecules), hence generally referred to as CD1d-restricted T 
cells. They function by secreting cytokines like IFNγ, IL-4, TNFα and GM-CSF. 
These cells are known for recognizing glycolipids from pathogens such as 
Mycobacterium tuberculosis and are also implicated in autoimmunity and cancer 
(Bendelac et al., 2007). Gamma–delta T cells (γδ T) express a TCR receptor 
comprised of γ and δ chains, unlike conventional αβ T cells. Although capable of 
generating more TCR repertoire diversity than αβ T cells, these cells tend to 
have restricted TCR repertoires. Despite the presence of functional TCRs, these 
cells are at the border between innate and adaptive immunity, primarily because 
their TCR can also function as a pattern recognition receptor and in some cases, 
they have been ascribed a phagocytic function (Morita et al., 2000). Like NKT 
cells, these cells primarily recognize lipid antigens and are thus useful for 
	   4 
clearance of bacterial and viral infections, but also have clear roles in 
autoimmunity, hypersensitivity and tumor immunity (Cai and Tucker, 2001). 
  The innate immune response is often overlapped by adaptive immunity, 
which sets in days after infection, but provides a more directed and lasting 
response, retaining memory for subsequent encounters. This system is present 
only in higher forms of life and functions due to the specificity of the antigen 
receptors characteristic of its principal components, i.e. B and T lymphocytes. B 
and T lymphocytes both develop in the bone marrow. Following maturation in the 
bone marrow (for B cells) and thymus (for T cells), these ‘naïve’ T cells circulate 
in the body, bearing a highly specific receptor on their surface. Following 
interaction with the cognate antigen, these cells get activated into effector 
lymphocytes. In the case of B cells, antigen recognition through the BCR leads to 
generation of memory B cells and plasma cells. Plasma cells secrete antibodies 
with the same antigenic specificity as the surface BCR, thus conferring humoral 
immunity to the specific pathogen. TCR triggering of immature thymic T cells 
generates either effector cytotoxic CD8 or helper CD4 T cells or regulatory T 
cells. Memory B and T cells survive longer to provide lasting immunity for 
subsequent exposures. Cytotoxic CD8 T cells mediate direct killing of the virus-
infected or cancer cells by recognizing the antigen complexed with an MHC 
Class I molecule. Their killing is directed by release of cytolytic proteins such as 
granzyme and perforin or by up-regulating Fas expression on their surface and 
thus triggering death of the FasL-expressing target cell. Cytotoxic T cells are 
protective in a number of autoimmune diseases such as diabetes, arthritis and 
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liver injury following viral infections (Pender, 2012). Helper CD4 T cells recognize 
antigen in the context of Class II MHC and differentiate into diverse subtypes 
based on the cytokine cues and provide help in a number of inflammatory and 
infectious settings, in addition to providing specialized help to B cells for 
protective humoral responses.  
 
Helper T cell subsets 
Following recognition of a cognate antigen delivered by professional 
antigen-presenting cells (APCs) in the context of MHC class II, naïve T cells have 
the potential to differentiate into various helper CD4 T cell subsets. Priming of 
naïve T cells by APCs is mediated by three distinct signals that are required for 
optimal activation and differentiation to specialized helper CD4 T cell lineages 
specialized to combat different types of pathogens. Signal 1 comprises 
recognition of a specific peptide-MHC complex on the APC with the T cell 
receptor. Signal 2 referred to as co-stimulation is essential for survival and clonal 
expansion of antigen-specific T cells. Antigen recognition in the absence of co-
stimulation can lead to functional inactivation or deletion of the activated T cells. 
The decision to differentiate into a specific T helper cell subset is provided by the 
cytokines present in the local milieu (Signal 3), particularly, those made by the 
priming APCs in response to the pathogenic insult. Most cytokines signal through 
the JAK/STAT pathway linking receptor-associated Janus kinases (JAKs) to the 
Signal Transducer and Activators of Transcription (STAT) family of transcription 
factors. Cytokine-mediated engagement of the receptor triggers activation of 
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JAKs and phosphorylation of the receptor cytoplasmic domains, providing 
docking sites for STATs. Phosphorylation of the STATs by JAKs allows their 
dimerization and translocation to the nucleus, where they function as 
transcription factors to initiate a specific gene expression program. There are four 
members in the JAK family (Jak1, Jak2, Jak3 and Tyk2) and seven STATs 
(STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b and STAT6). The 
differentiation of helper T cells to different subsets is mediated by specific 
cytokines, activating a specific set of JAK and STAT members that ultimately 
dictates their effector functions (Figure 1).  
The initial paradigm of helper T cell differentiation was the description of 
Th1 and Th2 subsets by Mossman and Coffman in 1986 (Mosmann et al., 1986), 
with Th1 and Th2 cells being critical for immunity to intracellular and extracellular 
pathogens, respectively. These initial studies provided a well-defined framework 
to understand mechanisms of gene regulation and cell fate specification and 
gave enormous insights into T cell responses to diverse microbial pathogens. 
However, the Th1/Th2 paradigm failed to explain several observations pertaining 
to immunity and autoimmune responses. This led to the eventual discovery of 
additional subsets – Th17, regulatory T cells (Tregs), Th9, Th22 and Tfh cells. 
Functional specialization to these different helper T cell subsets is achieved 
through differential expression of lineage-defining transcription factors and 
cytokine signatures that are both counter-regulatory and self-reinforcing in 
nature. These intrinsic and extrinsic cues guide the development of stable T 
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helper cell lineages that are crucial for proper immune-regulation and host 
defense.  
 
 
 
 
 
 
Figure 1: Helper T cell differentiation program is guided by an 
orchestrated interplay of priming cytokines and corresponding STAT 
family members. 
Naïve T cells differentiate into various helper T cell subsets based on the 
cytokines secreted by the priming antigen-presenting cells (APCs) and the 
strength of T cell signals. Cytokine signaling activates the corresponding 
JAK/STAT pathway to initiate the transcriptional program, with expression of 
specific transcription factors and cytokines key to each subset, that underlie 
their protective and antagonistic effects in diverse immune settings. 
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Th1 cells 
Th1 cells are primarily responsible for protective immunity to intracellular 
pathogens (Hsieh et al., 1993; Mosmann and Coffman, 1989; Zhu and Paul, 
2008). In humans, Th1 cells are particularly important for resistance to 
mycobacterial infections. Priming of a naïve CD4+ T cell precursor to the Th1 
lineage is driven by IL-12 produced by macrophages and dendritic cells. IL-12-
induced activation of STAT4 is critical for Th1 development (Hsieh et al., 1993; 
Kaplan et al., 1996b). Commitment to the Th1 lineage is further enhanced by 
activation of STAT1 by IFNγ made by innate immune system cells such as NK 
cells, macrophages, and dendritic cells. The master Th1 transcription factor, T-
bet (Tbx21) is induced upon TCR stimulation and downstream of IFNγ/STAT1 
activation (Lighvani et al., 2001; Szabo et al., 2000). T-bet is expressed 
preferentially in Th1 cells and forced expression of T-bet in committed Th2 cells 
can also skew them towards Th1 fate (Mullen et al., 2001; Szabo et al., 2000). T-
bet induces IFNγ expression in T cells and also up-regulates IL-12Rb2, thereby 
increasing the responsiveness of the developing Th1 cells to IL-12/STAT4 
signaling leading to production of more IFNγ. Thus the collaboration between IL-
12 and IFNγ-mediated signaling events is required for full commitment to the Th1 
lineage (Murphy and Reiner, 2002). IL-18 has also been reported to act in 
combination with IL-12 to up-regulate IFNγ in Th1 cells. Thus, mice deficient in 
components of the Th1 differentiation pathway (IL-12, IL-12 receptor, STAT1, 
STAT4, IFNγ and IL-18) exhibit defective Th1 responses to bacterial infections 
(Meraz et al., 1996; Tarleton et al., 2000). Transcription factors homeobox-1 (Hlx) 
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(Mullen et al., 2002), Runx3 (Djuretic et al., 2007; Kohu et al., 2009) and ERM 
(Ouyang et al., 1999) are expressed in Th1 cells and have a role in IFNγ 
production in Th1 cells. The Th2 transcription factor, Gata3, has been 
demonstrated to down-regulate both IFNγ and IL-12Rβ2 expression (Lee et al., 
2000; Ouyang et al., 1998). Similarly, the Th2 cytokine, IL-4 has also been 
shown to down-regulate IL-12Rβ2 expression on developing cells, thereby 
skewing them towards Th2 fate.  
The signature cytokines for the Th1 lineage are IFNγ, IL-2 and 
lymphotoxin alpha (de Jong et al., 1998). IFNγ is important to increase the 
microbicidal activity of macrophages (Suzuki et al., 1988). IL-2 is important for 
CD4+ T cell memory; IFNγ+IL-2+ CD4 T cells are considered as precursors of 
Th1-memory cells (Darrah et al., 2007). Together with IL-2, IFNγ promotes 
differentiation of CD8 T cells into actively cytotoxic lymphocytes (Williams et al., 
2006). LTα is involved in activation and recruitment of effector cells to infection 
sites and is implicated as tissue damage factor in autoimmune diseases such as 
rheumatoid arthritis and multiple sclerosis (Selmaj et al., 1991; Suen et al., 
1997). Th1 cells support the production of opsonizing antibodies (predominantly 
IgG). Chemokine receptors CXCR3 and CCR5 are preferentially expressed on 
Th1 cells and mediate homing of these cells to sites of infection (Bonecchi et al., 
1998; Sallusto et al., 1998). Inappropriate Th1 responses have been implicated 
in mouse models of a number of autoimmune and inflammatory pathologies 
(experimental autoimmune encephalomyelitis, EAE; experimental autoimmune 
uveitis, EAU; T cell transfer models of colitis) (Caspi et al., 1996; Fuss et al., 
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1999; Germann et al., 1996; Merrill et al., 1992). Polymorphisms in the gene 
encoding T-bet (Tbx21) have been associated with increased incidence of 
asthma and airway hyper-responsiveness (Raby et al., 2006). Mutations in IL-
12Rβ1 in humans have been linked with increased susceptibility to mycobacterial 
and salmonella infections (de Jong et al., 1998), while mutations in the human 
IFNγ or IFNγR1 genes are associated with increased susceptibility to intracellular 
infections (Newport et al., 1996).  
 
Th2 cells 
Th2 cells mediate host defense against extracellular parasites, including 
helminth infections, and are critical for protective humoral immune responses 
(Paul and Seder, 1994; Zhu and Paul, 2008). Priming of naïve T cells by IL-4 
activates STAT6, which is required for Th2 cell development (Kaplan et al., 
1996a; Shimoda et al., 1996). STAT6 activation is both necessary and sufficient 
to induce the Th2 lineage master transcription factor, Gata3 (Kurata et al., 1999; 
Zhu et al., 2001). Gata3 then activates transcription of the characteristic Th2 
cytokines, IL-4, IL-5, IL-13, and can also auto-activate its own expression 
(Ouyang et al., 1998). Ectopic expression of Gata3 in Th1 lineage induces IL-4 
production. At the same time, deletion of Gata3 in Th2 cells blocks IL-5 and IL-13 
production, but has modest effects on IL-4, consistent with the presence of Gata3 
binding sites in the IL-5 and IL-13 promoters (Zhu et al., 2004). Along with the IL-
4-induced activation of Gata3, the gamma-chain cytokines (IL-2, IL-7 and TSLP)-
driven activation of STAT5 is required to cooperate with Gata3 for full Th2 
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differentiation (Zhu et al., 2003). Other transcription factors, STAT3, cMAF and 
IRF4 are also expressed in Th2 cells and are required for Th2 differentiation (Kim 
et al., 1999; Lohoff et al., 2002; Stritesky et al., 2011). Gfi-1 is an IL-4 inducible 
factor that allows for the preferential expansion of Gata3-expressing Th2 cells 
(Zhu et al., 2006). Th2 differentiation is strongly potentiated by a positive 
feedback loop involving autocrine activation of IL-4 transcription by exogenous 
IL-4 and the ability of Gata3 to auto-activate its own transcription. Th2 responses 
in mice deficient in the Th2 inhibitory transcription factor Bcl6 occur in an IL-
4/STAT6 independent manner, highlighting a STAT6-independent pathway of 
Th2 differentiation (Dent et al., 1999). Ectopic expression of the Th1 transcription 
factor, T-bet in developing T cells promotes down-regulation of IL-2 and Th2 
cytokines, demonstrating antagonistic regulation of Th2 differentiation by Th1 
pathway (Usui et al., 2006).  
Th2 cells produce IL-4, IL-5, IL-9, IL-10, IL-13, IL-25 and amphiregulin.   
IL-4 is the key positive feedback cytokine for Th2 differentiation and along with 
IL-13 is required for class switching to IgE in B cells and alternative macrophage 
activation (Kopf et al., 1993). IL-5 is required for eosinophil recruitment, 
proliferation and survival (Coffman et al., 1989), IL-9 promotes mast cell 
activation and induces mucin production in epithelial cells during allergic 
reactions (Longphre et al., 1999), IL-10 suppresses Th1 cell proliferation (Moore 
et al., 2001), and IL-13 mediates airway hyper-responsiveness, mucus secretion 
and is important in helminth expulsion (Wynn, 2003). IL-25 functions as an 
initiating and amplifying factor for Th2 responses and also induces the production 
	   12 
of eosinophil recruiting chemokines, RANTES (CCL5) and eotaxin (CCL11) (Fort 
et al., 2001). Amphiregulin induces epithelial cell proliferation and is important to 
restore epithelial integrity and tissue homeostasis (Zaiss et al., 2006). 
Chemokine receptors CCR3, CCR4, CCR8 and CRTh2 are preferentially 
expressed on Th2 cells (D'Ambrosio et al., 1998; Sallusto et al., 1997). 
Exaggerated Th2 responses are associated with allergic reactions to 
environmental and food antigens and also airway inflammation and hyper-
responsiveness in asthmatic individuals (Holgate, 1999). Individuals with Gata3 
haploinsufficiency develop hypoparathyroidism, sensorineural deafness, and 
renal dysplasia (HDR) syndrome (Van Esch et al., 2000). Polymorphisms in 
Gata3 in Finnish populations are associated with elevated IgE and increased 
susceptibility to asthma (Pykalainen et al., 2005). Variants of IL4Rα have been 
linked to atopic asthma, elevated IgE and severe atopic dermatitis (Hershey et 
al., 1997).  
 
Th17 cells 
Th17 cells are important for host protection from extracellular bacteria and 
fungal infections (Weaver et al., 2006). The discovery of IL-23 in the early 2000s 
called for reassessment of the relative contribution of IL-12 and IL-23 in the 
pathogenesis of experimental autoimmune encephalomyelitis (EAE) to explain 
the differential disease outcomes with deficiency of IL-12 and IL-23 (since both 
cytokines share the IL12p40 subunit) (Cua et al., 2003). These studies led to the 
identification of Th17 cells, as a separate lineage from Th1/Th2 cells, that are key 
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players in the pathogenesis of many organ-specific autoimmune diseases, 
initially considered to be dependent on Th1 cells (Harrington et al., 2005; Park et 
al., 2005). Naïve T cells activated in the presence of IL-6 and TGFβ promote 
Th17 development (Bettelli et al., 2006; Mangan et al., 2006; Veldhoen et al., 
2006). IL-6 driven activation of STAT3, up-regulates the Th17 master 
transcription factor, RORγt (Ivanov et al., 2006). Ectopic expression of RORγt 
induces IL-17 production in T cells. IL-21, a cytokine also produced by Th17 cells 
can replace IL-6 to induce RORγt and IL-17 expression (Korn et al., 2007a; 
Nurieva et al., 2007). IL-23, another STAT3-inducing cytokine, is not required 
during Th17 priming, but is critical for survival and maintenance of the Th17 fate 
(Stritesky et al., 2008; Veldhoen et al., 2006). Thus, differentiation to the Th17 
lineage is dependent on three steps: Differentiation stage mediated by the innate 
immune cell derived Th17-promoting cytokines, IL-6 and TGFβ; amplification 
step driven by IL-21, and phenotype maintenance stage mediated by IL-23. 
Since IL-6, IL-21 and IL-23 signal via STAT3, STAT3 is indispensible for Th17 
differentiation (Harris et al., 2007; Mathur et al., 2007). Other transcription factors 
– RORα, cMAF and IRF4 are up-regulated in Th17 cells and required for optimal 
Th17 differentiation (Brustle et al., 2007; Hiramatsu et al., 2010; Yang et al., 
2008b). The aryl hydrocarbon receptor is highly expressed in Th17 cells and is 
important for production of IL-22 (Veldhoen et al., 2008a). Th1 cytokine, IFNγ 
and Th2 cytokine, IL-4 negatively regulate Th17 differentiation (Harrington et al., 
2005; Veldhoen et al., 2008a). IL-2 induced STAT5 can compete with STAT3 and 
hence is also an inhibitory cytokine for Th17 cells (Laurence et al., 2007; Yang et 
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al., 2011). In addition, IL-2 is important for Foxp3 induction and Treg 
development, which is antagonistic to Th17 differentiation program (Burchill et 
al., 2007b; Davidson et al., 2007).   
Th17 cells produce IL-17A, IL-17F, IL-21 and IL-22. Both IL-17A and IL-
17F are important for neutrophil recruitment during protective responses to 
extracellular bacteria and fungi. In addition to its role as a positive feedback 
cytokine in Th17 amplification phase, IL-21 also has functions in CD8 T cells, B 
cells and DCs (Leonard and Spolski, 2005). IL-22 is important for immunity to 
bacteria such as Klebsiella pneumoniae and Citrobacter rodentium (Aujla et al., 
2008). IL-22 protects hepatocytes during liver inflammation and mediates IL-23 
dependent skin inflammation (Zenewicz et al., 2007). Th17 cells preferentially 
express CCR6 and CCR4 (Acosta-Rodriguez et al., 2007). IL-17A also induces 
other pro-inflammatory cytokines like IL-6 and is implicated in several organ-
specific autoimmune diseases like experimental autoimmune encephalomyelitis 
(EAE), collagen-induced arthritis (CIA) and mouse models of type1 diabetes 
(Emamaullee et al., 2009; Komiyama et al., 2006; Nakae et al., 2003). 
Pathogenic Th17 cells have been implicated in human patients with autoimmune 
disease such as psoriasis, multiple sclerosis, type1 diabetes and rheumatoid 
arthritis. Individuals with Hyper-immunoglobulin E or Job’s Syndrome (dominant 
negative mutations in STAT3) show increased susceptibility to staphylococcal 
and fungal infections due to inability to develop Th17 cells (Holland et al., 2007; 
Milner et al., 2008). Patients with chronic mucocutaneous candidiasis (CMC) 
exhibit either an IL17RA autosomal recessive deficiency or IL17F autosomal 
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dominant deficiency and are subject to chronic infections with Candida albicans 
and S. aureus (Puel et al., 2011). Clinical trials with neutralizing antibody to IL-
17A have been successful in treating psoriasis, rheumatoid arthritis, and multiple 
sclerosis (Genovese et al., 2010; Leonardi et al., 2012). However, exacerbations 
noted in Crohn’s disease patients has cast doubt on universal pro-inflammatory 
nature of Th17 cells and led to identification of regulatory Th17 (rTh17) cells in 
the gut that are important for mucosal tolerance (Esplugues et al., 2011; 
Sandborn et al., 2008).  
 
Tfh cells 
The concept of T cell-help to B cells for protective humoral immune 
responses was known for over 30 years, but the exact nature of these helper T 
cells remained controversial. Progress in recent years in trying to characterize 
the cell surface markers associated with this helper T cell lineage has led to the 
identification of T follicular helper (Tfh) cells as a distinct cell lineage separate 
from Th1, Th2 and Th17 cells (Chtanova et al., 2004; Kim et al., 2001; King et al., 
2008; Vinuesa et al., 2005). Tfh cells are characterized by increased expression 
of the B cell follicle homing receptor CXCR5 (Breitfeld et al., 2000; Schaerli et al., 
2000), the co-stimulatory molecule, ICOS (Bauquet et al., 2009; Choi et al., 
2011) and the inhibitory receptor, PD-1 (Haynes et al., 2007). In vitro, Tfh cells 
differentiate in the presence of STAT3-inducing cytokines IL-6 and IL-21 
(Chtanova et al., 2004; Nurieva et al., 2008). These factors induce the 
transcriptional repressor Bcl6 that has been demonstrated as the lineage- 
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defining factor for Tfh cells by three independent groups in 2009 (Johnston et al., 
2009; Nurieva et al., 2009; Yu et al., 2009). Bcl6 is both required and sufficient 
for Tfh differentiation as shown by complete lack of Tfh cells in Bcl6-deficient 
mice and ectopic expression of Bcl6 capable of up-regulating hallmark Tfh genes 
– CXCR5, CXCR4, PD-1, ICOS, IL-6R, IL-21R and down-regulating CCR7, both 
in vitro and in vivo (Yu and Vinuesa, 2010). Bcl6 expression in T cells is 
important for CXCR5 expression, T cell migration into follicles and germinal 
center formation. Bcl6 directs Tfh differentiation by (1) repressing Th1, Th2 and 
Th17 differentiation of T cells, by direct binding or inhibiting the function of their 
transcriptional regulators (Nurieva et al., 2009; Yu et al., 2009), (2) antagonistic 
regulation of BLIMP1, which inhibits Tfh differentiation and promotes 
differentiation to effector T cell lineages (Johnston et al., 2009) and/or by 
repressing miRNAs that target Tfh genes (eg; Bcl6 represses miR-17-92 that 
targets CXCR5 and miR101-103 that targets ICOS) (Yu et al., 2009). Expression 
of CXCR5 allows Tfh cells to home to the B cell follicles where the CXCR5 
ligand, CXCL13 is expressed (Ansel et al., 1999). Although expression of neither 
CXCR5, Bcl6, ICOS or IL-21 is an exclusive feature of Tfh cells, cells that are 
CXCR5high, ICOShigh, PD-1high, express high levels of Bcl6 and low levels of T-bet, 
Gata3, RORγt, and Foxp3 and secrete high levels of IL-21 are best defined as 
Tfh cells (Yu and Vinuesa, 2010). IL-21 promotes Tfh cell survival in an autocrine 
manner and is also important for GC B cell survival, affinity maturation and 
differentiation (Linterman et al., 2010; Vogelzang et al., 2008; Zotos et al., 2010). 
However, both IL-6 and IL-21 alone can induce Tfh cells, in vivo and in vitro, 
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indicating redundancy in the actions of these two STAT3 activating cytokines in 
Tfh differentiation (Eto et al., 2011; Poholek et al., 2010). Loss of Tfh cells was 
reported in CD4-specific STAT3 deficient mice, however, another study showed 
the presence of CXCR5+ Tfh cells in a STAT3-deficient setting and STAT3 
seems dispensable for human Tfh differentiation (Eddahri et al., 2009; Schmitt et 
al., 2009). IL-12 acting via STAT4 has been reported to induce Tfh genes, Bcl6 
and IL-21 (Ma et al., 2009; Nakayamada et al., 2011; Schmitt et al., 2009). Thus, 
STAT4 may replace STAT3 functions in terms of Tfh differentiation. The 
transcription factor cMAF regulates IL-4 and IL-21 production, which are major 
cytokines made by GC Tfh cells (Bauquet et al., 2009; Kroenke et al., 2012). 
cMaf-deficient mice have defective Tfh differentiation in vivo. Mice deficient in 
BATF have impaired Tfh development, defects in GC formation and B cell class-
switch recombination (Betz et al., 2010; Schraml et al., 2009). BATF mediates 
these effects via intrinsic functions in both B and T cells, and also binds to the IL-
21 promoter. Mice lacking IRF4 are also deficient in Tfh cells (Kwon et al., 2009). 
Since Bcl6 and IRF4 are mutually antagonistic factors in GC B cells (Saito et al., 
2007) and IRF4 can induce the Tfh antagonistic factor BLIMP1 in CD4 T cells 
(Kwon et al., 2009), the exact mechanism for the role of IRF4 in Tfh cells needs 
further investigation. 
Subsets of patients with common variable immunodeficiency (CVID) lack 
ICOS and these patients lack memory B cells and Tfh cells, which may be 
associated with increased susceptibility to various bacterial, viral and fungal 
infections and lack antigen-specific IgG responses to vaccines (Bossaller et al., 
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2006; Grimbacher et al., 2003; Warnatz et al., 2006). Individuals with X-linked 
lympho-proliferative disease (XLP) have mutations in Sh2d1a (which encodes 
SAP) have increased susceptibility to childhood infections, particularly, Epstein-
Barr virus (EBV). This is due to extreme loss of GCs and memory B cells in these 
patients (Ma et al., 2006; Malbran et al., 2004). Increased Tfh activity, 
dysregulated GCs and autoantibodies have been reported in a number of mouse 
models of autoimmune diseases like systemic lupus erythematosus (SLE), 
rheumatoid arthritis and diabetes (Hutloff et al., 2004; Kendall et al., 2007; Luzina 
et al., 2001; Weyand and Goronzy, 2003). In addition, spontaneous GCs are 
typical in spontaneous models of lupus, insulitis and arthritis (namely MRL, 
MRL/lpr, Sanroque, NOD and K/BxN) (Hutloff et al., 2004). Circulating 
CD4+CXCR5+ Tfh cells are present in humans with systemic autoimmunity and 
this population is expanded in 20-30% patients with lupus and Sjogren’s 
syndrome (Kang et al., 2011; Simpson et al., 2010). Tfh cells may also be 
involved in lymphomagenesis as indicated by presence of Tfh-like cells (Bcl6+, 
PD-1+, ICOS+) in patients with angioimmunoblastic T-cell lymphoma (ATL) 
(Ellyard et al., 2012).  
 
Th9 cells 
Latest addition to the expanding genre of helper T cell subsets include 
Th9 cells and Th22 cells that secrete IL-9 and IL-22 as signature cytokines, 
respectively. Th9 cells differentiate in vitro following treatment of naïve CD4+ T 
cells with IL-4 and TGFβ or by culturing Th2 cells in the presence of TGFβ 
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(Dardalhon et al., 2008; Veldhoen et al., 2008b). Unlike Th2 cells, Th9 cells 
secrete high IL-9 and reduced levels of Th2 cytokines (IL-4, IL-5 and IL-13) 
(Chang et al., 2010). The role of TGFβ in inducing IL-9 production was originally 
reported in 1994 by Schmitt et al, who also reported that IL-4 could potentiate 
and IFNγ could inhibit this effect (Schmitt et al., 1994). Both IL-4 and TGFβ-
induced transcription factors and signaling cascades are important for optimal IL-
9 production, as cells deficient in either component fail to differentiate into Th9 
lineage (Dardalhon et al., 2008; Goswami et al., 2012; Veldhoen et al., 2008b). 
Signaling via TGFβ induces PU.1, an ETS-family transcription factor that is key to 
the development of Th9 cells (Chang et al., 2010). PU.1 is preferentially 
expressed in Th9 cells, wherein PU.1 negatively regulates Th2 cytokine 
production by interfering with the interaction of IRF4 and Gata3 (Chang et al., 
2009; Chang et al., 2010; Chang et al., 2005). Pu.1-deficient Th9 cells secrete 
reduced IL-9 levels, while ectopic PU.1 expression rescues production of IL-9, 
partially by direct binding to the IL-9 promoter (Chang et al., 2010). IL-4 acting via 
STAT6 functions indirectly in priming Th9 differentiation, by counteracting the 
negative regulation provided by Foxp3 and T-bet in Th9 cells (Goswami et al., 
2012). In addition, IL-4 and STAT6 also induce the expression of other 
transcription factors (Gata3, IRF4, cMAF) that positively regulate Th9 fate 
(Goswami et al., 2012; Jabeen and Kaplan, 2012).  
The hallmark Th9 cytokine, IL-9, initially considered as a Th2 cytokine 
implicated in protective immunity to helminth infections, has been shown to 
promote allergic responses (Faulkner et al., 1998; Khan et al., 2003). IL-9 
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promotes inflammation by acting as a survival factor for mast cells, and by 
secreting mediators like chemokines that recruit cells to sites of inflammation 
(Goswami and Kaplan, 2011; Neill and McKenzie, 2010). Pathogenic potential of 
Th9 cells has been demonstrated in a number of mouse models of autoimmune 
diseases, namely T cell transfer model of colitis (Dardalhon et al., 2008), EAE 
(Jager et al., 2009), ocular inflammation (Tan et al., 2010) and allergic airway 
inflammation (Chang et al., 2010; Cheng et al., 2002; Temann et al., 2007). 
Increased IL-9 levels have also been reported in stimulated PBMCs from atopic 
children and BAL of asthmatic patients compared to healthy controls (Chang et 
al., 2010; Erpenbeck et al., 2003).  
 
Th22 cells 
Naïve human CD4+ T cells differentiate into Th22 cells in vitro in the 
presence of IL-6 and TNFα (Eyerich et al., 2009; Trifari et al., 2009). Similar to 
Th17 cells, Th22 cells express IL-22, CCR4, and CCR6, but in contrast, they also 
express CCR10 and several fibroblast growth factors (FGFs). In addition, Th22 
cells do not express IL-17, CCL20, IL-23R, CD161 (Th17 markers), IL-4 (Th2 
marker), or IFN-gamma (Th1 marker). Collectively, these characteristics 
distinguish Th22 cells as a novel T helper cell lineage that is distinct from the 
Th17, Th2, and Th1 subtypes (Eyerich et al., 2009; Trifari et al., 2009). The 
ligand-dependent transcription factor Aryl hydrocarbon receptor (Eddahri et al.) 
regulates the expansion of the IL-22 expressing T cells (Ramirez et al., 2010; 
Trifari et al., 2009). RNAi-mediated knockdown of AHR in human memory T cells 
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reduced IL-22 production from these cells, whereas IL-17 was not affected 
(Trifari et al., 2009). Similarly, Th17 cells from Ahr-deficient mice failed to 
produce IL-22 (Veldhoen et al., 2008a). The cytokine IL-22, an IL-10 family 
member (Wolk et al., 2010), is a unique cytokine produced by immune cells - 
Th1, Th17, gamma-delta T cells but CD4+Th22, IL-22 producing CD8 T and 
innate lymphoid cells (LTi and NK22) are the predominant producers of IL-22 
(Trifari and Spits, 2010). IL-22 bridges the immune and the non-hematopoietic 
stromal compartment by acting only on epithelial cells, keratinocytes and 
myofibroblasts, which express IL-22R. Expression of the CCR4 and CCR10 skin-
homing receptors on Th22 cells suggests that these cells are likely recruited to 
the skin, where they may contribute to host defense against microbial pathogens, 
and promote tissue repair or remodeling (Pickert et al., 2009; Zheng et al., 
2007a). IL-22 is up-regulated in rheumatoid arthritis, crohn’s disease, psoriasis 
and atopic dermatitis patients, whereas it is down-regulated in the sera of 
patients with sarcoidosis and systemic lupus erythematosus (Zhang et al., 2011). 
Multiple studies indicate that Th22 cells may also be involved in the pathogenesis 
of inflammatory skin disorders such as psoriasis, atopic eczema, and allergic 
contact dermatitis (Eyerich et al., 2009; Fujita, 2012; Vollmer et al., 1994). 
 
 Treg cells  
The immune system has developed elaborate mechanisms to enable 
effective immune responses against the inestimable number and types of 
pathogenic challenges. These responses are possible due to the diversity of 
	   22 
lymphocyte antigen receptors generated in the process of somatic gene 
rearrangements. While this process of random gene rearrangements prepares 
the host to respond to the rapidly evolving infectious agents, it also creates the 
danger of mounting harmful immune responses to self-components. Cell-intrinsic 
mechanisms of recessive tolerance that ensure the deletion or functional 
inactivation of self-reactive T cells are operative both in the thymus and 
periphery. However, these mechanisms are often insufficient and perfected by 
complementary dominant tolerance mediated by regulatory T cells acting in trans 
(Josefowicz et al., 2012a). The initial effector phase in any immune response is 
followed by a shift to the regulatory subset that limits the exaggerated response 
and balances the immune outcome, without excessive damage to the host. While 
there are other suppressive lymphoid subsets, regulatory T cells (Tregs) 
represent a major dedicated immune-regulatory subset of CD4 T cells, essential 
for dominant control of peripheral tolerance and maintenance of immune 
homeostasis.  
 
Identification of “suppressor T cells” 
The earliest evidence for the presence of a “suppressor” T cell population 
was noted in studies wherein thymectomy of neonatal mice between 2 and 4 
days of age lead to a fatal autoimmune disease, that could be prevented by 
adoptive transfer of thymocytes or splenocytes from adult euthymice mice 
(Asano et al., 1996; Bonomo et al., 1995; Nishizuka and Sakakura, 1969). This 
suggested that a suppressor T cell population emerged from the thymus after 3 
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days that controlled the development of autoimmunity. Chicken-quail chimera 
transplantation experiments suggested that grafted thymic epitehelium was 
necessary for xenograft tolerance, thus implicating a population of thymus-
derived suppressor cells in the control of allo-reactivity (Ohki et al., 1987). These 
initial autoimmunity and transplant tolerance studies culminated with the 
identification of a subset of CD4 T cells that constitutively expressed the IL-2R 
alpha chain (CD25), referred as regulatory T cells or Tregs, by Sakaguchi and 
colleagues in 1995 (Sakaguchi et al., 1995). Transfer of CD4 T cells depleted of 
the CD25+ population into athymic nude mice triggered an autoimmune 
inflammatory pathology, but transfer of intact CD4 T cell population did not. 
These CD4+CD25+ T cells were able to limit inflammation in models of 
autoimmunity and transplant rejection (Fehervari and Sakaguchi, 2004; Shevach, 
2000). However, the presence of CD25 on activated T cells impeded efforts in 
distinguishing these suppressor cells from activated inflammatory CD4+ T cells. 
 
Treg transcription factor “Foxp3” 
The Treg field gained momentum in 2003 with the identification of the 
transcription factor Foxp3 as the defining factor for this regulatory lineage. 
Mutations in the X-chromosome encoded Foxp3 gene were identified in human 
patients with IPEX disease (immune dysregulation, polyendocrinopathy, 
enteropathy, X-linked) and an analogous spontaneous disease in Scurfy mutant 
mice, that resulted in fatal, early-onset T cell-mediated autoimmune disease 
manifesting as diabetes, thyroiditis, hemolytic anemia, hyper-IgE, dermatitis, 
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splenomegaly and lymphoadenopathy and ‘cytokine storm’ (Bennett et al., 2001; 
Brunkow et al., 2001; Chatila et al., 2000; Wildin et al., 2001). This disease only 
affected hemizygous Foxp3 mutant males, while heterozygous mutant females 
were protected, owing to the presence of functional Foxp3 wild-type genes on 
one X-chromosome (Godfrey et al., 1994). This indicated that Foxp3 mutations 
do not affect random X-chromosome inactivation in T cells (Fontenot et al., 
2005b; Gavin et al., 2007). Expression of Foxp3 is specifically high in 
CD4+CD25+ T cells and not in naïve or activated CD4+ T cells. Importantly, 
forced expression of Foxp3 in conventional T cells converts them to Treg 
phenotype, exhibiting anergy and suppressive potential (Hori et al., 2003). 
Transfer of Foxp3+ Tregs to neonatal Scurfy can rescue the autoimmune disease 
phenotype, and the disease noted in mice with T cell specific targeted deletion of 
Foxp3 phenocopies the germline Foxp3 mutant mice, thus highlighting the lack of 
Foxp3 in T cells to be responsible for the autoimmune pathology in Scurfy mice 
(Fontenot et al., 2003; Khattri et al., 2003). Conditional deletion of Foxp3 in adult 
Foxp3DTR mice triggered similar fatal multiorgan immune disease, indicating that 
continuous expression of Foxp3 in Tregs is essential throughout the lifespan to 
prevent autoimmunity (Kim et al., 2007; Lin et al., 2007; Wan and Flavell, 2007; 
Williams and Rudensky, 2007).  
 
Treg differentiation in the thymus and periphery 
Treg cells in the periphery have two origins – the ones that commit to the 
Treg fate in the thymus during development (referred as natural or ‘nTregs’) and 
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those that can be induced in the periphery from naïve CD4 T cells through 
signals mediated by TCR in the presence of the cytokine, TGFβ (referred as 
induced or ‘iTregs’). At this point, there are no well-defined markers 
differentiating the two Treg sub-types in vivo. Further, it is not yet completely 
clear whether these two modes of Treg differentiation serve different or 
complementary functions in vivo nor is their relative contributions to the overall 
Treg pool under basal conditions and in response to different immune challenges 
well understood (Curotto de Lafaille and Lafaille, 2009).   
High expression of CD25, CD5 and CTLA-4 in Tregs (molecules up-
regulated with acute or chronic TCR activation) indicated that TCR signals of 
increased strength favor Treg cell selection during thymic differentiation (Azzam 
et al., 2001; Carter et al., 2005; Wong et al., 2001). Several lines of experiments 
support an instructive role for TCR signaling in Foxp3 induction and Treg 
differentiation (Hsieh et al., 2004). TCR repertoire analysis of Tregs and non-
Tregs showed that Treg TCRs were of broad variety, only partially overlapping 
with the TCR sequences of non-Treg cells and were biased towards self-
reactivity (Pacholczyk et al., 2006; Pacholczyk and Kern, 2008; Wong et al., 
2007b). Treg cell selection is mediated by TCRs with affinities for self-peptide 
ranging between positive selection of conventional CD4 T cells and negative 
selection of high-affinity self-reactive T cells (Josefowicz et al., 2012a). In 
addition to TCR signaling, CD28 co-stimulatory signals also play a cell-intrinsic 
role in Treg fate determination, as noted by marked reduction in Treg frequencies 
in CD28-deficient and CD80/CD86-deficient mice (Salomon et al., 2000; Tai et 
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al., 2005). Several transcription factors downstream of TCR and CD28 signaling 
– NFAT, NFkB and AP-1 play a positive role in transcriptional control of Foxp3 
via direct binding to the regulatory elements in the Foxp3 locus (Mantel et al., 
2006). The fact that the Treg cell TCR repertoire exhibited partial overlap with 
non-Treg cells indicated the importance of additional signals in Treg fate 
determination. These secondary signals were afforded by the gamma-chain 
signaling cytokines, primarily, IL-2 and to a lesser degree, IL-7 and IL-15 (Vang 
et al., 2008).  Mice lacking IL-2 or IL-2Rα chain showed an almost 50% reduction 
in numbers of Foxp3+ thymocytes (Burchill et al., 2007a; Fontenot et al., 2005a). 
Hsieh et al thus proposed a two-step model for thymic Treg differentiation: 
Increased TCR signals up-regulate CD25 on thymic Treg precursors that 
increases the affinity of developing thymocytes for IL-2 and the IL-2 signals lead 
to subsequent Foxp3 induction and thus Treg differentiation (Burchill et al., 2008; 
Lio and Hsieh, 2008). Indeed, the transcription factor STAT5 activated 
downstream of IL-2 and other gamma-chain cytokines, has binding sites in the 
Foxp3 promoter and Foxp3 CNS2 element and exerts positive effects on Foxp3 
expression (Burchill et al., 2007b; Yao et al., 2007). Apart from IL-2, ablation of 
transforming growth factor beta receptor I (TGFβRI) in developing thymocytes led 
to a transient but substantial drop in the generation of thymic Tregs during the 
first week of life, that was restored to levels comparable to wild-type later in 
development (Liu et al., 2008). This suggested that similar to its role in iTreg 
differentiation, TGFβ signaling may be important to regulate thymic Treg 
differentiation through interaction with the SMAD-NFAT binding site in Foxp3-
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CNS1 element (Tone et al., 2008). However, recent studies have identified that 
TGFβ signaling in the thymus is essential to provide survival signals to 
thymocytes by inhibiting Bim-dependent apoptosis and is dispensable for Foxp3 
up-regulation (Ouyang et al., 2010). 
Unlike thymic nTregs, peripheral differentiation of Tregs or iTregs likely 
occurs in response to non-self antigens, i.e. allergens, food or commensal 
microbiota, etc.. (Hsieh and Rudensky, 2005; Kretschmer et al., 2005; Lathrop et 
al., 2008). The TCR repertoire of iTregs is distinct from thymic Foxp3+ Tregs and 
non-Tregs, as illustrated by TCRs on Tregs from the colon being different from 
lymph node Tregs TCRs (Lathrop et al., 2011; Lathrop et al., 2008). Experimental 
evidence points towards high-affinity TCR signaling and sub-optimal co-
stimulation (increased CTLA-4 and low CD28 signaling) as optimal conditions for 
Foxp3 induction and iTreg differentiation (Benson et al., 2007; Zheng et al., 
2006). In addition, TGFβR signaling acting via Foxp3-CNS1 element is essential 
for most cases of peripheral induction of Foxp3 (Chen et al., 2003; Zheng et al., 
2004). IL-2-dependent STAT5 signals also favor Foxp3 up-regulation in 
peripheral CD4 T cells (Davidson et al., 2007; Horwitz et al., 2008). In the 
presence of TGFβ, IL-2 inhibits differentiation to the antagonistic Th17 lineage 
(Laurence et al., 2007). Downstream of TCR and IL-2 signaling, sustained Akt 
activation inhibits stable Foxp3 expression in peripheral CD4 T cells (Wong et al., 
2007a). This is supported by recent observations that Foxo1 and Foxo3A, which 
are inactivated by Akt, can directly bind to Foxp3 promoter and CNS2 element 
and up-regulate Foxp3 expression (Harada et al., 2010; Kerdiles et al., 2010).  
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Three main subsets of iTregs that are induced in the periphery have been 
described, based primarily on the cytokines that mediate their induction and 
function – Type 1 regulatory T (Tr1) cells are IL-10-dependent (Pot et al., 2009; 
Vieira et al., 2004), T helper 3 (Th3) cells are TGFβ-dependent (Carrier et al., 
2007) and iTR35 are IL-35-dependent (Collison et al., 2010). Mucosal sites such 
as GALT and mesenteric lymph nodes have been reported as ideal environments 
favoring iTreg differentiation in response to chronic exposure to commensals and 
food derived antigens. The CD103+ DCs present at these sites produce TGFβ 
and retinoic acid (RA) that are optimal signals for Foxp3 induction in CD4 T cells 
(Benson et al., 2007; Coombes et al., 2007; Sun et al., 2007). 
 
Foxp3-mediated regulation of Treg transcriptional and functional program 
The concept of a lineage-defining transcription factor is based on the 
premise that such a factor should be both necessary and sufficient to endow the 
phenotypic and functional attributes of the specific lineage. Early observations of 
a fatal autoimmune disease resembling the human disease IPEX in Foxp3-
deficient scurfy mice and enforced Foxp3 expression able to induce suppressor 
potential in conventional T cells, led to the identification of Foxp3 as the ‘master’ 
or ‘lineage-specifying’ transcription factor for regulatory T cells (Fontenot et al., 
2005b; Gavin et al., 2007; Hori et al., 2003). A series of experiments were 
subsequently performed to understand the molecular underpinnings of Treg fate 
specification by Foxp3. Treg-specific expression of Foxp3 conferred the defining 
features in Tregs: anergy (lack of proliferation following TCR stimulation in vitro) 
	   29 
and suppressive capacity (Gavin et al., 2007). Treg cells are unable to produce 
IL-2 or other gamma-chain cytokines, and they express reduced levels of IL-7Rα. 
However, they up-regulate CD25 (IL-2Rα) in a Foxp3-dependent manner, which 
is essential for Treg consumption of local IL-2 made by activated T cells and thus 
their survival and proliferation. Treg-specific expression of Foxp3 also ensures 
that Treg cells do not express effector cytokines of Th1, Th2 and Th17 lineages, 
which otherwise could lead to dire consequences, considering the potentially 
self-reactive TCRs on Tregs (Lin et al., 2007; Wan and Flavell, 2007). To assess 
the direct contributions of Foxp3 in the Treg lineage and to segregate any effects 
from signals that precede or promote its expression in Tregs, two different mouse 
models with nonfunctional Foxp3 protein expression (Foxp3gfpKO and Foxp3ΔEGFP) 
were tested by different groups (Gavin et al., 2007; Lin et al., 2007). The resulting 
GFP+ ‘Foxp3-less’ T cells retained many of the key Treg features, including the 
inability to produce IL-2 and an anergic phenotype, however, they lacked 
suppressive ability, stability and displayed reduced expression of hallmark Treg 
suppressor genes. These experiments indicated that Foxp3 amplifies and 
stabilizes features such as anergy, IL-2 dependence and expression of negative 
regulators of T cell activation (CTLA-4, GITR, TRAIL) induced by TCR signaling 
in developing Treg precursors (Josefowicz et al., 2012a). Nevertheless, Foxp3 
expression is indispensible for the Treg suppressor program and repression of 
effector cytokine gene expression. Foxp3 stabilizes Treg lineage features by 
regulating cell surface and signaling molecules (e.g. PDE3B), thereby 
maintaining Treg cell homeostasis and stability in response to different 
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environmental cues. Considering that part of the Treg transcriptional program is 
already derived from influences of TCR, IL-2 and TGFβ signaling separate from 
Foxp3-mediated effects, it is likely that a higher order regulation exists in the 
Treg lineage, upstream of Foxp3 (Hill et al., 2007; Sugimoto et al., 2006). 
Possible involvement of Ikaros family of transcription factors, specifying Treg fate 
upstream of Foxp3 has been proposed (Chatila, 2007). The Treg transcriptional 
and functional landscape relies on the high expression of Foxp3 specific to 
Tregs, as mice with attenuated Foxp3 protein expression (referred as ‘FILIG’ 
mice) develop fatal autoimmune disease, resembling Foxp3-deficient scurfy 
mice. FILIG Tregs exhibited impaired suppressor potential due to decreased 
Treg signature genes and secreted Th2 cytokines, resulting in Th2 differentiation 
of effector T cells (Wan and Flavell, 2007). In addition, Foxp3 has also been 
shown to stabilize and positively regulate its own expression (Bruno et al., 2009; 
Rudra et al., 2009), either via IL-2 signaling or by repressing antagonistic 
transcription factors like RORγt (Zhou et al., 2008a). Indeed continuous 
expression of Foxp3 in Treg cells throughout the lifespan is essential to maintain 
the suppressor program, as its deletion in mature Tregs results in loss of function 
and conversion of Tregs to pro-inflammatory cytokine producing effector T cell 
lineages (Williams and Rudensky, 2007). Genome wide analysis combining ChIP 
and tiling arrays have identified that Foxp3 directly binds to 20-30% of the Foxp3-
dependent genes, and functions as both a transcriptional activator and repressor, 
mediating distinct regulation in the thymus and periphery (Birzele et al., 2011; 
Marson et al., 2007; Zheng et al., 2007b). This dual regulation is possible due to 
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Foxp3-dependent specific histone modifications at binding sites in its target 
genes. Foxp3 target genes in the thymus primarily encode factors implicated in 
gene regulation and chromatin remodeling, while those shared in the periphery 
include Treg surface markers and intracellular signaling regulators. In addition, 
Foxp3 also establishes its developmental and functional program indirectly in 
conjunction with other transcription factors (PRDM1, CREM, IRF6, ZFPN1A2, 
STAT5, STAT4, STAT3, T-BET, IRF4, HIF1α). Foxp3 functioning as a homo-
oligomer was demonstrated to interact with number of transcription factors NFAT, 
AML1/Runx1, HAT/HDAC complex, and NFκB to mediate its functions (Bettelli et 
al., 2005; Lopes et al., 2006). The Foxp3-NFAT interaction occurs via the 
forkhead (FKH) domain of Foxp3 and blocks NFAT-mediated transcription of IL-
2, IL-4 and induces CTLA-4 and CD25 expression, thus conferring suppressor 
potential in activated T cells (Wu et al., 2006). Interaction of AML1/Runx1 with 
the N-terminal region of Foxp3 between the FKH and leucine zipper is important 
for repression of IL-2 and suppressive activity of Tregs (Ono et al., 2007). 
Acetylation of Foxp3 by HATs such as TIP60 increases Foxp3 binding to the IL-2 
promoter, thereby facilitating optimal repression of IL-2 (Li et al., 2007a). Foxp3 
can also regulate the Treg transcriptional and functional program indirectly by 
targeting microRNAs. Indeed, Treg-specific deletion of miRNA-processing 
enzymes resulted in fatal autoimmunity resembling Foxp3-deficient scurfy mice 
and the resultant Tregs lost suppressor activity and gained effector 
characteristics (Liston et al., 2008; Zhou et al., 2008b). Foxp3 was shown to 
directly bind miR-155, which is critical for Treg homeostasis (Lu et al., 2009a).  
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Mechanisms of Treg-mediated immune suppression 
Treg cells have emerged as key players in dominant tolerance and are 
implicated in curtailing inflammatory responses in a number of autoimmune 
diseases (Sakaguchi et al., 2008). They can modulate or suppress function of a 
wide variety of cell populations, in diverse anatomical locations. Recent literature 
also demonstrates a role for Tregs in non-immunological contexts; i.e. adipose 
tissue Tregs control metabolic disorders, heart diseases, etc. (Ait-Oufella et al., 
2006; Feuerer et al., 2009; Mor et al., 2007). In certain cases, however, this 
suppressive function of Tregs can also limit beneficial protective responses 
against infections and anti-tumor immunity (Belkaid, 2007; Kretschmer et al., 
2006; Rouse et al., 2006). Considerable progress has been made over the past 
several years in delineating the molecular mediators that contribute to the Treg 
arsenal. The Treg transcription factor Foxp3 confers a unique gene expression 
profile in Tregs that endows them with the suppressor potential. The different 
contact-dependent and contact-independent mechanisms used by Tregs can be 
grouped into four broad categories: (1) suppression by inhibitory cytokines, (2) 
suppression by cytolysis, (3) suppression by metabolic disruption and (4) 
suppression via modulation of dendritic cell maturation or function (Shevach, 
2009; Workman et al., 2009). Deletion of any one of these mechanisms does not 
phenocopy the disease in Scurfy mice. This suggests that either the key 
suppressive mechanism is yet to be identified, or that Treg suppression 
encompasses a multitude of molecules, with different mechanisms being 
operative based on the environment or context in which the Treg resides, the 
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target cell type that needs to be suppressed, or the specific disease and 
anatomical location under consideration (Vignali, 2008; Vignali, 2012; Vignali et 
al., 2008).  
Inhibitory cytokines (IL-10, TGFβ and the recently characterized IL-35) are 
expressed by Tregs and are the most extensively assessed cell-contact 
independent mode of Treg suppression (Asseman et al., 1999; Bettini and 
Vignali, 2009; Collison et al., 2007; Li et al., 2007b). Each of these cytokines also 
function independently via a unique induced Treg population, namely Tr1 cells 
that function via IL-10, Th3 cells that are TGFβ-dependent and iTr35 cells that 
suppress via IL-35 (Carrier et al., 2007; Collison et al., 2010; Pot et al., 2011). 
While the suppressive importance of both IL-10 and TGFβ in in disease models 
of inflammatory bowel disease, allergy and asthma has been well accepted 
(Hawrylowicz and O'Garra, 2005; Joetham et al., 2007), their importance for 
thymic nTreg function is not clear (Shevach, 2006). Ectopic expression of IL-35, 
similar to Foxp3, was capable of inducing suppressive potential in conventional 
CD4 T cells, suggesting that preferential Treg-specific expression of IL-35 is 
essential for maximal suppressive activity. Suppressive potential of IL-35 has 
been documented in five different disease settings using mouse models of IBD, 
homeostatic proliferation, Foxp3-deficient rescue, Trichuris muris infection and 
B16 melanoma (Collison et al., 2010; Collison et al., 2007) and IL-35 is also 
essential for the suppressor function of human Tregs (Chaturvedi et al., 2011). 
While Tregs lacking either IL-10 or IL-35 exhibited defective suppressor potential, 
IL-10/IL-35 double deficient Tregs were fully functional in vitro and in vivo 
	   34 
comparable to wild-type Tregs. This was attributed to the compensatory increase 
in Cathepsin E (CTSE) expression on the double-deficient Tregs, that were 
functional via CTSE-induced release of TRAIL (member of the TNF superfamily 
that can mediate apoptosis, programmed necrosis or inhibit proliferation) (Pillai et 
al., 2011). Thus, loss of a particular suppression mechanism can induce 
compensatory inhibitory mechanisms in Tregs.  
Cytolysis by Tregs is mediated by granzyme A in humans and granzyme B 
in mouse Tregs (Gondek et al., 2005). Granzyme B-deficient mouse Tregs 
exhibit reduced suppressor potential, and their cytolysis of effector T cells was 
perforin-independent. Tregs mediate B cell killing via granzyme B-dependent and 
partially perforin-dependent mechanism that leads to inhibition of B cell function. 
While granzyme B-dependent killing of target cells is reported in a number of 
Treg-dependent skin graft tolerance and tumor settings (Cao et al., 2007), recent 
literature indicates that Tregs can also induce apoptosis in T cells via TRAIL DR5 
(TNF related apoptosis inducing ligand-death receptor 5) pathway (Ren et al., 
2007). In addition to increased granzyme expression, galectin-1 (LGALS1), which 
is known to induce T cell apoptosis is also up-regulated in both mouse and 
human Tregs (Garin et al., 2007).   
 Treg suppression via metabolic disruption encompasses different 
mechanisms. Increased CD25 (IL-2Rα) expression has been suggested to 
endow Tregs with preferential IL-2 consumption, thus functioning as an “IL-2 
sink” and inducing apoptosis by depriving conventional T cells from their 
essential survival factor (Pandiyan et al., 2007). This was supported by 
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observations that T cells co-cultured with Tregs die by apoptosis in vitro, and T 
cells deficient in Bim, a pro-apoptotic Bcl2-family member, are resistant to this 
mode of Treg suppression (Bouillet et al., 1999). However, these findings have 
been contradicted by other reports showing that Bim-deficient, Bim/Puma-double 
deficient and Bcl2 transgenic T cells are all equally susceptible to Treg 
suppression as wild-type T cells (Szymczak-Workman et al., 2011). Since IL-2 
signaling contributes significantly to Treg homeostasis, it may be difficult to 
reconcile its separate role in Treg-mediated suppression. In addition, the 
ectoenzymes CD39 and CD73 expressed by Tregs were shown to induce 
pericellular adenosine, which can suppress effector T cells through activation of 
adenosine receptor 2A (Deaglio et al., 2007). Adenosine binding to the receptor 
has also been shown to induce iTregs by inhibiting IL-6 and promoting TGFβ 
secretion (Zarek et al., 2008). Tregs have also been shown to mediate direct 
suppression by the transfer of the second messenger cAMP into conventional T 
cells via gap junctions (Bopp et al., 2007).   
Treg cells can also exert indirect effects on T cells by modulating the 
maturation and function of dendritic cells that are essential for effector T cell 
activation. This is mediated via interactions between Treg surface molecules 
CTLA-4 and LAG-3 with CD80/CD86 and MHC class II on APCs, respectively, 
resulting in reduced activation of T cells by the interacting APCs (Cederbom et 
al., 2000; Liang et al., 2008; Oderup et al., 2006; Read et al., 2000). Indeed, 
intravital imaging studies have revealed direct interactions between Tregs and 
DCs in vivo (Tadokoro et al., 2006; Tang et al., 2006). In addition, Treg cells can 
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also induce production of indoleamine 2,3-dioxygenase (Akbari et al.) by DCs, an 
enzyme that can catabolize tryptophan into pro-apoptotic metabolites, that can 
facilitate suppression of effector T cells (Fallarino et al., 2003; Mellor and Munn, 
2004). 
 
Phenotypic and functional specialization of Treg cells 
Since regulatory T cells are the key players in maintaining immune 
tolerance and homeostasis, their activities need to be finely tuned to strike the 
balance between restraining deleterious inflammatory responses in various 
autoimmune conditions, while allowing protective responses against infections 
and tumors. Treg cells mediate their function by curtailing the activities of diverse 
cell types of the innate and adaptive immune response. Considering the ever-
increasing list of diverse immunological and non-immunological responses and 
pathologies that are under control of this suppressor T cell subset, it is not too 
surprising to identify ‘sub-phenotypes’ or ‘flavors’ of this regulatory lineage that 
are phenotypically and functionally specialized to ensure optimal regulation 
(Campbell and Koch, 2011; Feuerer et al., 2010; Shevach, 2006). These different 
‘sub-phenotypes’ are characterized by (i) differential expression of transcription 
factors that mediate functional specialization to control different types of immune 
responses, (ii) differential expression of chemokine receptors that enable 
trafficking of these cells to diverse lymphoid and non-lymphoid compartments, 
(iii) differential utilization of suppressor mechanisms to control diverse target cell 
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types in diverse environmental and disease contexts and (iv) different cytokine or 
metabolite cues that regulate their differentiation and function.  
 Recent studies have highlighted that Treg cells undergo functional 
specialization in the periphery by co-opting the transcriptional program of specific 
effector T cells they suppress (Figure 2). Thus, Th1-Tregs express the Th1 
transcription factor T-bet and Th1-associated chemokine receptor CXCR3 and 
are specialized for Th1 regulation (Koch et al., 2009). T-bet is the master Th1 
transcription factor specifying differentiation, migration and IFNγ production in 
Th1 cells. Thus, expression of T-bet endows Tregs to adopt the Th1 program and 
accumulate at sites of Th1 inflammatory responses (e.g. mycobacterium 
tuberculosis infection). T-bet-deficient Tregs fail to control Th1 responses when 
adoptively transferred to Foxp3-deficient scurfy mice, demonstrating the selective 
failure in control of Th1 inflammation. This acquisition of T-bet expression 
requires intact IFNγ/STAT1 signaling in Tregs. However, unlike Th1 cells wherein 
the Th1 program is stabilized by IL-12/STAT4 activation of IFNγ, this pathway is 
blocked in Tregs, potentially to maintain the characteristic Treg signature in T-
bet+CXCR3+ Tregs and prevent them from converting to Th1 effectors. Similarly, 
expression of the Th2 differentiation factor, IRF4, endows Tregs with the ability to 
control Th2 responses (Zheng et al., 2009). Mice with Treg-specific deletion of 
IRF4 develop spontaneous Th2-mediated autoimmune lesions in pancreas, 
stomach and kidneys, and exhibit increased Th2 cells, spontaneous germinal 
centers, elevated serum IgG and IgE antibodies (Th2 isotypes) and increased 
plasma cells. IRF4 is also important for differentiation of Th17 and Tfh cells. 
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Thus, expression of IRF4 in Th2-Tregs may also be important for control of 
aberrant Th17 and Tfh responses as noted by increased GC activity and 
autoantibodies. Similar to T-bet and IRF4, Treg-specific expression of the Th17 
transcription factor STAT3 is essential for control of Th17 responses (Chaudhry 
et al., 2009). Deletion of STAT3 in Tregs provokes spontaneous intestinal 
inflammation with increased numbers of infiltrating Th17 cells, highlighting the 
selective failure in control of Th17 responses. STAT3 expression up-regulates 
chemokine and cytokine receptors (CCR6, IL-1R, IL-6R) in the Th17-Tregs that 
enable these Tregs to migrate effectively to sites of Th17 inflammation. STAT3-
deficient Tregs exhibit increased expression of IL-6 and TGFβ, that can further 
amplify the Th17 inflammatory responses. Expression of the Tfh transcription 
factor Bcl6 in Tregs has recently been demonstrated to be essential for Treg-
control of aberrant germinal center responses and autoantibody formation 
(Chung et al., 2011; Linterman et al., 2011). These Tfh-Tregs or Tfr cells share 
phenotypic characteristics with conventional Foxp3+ Tregs and Tfh cells, derive 
from Foxp3+ natural Treg precursors and are dependent on Bcl6 to adopt the Tfh 
cell development program. Immunization with protein antigen mediates trafficking 
of these cells to the germinal centers where they regulate the quality of the 
germinal center reaction in terms of affinity maturation of antibodies, 
differentiation to plasma cells and limiting outgrowth of non-antigen specific B 
cells. Thus, the transcription factors T-bet, IRF4, STAT3 and Bcl6 define unique 
functionally specialized sub-phenotypes of Tregs that each control a distinct 
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class of immune responses, suggesting that Tregs and effector T cells 
differentiate in parallel in the periphery in response to diverse inflammatory cues.  
 Treg cells express a diverse array of chemokine receptors and adhesion 
molecules that enable trafficking to lymphoid and non-lymphoid compartments, in 
the presence or absence of overt inflammation (Huehn et al., 2004; Sather et al., 
2007). Expression of CD62L and CCR7 is required for Treg migration and 
retention in lymphoid tissues, as demonstrated by failure of CCR7-deficient Tregs 
to control colitis (Schneider et al., 2007). Expression of P- and E- selectin ligands 
directs Treg homing to skin (Dudda et al., 2008), CD103 to gut-associated 
lymphoid tissues (Suffia et al., 2005), CCR9 to small intestine (Guo et al., 2008), 
CXCR6 to liver (Lim et al., 2006) and CXCR4 to bone marrow, peyer’s patches 
and tumor sites (Wald et al., 2006). In addition to guiding migration to different 
anatomical locations, differential chemokine receptor expression on Tregs also 
permits effective control of diverse immune responses – CXCR3 for control of 
Th1 responses (Koch et al., 2009), CCR4 and CCR8 for Th2 responses (Zheng 
et al., 2009), CCR6 for Th17 responses (Chaudhry et al., 2009) and CXCR5 for 
control of germinal center responses (Chung et al., 2011; Linterman et al., 2011). 
Visceral adipose tissue (VAT) Tregs display a unique chemokine receptor 
expression pattern (elevated CCR1, CCR2, CCR9 and CXCL10 and low CXCR3) 
that is guided by PPARγ, the transcription factor that regulates accumulation, 
phenotype and function of this subset (Cipolletta et al., 2012). A point to note is 
that Tregs in distinct tissues exhibit a distinct TCR repertoire, suggestive of Treg 
priming in response to tissue-specific antigens can guide their expression of 
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chemokine receptors and thus migration to different compartments to restrain 
immune responses.  
 The four major suppressive mechanisms of Tregs (release of inhibitory 
cytokines, cytolysis, metabolic disruption and DC-mediated suppression) seem to 
be differentially utilized by Tregs in the lymphoid and non-lymphoid 
compartments. The inhibitory cytokine IL-10 is particularly important for 
maintaining homeostasis at mucosal sites like lungs, gut and skin (Rubtsov et al., 
2008), but is not required for control of systemic autoimmunity. TGFβ has also 
been implicated in control of colitis and allergic inflammation. In addition, induced 
or extra-thymically generated Tregs have been demonstrated to specifically 
regulate inflammatory responses at mucosal sites (Josefowicz et al., 2012b). On 
the other hand, Treg surface markers like CTLA4 and GITR function via inhibiting 
the immune-stimulatory activity of DCs in the lymphoid compartment (Tadokoro 
et al., 2006).  Therefore, deletion of CTLA-4 on Tregs leads to splenomegaly and 
lympho-adenopathy, massive multi-organ autoimmunity including myocarditis 
(Wing et al., 2008). Similarly, deletion of GITRhigh Tregs induces autoimmune 
myocarditis and other organ-specific autoimmune diseases such as gastritis and 
thyroiditis (Wing et al., 2008).  
 In addition, naïve T cells can be induced to express Foxp3 by various 
means: in vitro culture with TGFβ and IL-2, chronic stimulation with sub-optimal 
dose of antigen, oral delivery of antigen or homeostatic expansion (Chen et al., 
2003; Kretschmer et al., 2005; Mucida et al., 2005). The transcriptional profile of 
these converted Treg populations is different from the thymus-derived Tregs. In 
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addition, there exists considerable heterogeneity in these converted Tregs 
subsets generated in response to diverse cytokine and environment cues 
(Feuerer et al., 2010). Tregs converted under ‘homeostatic’ conditions (following 
transfer of Foxp3- CD4+ T cells into lymphopenic RAG-deficient mice) acquire a 
highly proliferative and activated KLRG1+CD103+ phenotype. These Tregs 
preferentially express suppressor genes (CD39 and Ebi3) and transcription 
factors, T-bet and Eomes. Tregs recovered from the lamina propria (which are 
potential in vivo equivalents of TGFβ-converted Tregs) share many features with 
the homeostatically-converted Tregs (Feuerer et al., 2010). Tregs generated in 
response to low-dose antigen (DEC-peptide converted) were relatively quiescent, 
exhibiting high expression of Ctla4 and Il10 and transcription factors, Irf4, Jun 
and Fos (Feuerer et al., 2010). IL-2R signaling was recently demonstrated to 
induce the generation of terminally differentiated KLRG1+ Treg subset, that 
marks highly activated antigen-responsive cells with high expression of Treg 
suppressor genes and which localize mainly to mucosal sites (Cheng et al., 
2012). The requirement for IL-2R signaling suggests that these Tregs develop at 
sites with strong auto-reactive T cell responses with high IL-2 levels or persistent 
antigen exposure such as the gut mucosa. 
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Figure 2: Functional heterogeneity exhibited by Treg cells. 
Similar to naïve T cells, Treg cells also undergo functional specialization in the 
periphery. Thus, in addition to expressing Foxp3, Treg cells tend to co-opt the 
transcriptional program of the effector T cells they suppress. Whether these 
functionally heterogeneous Treg populations are permanently fixed or 
transient forms that allow effective control of the specific helper T cell 
response needs further investigations.  
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Stability and plasticity of Treg cells  
Studies with genetic tagging of Tregs have yielded compelling evidence 
for the stability of this regulatory T cell lineage in healthy immune settings. 
Foxp3+ Tregs adoptively transferred into lymphopenic or Treg-deficient mice 
maintain high levels of Foxp3 expression, suggesting that majority of the Tregs 
remain stable in non-inflammatory contexts (Floess et al., 2007; Gavin et al., 
2007; Rubtsov et al., 2010). However, growing literature in the field also indicates 
that in inflammatory environmental settings, Treg cells can lose Foxp3 
expression and/or acquire effector T cell features, suggesting that the Treg 
transcriptional program is not permanently imprinted (Korn et al., 2007b; Tang et 
al., 2008; Wan and Flavell, 2007; Zhou et al., 2009c). Indeed, sustained 
expression of Foxp3 in the Treg lineage is critical for maintaining regulatory 
activity throughout the lifespan, as shown by the lethal autoimmune disease 
triggered following ablation of Foxp3 in Tregs in adult mice (Williams and 
Rudensky, 2007). Foxp3 expression in Tregs at any particular time derives from 
a combination of intrinsic cues that regulate and maintain its expression and 
extrinsic signals that influence Treg phenotype and function in diverse settings.   
Foxp3 expression in Tregs is regulated via TCR signaling, CD28 co-
stimulation and the signaling pathways activated downstream (NFAT, NFκB, 
AP1, CREB, ATF) (Sauer et al., 2008). In addition, IL-2 and TGFβ acting via 
STAT5 and SMAD phosphorylation, respectively, are also important for stable 
Foxp3 expression in Tregs. Continued TCR stimulation and constitutive 
activation of PI3K/mTOR pathway down-regulates Foxp3, while treatment with 
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Rapamycin, an inhibitor of this pathway, augments Foxp3 expression 
(Haxhinasto et al., 2008). The transcription factor Runx1 and its cofactor Cbfβ 
are indispensible for optimal Foxp3 expression in Tregs. Mice harboring Runx1 
or Cbfβ-deficient Tregs develop autoimmunity associated with splenomegaly and 
lymphadenopathy, serum autoantibodies and hyper-IgE production (Egawa et al., 
2007; Kitoh et al., 2009). This is primarily due to attenuated Foxp3 expression, 
reduced Treg suppressor genes and secretion of the effector cytokine, IL-4 by 
Runx1 or Cbfβ-deficient Tregs. This demonstrates that a critical role for Foxp3 in 
the Treg lineage is to suppress Treg acquisition of effector features, which can 
lead to deleterious consequences due to the self-reactive TCRs on Treg cells. 
The Th2 master regulator, Gata3, expressed in Tregs in an IL-4/STAT6 
independent manner, has recently been identified to be vital for optimal induction 
and maintenance of Foxp3 expression (Wang et al., 2011; Wohlfert et al., 2011). 
Gata3 directly binds to a regulatory region in the Foxp3 locus and promotes the 
activity of cis-acting elements in the Foxp3 gene, thereby exerting its positive 
influence on Foxp3 and Treg suppression capacity. Thus, Gata3-null Tregs 
exhibit reduced Foxp3 and acquire expression of Th1, Th2 and Th17 effector 
cytokines. Mice lacking the key microRNA-processing enzymes, Dicer and 
Drosha, in the Treg lineage develop fatal spontaneous multi-organ autoimmunity 
resembling Foxp3-deficient scurfy mice, suggesting that miRNAs are a major 
regulator of Foxp3 expression and Treg stability. Tregs from microRNA-deficient 
mice exhibit reduced suppressor function and stability and skew towards effector 
lineages (Liston et al., 2008; Zhou et al., 2008b). In this context, miRNA-10a was 
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recently shown to positively regulate Foxp3 expression and mark stable Treg 
cells, although genetic ablation of this miRNA did not affect Treg numbers or 
Foxp3 expression (Jeker et al., 2012). Foxp3 expression in Tregs is further 
maintained by a positive feedback loop provided by Foxp3 itself. In addition, 
Foxp3 expression is also regulated by epigenetic modifications of the conserved 
non-coding sequences in Foxp3 locus. In particular, complete demethylation of 
the Treg-specific demethyated region (TSDR) corresponds to stability of Foxp3 
expression, as conventional T cells or induced Tregs have a fully or partially 
methylated TSDR, respectively (Floess et al., 2007; Huehn et al., 2009). Thus, 
stable Foxp3 expression is further reinforced by epigenetic marks that permit the 
development of a stable suppressor lineage.   
 A number of extrinsic factors also impact stability of Foxp3 expression. 
Pro-inflammatory cytokines of Th1, Th2 and Th17 lineages present in diverse 
inflammatory settings mediate antagonistic down-regulation of Foxp3 and in 
some cases, conversion of Tregs to effector T cells (Pasare and Medzhitov, 
2003). Transcription factors T-bet, Gata3 and RORγt afford negative cross-
regulation for Treg differentiation (Dardalhon et al., 2008; Mantel et al., 2007; 
Takaki et al., 2008). Gata3 and STAT6 have been demonstrated to inhibit iTreg 
differentiation by direct binding to regulatory elements in the Foxp3 locus. The 
inflammatory cytokine IL-6 in conjunction with IL-1 and IL-23 induces RORγt and 
down-regulates Foxp3 leading to concomitant production of IL-17 by the Foxp3- T 
cells (Lal et al., 2009; Yang et al., 2008a). IL-2 deficiency within inflamed 
pancreatic islets leads to selective Foxp3 down-regulation in the diabetic setting 
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(Tang et al., 2008). Heterogeneity in Treg population may underlie some of the 
observed plasticity such that the committed Treg fraction (CD25+Foxp3+) is 
stable, while only the small un-committed (CD25negFoxp3+) Treg fraction is 
unstable and more prone to reprogramming under inflammatory setting (Komatsu 
et al., 2009). Also, such unstable or plastic CD25-Foxp3+ Tregs have been shown 
to convert to follicular helper T cells and promote the formation of germinal 
centers in mouse Peyer’s patches (Tsuji et al., 2009).  
Previous studies using GFP-tagged Tregs raised the concerns that the 
GFP- T cells that emerged in lymphopenic settings might derive from small 
numbers of contaminating non-Treg cells in the Treg preparations that underwent 
homeostatic proliferation in vivo (Murai et al., 2009). Recent studies therefore 
have employed novel dual reporter mouse models to definitively address the 
stability and the subsequent outcome for the Tregs that down-regulate Foxp3 in 
inflammatory contexts (Luche et al., 2007; Srinivas et al., 2001). In these models, 
Treg cells in a BAC Tg mice express GFP-Cre under control of the Foxp3 
promoter. These mice are mated to reporter mice that express an out-of-frame 
LoxP-flanked YFP inserted into the Rosa26 locus, such that in Foxp3+ Tregs, the 
activated Cre will excise the sequence flanked by the LoxP sites, thus 
permanently labeling these cells with YFP. Thus, even if Foxp3 expression is 
extinguished during the lifetime, these “exTregs” will still retain YFP expression, 
thus allowing for an effective strategy to distinguish Tregs that lost Foxp3 from 
those that never expressed it (Zhou et al., 2009c). These reporter mice helped 
identify a sizeable fraction of exTregs (10-20%) present in the peripheral 
	   47 
lymphoid organs even under homeostatic conditions, and this population 
increases significantly under inflammatory settings (~30%). These exTregs 
exhibit an activated memory phenotype, with production of effector cytokines 
(IFNγ and IL-17A based on the microenvironment) and are pathogenic in 
autoimmune disease settings. However, the notion of Treg instability has been 
challenged by studies using an inducible dual Foxp3 reporter mouse model, 
wherein GFP-Cre fusion with estrogen receptor (GFP-Cre-ERt2) is inserted into 
the Foxp3 locus and these mice are then mated to Rosa-YFP mice (Rubtsov et 
al., 2010). This system allows inducible tagging of Tregs, following treatment with 
the ER ligand, Tamoxifen. This system demonstrated that ~96% of Tregs remain 
stable, when tracked over months and there is a minimal Foxp3 down-regulation 
in immune-deficient settings. One major difference between the two reporter 
systems is that while the BAC-Tg system labels Tregs right from birth, the ER 
system is inducible and only labels about 30% of the Tregs. Thus, while the BAC-
Tg system labels all Tregs (even those cells that transiently turned on Foxp3, but 
didn’t develop into Tregs), the ER system may only label the most stable Foxp3-
expressing Tregs and fail to detect the unstable Tregs that have the potential to 
become exTregs. The fact that even with the ER system, a small (2-5%) of Tregs 
did down-regulate Foxp3 suggests that exTregs are indeed a true population of 
cells that down-regulate Foxp3 and can potentially be pathogenic, considering 
the self-reactive TCRs on Treg cells (Bailey-Bucktrout and Bluestone, 2011). 
They have also been demonstrated to confer a local advantage to the host by 
making effector T cells readily available at the site of infection. Indeed, during 
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Toxoplasma gondii infection, Treg cells reduce in numbers and the remaining 
Tregs make IFNγ that helps to counteract the infection (Oldenhove et al., 2009). 
Whether Treg instability is stochastic or reversible remains to be determined and 
such reversible instability may underlie the cause and protection in conditions 
such as chronic infections and relapsing-remitting multiple sclerosis (MS) (Kohm 
et al., 2002). Determining whether Treg instability is the consequence or an 
initiator for autoimmunity is critical to faithfully apply this regulatory subset for 
clinical purposes.  
 
Plasticity of helper T cells 
The classical view of helper T cell differentiation relies on the lineage 
commitment model wherein expression of a single transcription factor and 
concomitant cytokine profile underlies the distinct phenotype and function of each 
helper T cell subset. Helper T cell subsets were initially considered as terminally 
differentiated lineages, with irreversible commitment endpoints. This was mainly 
supported by experiments demonstrating that naïve T cells polarized to Th1 or 
Th2 fates for a certain number of cell divisions maintain their commitment even 
when placed into polarizing conditions favoring opposite lineages (Murphy et al., 
1996). This stable expression pattern was ascribed to the self-reinforcing and 
antagonistic regulation imposed by the lineage specific transcription factors. In 
addition, transmission of stable epigenetic marks at cytokine loci was proposed 
to further reinforce lineage commitment during subsequent rounds of cell division 
(Ansel et al., 2003; Bird et al., 1998; Grogan et al., 2001). Thus, signature 
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cytokines were shown to bear active epigenetic marks in their designated 
lineages and repressive marks in the opposing lineages (Wei et al., 2009). 
However, with the discovery of new players (Th17, Tregs, Tfh, Th9, Th22), this 
long-held view of helper T cells as distinct committed lineages, each defined by 
unique transcription factor, cytokine profile and effector function has been 
challenged in recent times. Accumulating studies in diverse autoimmune and 
inflammatory disease settings suggest that helper T cell plasticity is the norm to 
enable optimal protective responses in different contexts. What remains to be 
established yet is whether there are preferential directions for plasticity or 
whether multiple fates are unambiguously possible for each subset.  
 Flexibility in helper T cell differentiation is noted in terms of expression of 
transcription factors and the effector cytokines (Zhou et al., 2009a). The most 
striking example is the observation that Gata3+ Th2 cells differentiate to express 
Th1 genes (T-bet and IFNγ) in the context of viral infections (Hegazy et al., 
2010). Th2 cells also differentiate readily into an IL-9 secreting Th9 subset during 
control of helminth infections (Jager and Kuchroo, 2010). Pathogenic Th17 cells 
with the ability to express T-bet and IFNγ have been identified in a number of 
organ-specific autoimmune disease settings, although the opposite has not yet 
been reported (Hirota et al., 2011; Lee et al., 2009). Owing to the common 
requirement for TGFβ during differentiation of both Th17 and Treg lineages, 
considerable plasticity has been noted between these lineages based on the 
environmental milieu (Beriou et al., 2009; Bettelli et al., 2006; Zhou et al., 2008a). 
Foxp3+RORγt+ or Foxp3+IL-17+ CD4 T cells have been observed to develop in 
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vitro as well as detected in vivo in the small intestine in both mice and humans 
(Voo et al., 2009; Zhou et al., 2008a). The propensity of Tregs to differentiate into 
various effector T cell lineages has been reported extensively. T-bet+Foxp3+ 
Tregs produce IFNγ and are critical for protective immune responses in Th1 
inflammatory settings, such as Mycobacterium tuberculosis infection (Oldenhove 
et al., 2009). The Th2 transcription factor Gata3 is expressed at high levels in 
Tregs at mucosal sites and plays a critical role in maintenance of Foxp3 
expression during inflammatory responses (Wang et al., 2011; Wohlfert et al., 
2011). IRF4+Foxp3+ Tregs permit effective control of Th2 immune responses 
(Zheng et al., 2009). Expression of STAT3 in Tregs is required for optimal control 
of Th17-associated pathology (Chaudhry et al., 2009). In addition, Tregs can 
acquire expression of Bcl6 and differentiate to Tfh cells in the Payer’s patches 
and contribute to production of IgA and mucosal immunity (Tsuji et al., 2009). 
Bcl6+Foxp3+ Tregs with dual characteristics of Tregs and Tfh cells play key role 
in the control of aberrant GC and humoral responses (Chung et al., 2011; 
Linterman et al., 2011). Tfh cells also seem to exhibit considerable plasticity such 
that Th1, Th2, Th17 cell lineages can be differentiated to Tfh cells while Tfh cells 
can also differentiate and produce cytokines of Th1, Th2 and Th17 lineages (Lu 
et al., 2011a). The Tfh master regulator, Bcl6, is expressed in all CD4 T cells and 
not just Tfh cells (Lu et al., 2011a; Nakayamada et al., 2011). Indeed, Gata3+ 
Th2 cells have been shown to differentiate to Gata3+Bcl6+ Tfh cells during 
helminth infections (King and Mohrs, 2009; Zaretsky et al., 2009). In addition to 
variability in expression of transcription factors, cytokine expression in helper T 
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cells is also heterogeneous. Thus, while IL-21 is considered as a Tfh cytokine, its 
expression is not exclusive to Tfh cells as Th1, Th2, Th9 and Th17 cells also 
secrete IL-21 (Kaplan et al., 2011; Nakayamada et al., 2011; Suto et al., 2008; 
Wurster et al., 2002). Th1, Tregs and Th9 cells can also produce IL-10, initially 
considered as a Th2 cytokine (Saraiva and O'Garra, 2010). These and several 
other examples in literature highlight the emerging concept that helper T cell 
differentiation relies on the coordinated expression of multiple transcription 
factors and the degree, timing and context of their expression guides the 
development of helper T cells with diverse effector and regulatory functions 
(Nakayamada et al., 2012).  
 
MicroRNA-regulation of helper T cell differentiation and plasticity 
Since their recent discovery, microRNAs (miRs) have emerged as 
powerful regulators of gene expression in the mammalian immune system. 
These short 18-22 nucleotide single-stranded RNA molecules target the 3’-UTR 
of their target mRNAs and mediate post-transcriptional regulation of gene 
expression, either by mRNA degradation or translational inhibition (Ambros, 
2001; He and Hannon, 2004). More than 700 different microRNAs have been 
identified to date, several of these being highly conserved across species and 
with each one able to target multiple genes (Lodish et al., 2008; O'Connell et al., 
2010). The cells of the immune system express nearly 100 different microRNAs 
that are being identified to fine-tune gene expression in a wide range of 
processes ranging from cell development, differentiation and function. At the 
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same time, dysregulated miRNA expression is commonly associated with 
inflammation, autoimmunity and cancer (Calin and Croce, 2006). Expression 
profiling of T cells have identified a plethora of microRNAs that influence T cell 
development in the thymus and differentiation in the periphery (Merkerova et al., 
2008; Monticelli et al., 2005). Experiments with T cell specific deletion of the 
microRNA-processing enzyme, Dicer led to impaired T cell development and 
aberrant T cell differentiation (Cobb et al., 2005; Muljo et al., 2005). MiRNA-
cluster 17-92 guides T cell survival and selection by targeting pro-apoptotic 
molecules – Bim and Pten during thymic development (Xiao et al., 2008). MiR-
181a fine-tunes TCR signal strength and guides T cell selection by targeting a 
number of phosphatases (DUSP5, DUSP6, SHP2 and PTPN22) (Li et al., 
2007c). T cell responses in Dicer-deficient mice are skewed towards a Th1 
phenotype, demonstrating microRNA-mediated control of T cell differentiation 
(Cobb et al., 2005; Muljo et al., 2005). MiR-155 targets the Th2 transcription 
factor, maf and directs towards Th1 fate (Rodriguez et al., 2007; Thai et al., 
2007), while miR-326 drives Th17 differentiation by targeting a repressor of Th17 
cells, Ets1 (Du et al., 2009). MiR-29 family members inhibit Th1 differentiation by 
targeting the main Th1 transcription factors, T-bet and Eomes (Steiner et al., 
2011). The microRNA-mediated repression pathway is likely crucial for the 
development of T follicular helper cells, with miR-17-92 cluster targeting the 
follicle-homing chemokine receptor, CXCR5 and miR-101-103 targeting the co-
stimulatory molecule, ICOS (Yu et al., 2009). MiR-21 regulates the Th1 vs. Th2 
balance by targeting IL-12α, the Th1 polarizing myeloid cell cytokine and thus 
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indirectly promotes Th2 differentiation (Lu et al., 2011b; Lu et al., 2009b). Dicer 
or Drosha-deletion in the Treg lineage resembles the spontaneous inflammatory 
disease in Foxp3-deficient mice, highlighting the importance of miRNAs in Treg 
stability and suppressor function (Chong et al., 2008; Liston et al., 2008; Zhou et 
al., 2008b). The spontaneous disease in mice with Treg-specific deletion is 
triggered early in life, while the autoimmunity with T cell-specific deletion sets in 
later as the mice age. The Treg miRNA signature is Foxp3-dependent, and at the 
same time, miRs have been identified that regulate Foxp3 expression, 
suggesting a positive feedback loop between Foxp3 and miRNAs. A number of 
miRs are preferentially expressed in Tregs (miR-21, miR-223, miR-146, miR-22, 
miR-23a and b, miR-24, miR-214, miR-155) while several others are down-
regulated (miR-142-5p and 3p, miR-30 b, c, e and Let-7 family members) (Cobb 
et al., 2006). Subsequent studies have unraveled that these miRNAs regulate 
different facets of Treg biology. MiR-155 is important for Treg survival and 
homeostasis by targeting Socs1 and thus regulates their responsiveness to IL-2 
(Lu et al., 2009a). MiR-146a is critical for Treg control of Th1 inflammatory 
responses by targeting Stat1 (Lu et al., 2010). In the absence of this miRNA in 
Tregs, Tregs exhibit increased Stat1 phosphorylation, acquire a Th1-bias and fail 
to control Th1 responses. MiR-142-3p represses cAMP production, which is 
important for Treg suppressor function (Huang et al., 2009). MiR-10a has 
recently been demonstrated as a marker of stable Tregs, although the exact 
target genes were not identified (Jeker et al., 2012). MiR-21 can indirectly 
positively regulate Foxp3 expression in human Tregs, while miR-31 represses 
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Foxp3 expression (Rouas et al., 2009). Understanding the functional significance 
of the other Treg and T cell-specific miRNAs will advance our knowledge about 
the different mediators governing the biology of these cells and lead to 
development of more refined therapies for control of diverse pathologies.  
 
Regulation of gene expression by the transcription factor Bcl6 
The Bcl6 gene encodes a 706 amino acid (95 kDa) nuclear 
phosphoprotein that functions as a sequence-specific transcriptional repressor 
(Chang et al., 1996). This gene was originally cloned due to its involvement in 
chromosomal translocations affecting band 3q27 in non-Hodgkin’s lymphoma 
(NHL) (Baron et al., 1993; Kerckaert et al., 1993; Miki et al., 1994; Ye et al., 
1993a; Ye et al., 1993b). Bcl6 (also known as LAZ3 and ZBTB27) is a member of 
the POK/ZBTB family of transcription factors with critical roles in development, 
differentiation and lymphoma-genesis (Lee and Maeda, 2012). Similar to other 
POK/ZBTB family members (including LRF, BAZF, MIZ1, PLZF), the structure of 
Bcl6 protein comprises of 6 Kruppel-type C-terminal zinc-finger motifs and an N-
terminal POZ motif (also called BTB or ZIN) (Figure 3). The C-terminal zinc-
fingers are important for specific DNA binding (Kawamata et al., 1994), while the 
120 amino acid BTB/POZ domain allows for homo-dimerization or hetero-
dimerization with other proteins (Bardwell and Treisman, 1994; Okabe et al., 
1998). The POZ domain is mainly responsible for the repressor function of Bcl6 
due to its ability to recruit co-repressors such as N-CoR (nuclear co-repressor), 
SMRT/NcoR2 (silencing mediator of retinoic acid and thyroid hormone receptor), 
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BCOR (Bcl6 interacting corepressor), and HDACs (histone deactelyases) to 
promoter regions of target genes (Chang et al., 1996; Dhordain et al., 1997; 
Huynh and Bardwell, 1998; Huynh et al., 2000; Wong and Privalsky, 1998). The 
POZ domain also allows interactions of Bcl6 with other POK family members, 
particularly BAZF, MIZ-1 and PLZF (Lee and Maeda, 2012). The intervening 
central region between the POZ domain and the zinc-finger, which includes 3 
PEST motifs, has also been shown to mediate repression independently (Albagli 
et al., 1995; Parekh et al., 2007; Seyfert et al., 1996). Thus, the function of Bcl6 
in a particular cellular context is dependent on the availability of different co-
repressors or interacting partners in the nuclear milieu (Crotty, 2011; Parekh et 
al., 2008). The DNA-binding motif of Bcl6 shares close resemblance to the “GAS” 
motif recognized by the cytokine-induced STAT-family transcription factors (Dent 
et al., 1997; Seyfert et al., 1996). 
 
 
 
 
 
Figure 3: Schematic representation of Bcl6 protein.  
The 3 main domains of Bcl6 protein are displayed: BTB/POZ domain at the N-
terminal that mediates interactions with co-repressors and other BTB family 
members, central PEST domain with the phosphorylation (P) and Acetylation 
(Ac) sites that confers protein stability and also recruits co-repressors and the  
6 C-terminal Zn fingers that are critical for DNA binding.    
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Bcl6 as the master regulator of germinal center (GC) B cells  
Rearrangements of the Bcl6 gene have been associated with 30-40% of 
diffuse large cell lymphoma and 6-11% follicular lymphoma cases (Bastard et al., 
1994; Lo Coco et al., 1994; Otsuki et al., 1995). Most of these rearrangements 
involve translocation of heterologous promoters derived from other chromosomes 
to Bcl6 coding region leading to deregulated Bcl6 expression (Ye et al., 1995). 
Point mutations in the 5’ non-coding region of Bcl6 have also been linked to 
lymphomagenesis (Dalla-Favera et al., 1994; Migliazza et al., 1995). Bcl6-
associated lymphomas are frequently derived from germinal center (GC) B cells. 
Within the B cell lineage, the expression of Bcl6 is specifically confined to GC B 
cells and almost undetectable in pre-GC cells and terminally differentiated 
plasma cells (Cattoretti et al., 1995; Flenghi et al., 1995; Onizuka et al., 1995). 
The GC stage of B cell differentiation favors maturation of the antibody response, 
qualitatively and quantitatively with processes such as somatic hypermutation, 
affinity maturation, isotype-switching and memory B cell formation (MacLennan, 
1994). Bcl6 acts intrinsically in B cells to prevent the terminal differentiation of 
GC B cells to plasma cells or memory cells, via repression of plasma cell 
differentiation factor, BLIMP1 (Prdm1) (Reljic et al., 2000; Shaffer et al., 2000). 
Thus, mice deficient in Bcl6 lack GCs and fail to mount protective antibody 
responses (Dent et al., 1997; Fukuda et al., 1997; Ye et al., 1997). Constitutive 
expression of Bcl6 resulting from point mutations or translocations such as those 
in lymphomas, maintains B cells in the actively proliferating and mutating GC 
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phenotype leading to B cell transformation (Pasqualucci et al., 2003; Wang et al., 
2002).  
Considering the oncogenic role of Bcl6 in the B cell lineage, multiple target 
genes for Bcl6 have been characterized in this lineage. One of the key target 
gene is the plasma cell differentiation factor, BLIMP1 (Reljic et al., 2000; Shaffer 
et al., 2000). In addition, Bcl6 inhibits cell-cycle regulators (cyclin D2, p21cip1, 
p27kip1) and checkpoint controls (ATR, p53) that correspond with its role in 
promoting GC B cell proliferation and B cell transformation (Baron et al., 2002; 
Phan and Dalla-Favera, 2004; Phan et al., 2005; Shaffer et al., 2000). More 
recently, gene expression profiling in combination with ChIP-on-chip approaches 
have identified over 1200 genes whose promoters are bound by Bcl6 and down-
regulated in GC B cells (Basso et al., 2010; Ci et al., 2009). While a number of 
these gene targets confirm the previously recognized role for Bcl6 in B cell 
activation, differentiation and survival, these approaches have uncovered novel 
roles for Bcl6 in regulating signaling via Toll-like receptor, IFN-R, TGF-R, 
cytokine and Wnt pathways (Basso et al., 2010). Thus, the multitude of target 
genes and the cellular pathways they regulate suggest that the transcriptional 
modulation by Bcl6 in GC B cells orchestrates controlled expression of molecules 
critical for the GC reaction (Basso and Dalla-Favera, 2010).  
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Bcl6 as an arbiter of helper T cell differentiation program 
Bcl6 functions in Th1 cells  
Bcl6 expression is higher in Th1 cells, relative to Th2 cells, consistent with 
the role for Bcl6 in inhibiting Th2 gene expression program in Th1 cells (Cimmino 
et al., 2008; Mondal et al., 2010). The mechanisms for repression of Th2 
differentiation by Bcl6 include competition with STAT6 for binding to Th2 genes 
(Dent et al., 1997; Harris et al., 1999; Harris et al., 2005), binding to a silencer in 
the Il5 gene (Arima et al., 2002) and post-transcriptional control of the Th2 
transcription factor Gata3 (Kusam et al., 2003). Analogous to the regulation of B 
cell differentiation program, antagonistic regulation of the transcription factor 
BLIMP1 by Bcl6 in T cells is critical for the Th1 vs. Th2 development (Cimmino et 
al., 2008). BLIMP1 is highly expressed in Th2 cells and is critical for Th2 humoral 
responses in vivo, but is dispensable for Th2 differentiation in vitro. BLIMP1 
directly binds and represses Th1 genes, IFNγ and Tbx21 and thus polarizes 
towards Th2 fate (Cimmino et al., 2008). Thus, the repression of BLIMP1 by Bcl6 
in Th1 cells is critical to block the ability of BLIMP1 to inhibit Th1 gene 
expression. Yu et al reported increased percentages of IFNγ-producing cells 
within the Bcl6-deficient T cell compartment in SRBC-immunized Bcl6+/+: Bcl6-/- 
fetal-liver chimeras, suggesting that Bcl6 was not required for Th1 cell 
development (Yu et al., 2009). Bcl6 represses Th1 differentiation, via direct 
binding to the T-bet gene promoter (Yu et al., 2009). Retrovirus-mediated over-
expression of Bcl6 suppressed Th1 differentiation in a dose-dependent manner 
(Yu et al., 2009). This effect is consistent with Tfh cells (which express high 
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levels of Bcl6) isolated ex vivo and differentiated in vitro displaying low levels of 
Th1 genes, T-bet and IFNγ (Lu et al., 2011a). Similar results with ectopic Bcl6 
expression inhibiting T-bet and IFNγ gene expression were reported by Nurieva 
et al, who further demonstrated that this repression was dependent on the DNA-
binding ability of Bcl6 zinc-fingers (ZF3 and ZF5) (Nurieva et al., 2009). The Th1 
transcription factor T-bet was recently shown to physically associate with Bcl6 at 
its C-terminal zinc-finger domain and directly target promoters of genes involved 
in inhibiting Th1 differentiation, Socs1, Socs3 and Tcf7 (Oestreich et al., 2011). In 
addition, Bcl6 itself gets recruited at the IFNγ locus in a T-bet-dependent manner 
during later time points in Th1 differentiation and directly inhibits IFNγ 
transcription. Thus, the coordinated regulation of the Th1 gene program by T-bet 
and Bcl6 ensures maintenance of optimal levels of IFNγ essential for effective 
pathogen clearance. Forced expression of Bcl6 even in fully committed Th1 cells 
inhibits Th1 differentiation indicating that Bcl6 can polarize committed Th1 cells 
towards Tfh fate (Lu et al., 2011a). A recent study also provides ample evidence 
for the opposite scenario: differentiation of Tfh cells to Th1 effectors (Lu et al., 
2011a). In fact, priming of naïve T cells with the Th1-polarizing cytokine IL-12 
induces generation of IFNγ- and IL-21- secreting cells, which resemble both Th1 
and Tfh cells (Nakayamada et al., 2011). The Bcl6 gene locus is accessible in 
naïve CD4 T cells as well as fully differentiated Th1 cells (Lu et al., 2011a). Bcl6 
is induced following T cell stimulation and further following cytokine-induced 
activation of STAT4 and STAT3 (Nakayamada et al., 2011). Repression of Bcl6 
by T-bet during later time points is critical for full Th1 differentiation. Thus, 
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antagonistic regulation of T-bet and Bcl6 determines the eventual outcome for a 
developing helper T cell; with chronic antigenic stimulation favoring sustained 
Bcl6 expression and thus Tfh differentiation while conditions favoring sustained 
T-bet expression have reduced Tfh differentiation. The Tfh differentiation 
potential of Th1 cells is further subject to regulation by IL-2 induced STAT5 
signaling inhibiting Bcl6 expression in Th1 cells (Oestreich et al., 2012). Th1 cells 
maintained in low IL-2 conditions were subject to Bcl6 up-regulation by Foxo 
transcription factors, leading to repression of BLIMP1 and up-regulation of Tfh 
genes. 
 
Bcl6 functions in Th2 cells 
Earlier insights about the role of Bcl6 in the T cell lineage mainly came from 
studying the phenotype of Bcl6-deficient mice that develop a spontaneous Th2-
mediated inflammatory disease in their heart and lungs (Dent et al., 1997; Ye et 
al., 1997). The inflammation is predominantly Th2 biased, characterized by 
infiltration of monocytes, macrophages, eosinophils and Th2 cells. Increased 
numbers of IgE-positive B cells and mast cells have also been noted in Bcl6-
deficient mice. Bcl6-deficient mice also exhibit pronounced Th2 responses when 
immunized with a protein antigen in adjuvant, suggesting that the Th2 response 
can be antigen-dependent (Dent et al., 1998a). These initial studies 
characterized Bcl6 as a critical transcription factor for inhibiting Th2 differentiation 
in T cells. Mice doubly-deficient in Bcl6 and STAT6 or Bcl6 and IL-4 however 
developed similar Th2 inflammation in heart and lungs as Bcl6-deficient mice, 
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indicating that Bcl6 regulates Th2 gene expression program via an IL-4/STAT6-
independent pathway (Dent et al., 1998a). Post-transcriptional regulation of the 
master Th2 transcription factor Gata3 by Bcl6 explains the STAT6-independent 
Th2 gene expression of Bcl6-deficient T cells (Kusam et al., 2003). Transgenic 
mice overexpressing Bcl6 in CD4 T cells (lck-Bcl6 Tg strain) exhibit reduced Th2 
cytokines and eosinophil accumulation in the bronchoalveolar lavage (BAL) after 
aeroallergen challenge (Arima et al., 2002). Variants of Bcl6 gene have been 
associated with atopy characterized by high IgE titers and positive RAST scores 
to mixtures of house-dust mite and grass pollen in a large-scale study with British 
and Japanese populations (Adra et al., 1998). STAT factors and Bcl6 share 
common recognition motifs and Bcl6 can compete with STAT6 for repressing IL-4 
transcription (Harris et al., 1999; Harris et al., 2005). Bcl6 also has been shown 
to a bind to a silencer element in the IL-5 gene (Arima et al., 2002). Bcl6 
functions in the non-lymphoid compartment are also important in the regulation of 
Th2 differentiation. Bcl6 was noted to repress chemokine gene expression (MCP-
1, MRP-1, MCP-3) in macrophages that can contribute to increased Th2 
differentiation seen in Bcl6-deficient mice (Toney et al., 2000), particularly, since 
MCP-1 can itself prime Th2 responses indirectly by inhibiting IL-12 from 
monocytes and macrophages. In addition, Bcl6 also represses IL-6 transcription 
in macrophages, thus further inhibiting the promotion of hyper-Th2 responses by 
Bcl6-deficient APCs (Yu et al., 2005). Bcl6-deficient bone marrow mast cells 
(BMMCs) also produced increased Th2 cytokines following activation than wild-
type counterparts, indicating a role for Bcl6 in inhibiting Th2 genes in mast cells 
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(Ohtsuka et al., 2005). Bcl6-deficient dendritic cells (DCs) produce more IL-6 and 
less IL-12 than wild-type DCs, suggesting that repression of IL-6 by Bcl6 was 
also important to limit Th2 skewing (Ohtsuka et al., 2011). Forced expression of 
Bcl6 in developing Th2 cells significantly inhibited Th2 genes (Gata3 and IL-4) 
(Kusam et al., 2003) and this effect was dependent on Bcl6 zinc fingers (ZF3 and 
ZF5) (Nurieva et al., 2009). Similar results were obtained by Yu et al who 
reported almost 60% reduction of Gata3 protein following overexpression of Bcl6 
in Th2 polarized cells (Yu et al., 2009). These effects are concomitant with 
reduced expression of Th2 genes by Bcl6-expressing Tfh cells (Lu et al., 2011a). 
Positive epigenetic marks on Gata3 in Tfh cells and on Bcl6 in non-Tfh cells 
suggest potential for developmental plasticity between these lineages (Lu et al., 
2011a). Indeed, ex vivo isolated Tfh cells produced Th2 effector cytokines 
following repolarization in vitro, suggesting that Tfh cells could convert to Th2 
effectors. At the same time, Th2 effectors can be reprogrammed to Tfh fate 
following either forced expression of Bcl6 or differentiation under Tfh conditions. 
In vivo, Tfh cells have also been shown to differentiate from Th2 effectors 
following immunization with helminth antigens (King and Mohrs, 2009; Zaretsky 
et al., 2009).  
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Bcl6 functions in Th17 cells 
Considerable variations in the Th2 disease severity, and the pro-inflammatory 
nature of Th17 cells, prompted investigations into the contributions of Th17 cells 
to the inflammatory disease observed in Bcl6-deficient mice. Indeed, IL-17 levels 
in the heart and lungs segregated with disease severity similar to IL-4, 
suggesting that IL-17 and thus Th17 cells were associated with disease 
exacerbations in Bcl6-deficient mice (Mondal et al., 2010). Bcl6-deficient mice 
had increased IL-4 and IL-17 producing memory T cells, demonstrating that in 
addition to Th2, Bcl6 is also an inhibitor of Th17 responses. Highest Bcl6 levels 
(both transcript and protein) were noted in conditions favoring Th17 
differentiation relative to Th1 or Th2 conditions, implying functional role for Bcl6 
in the Th17 lineage. Bcl6-deficient naïve T cells demonstrated reduced Th17 
differentiated potential in vitro compared to wild-type T cells, owing to their 
preferred Th2 bias, which could be restored by either increasing the dose of 
TGFβ in culture, using sort-purified naïve CD4+ T cells (CD62L+CD44low) or 
Bcl6/IL-4 double-deficient T cells for differentiation. This demonstrated that the 
critical role for Bcl6 in Th17 differentiation is to inhibit IL-6 driven Th2 
differentiation that can negatively impact Th17 polarization. Ectopic expression of 
Bcl6 in T cells promoted a modest up-regulation of IL17, with no effect on RORγt, 
which could be attributed to its inhibitory effect on Th2 differentiation. Bcl6-
deficient macrophages produced increased levels of pro-Th17 cytokines (IL-6, 
TGFβ and IL-23) following LPS stimulation than wild-type macrophages and 
conditioned media from Bcl6-deficient macrophages augmented Th17 
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differentiation of T cells in vitro. Thus, the increased Th17 responses of Bcl6-
deficient T cells in vivo can be attributed to the pro-Th17 cytokine production of 
Bcl6-deficient macrophages. Thus the increased Bcl6 in Th17 conditions is 
critical to limit Th2 skewing and allow for optimal Th17 differentiation. While Bcl6 
overexpression modestly promotes IL-17, the role of Bcl6 in repressing pro-Th17 
cytokines in APCs seems more dominant in vivo. This result conflicts with work 
from Yu et al and Nurieva et al who demonstrated repression of IL-17 following 
Bcl6 overexpression. Nurieva et al demonstrated direct binding of Bcl6 to RORγt 
gene promoter contributing to the repression of IL-17 (Nurieva et al., 2009). 
While Yu et al attributed the down-regulation of IL-17 to inhibition of 
transcriptional activity of RORγt by Bcl6, but not its expression (Yu et al., 2009). 
Possible explanation for the observed discrepancy between these studies and 
the results from Mondal et al (Mondal et al., 2010) could be explained by the 
differences in duration of culture with Bcl6 retrovirus, with long-term cultures 
potentially favoring an outgrowth of Tfh cells. Th17 genes (RORγt and IL-17) are 
expressed at low levels in Bcl6-expressing Tfh cells (Lu et al., 2011a). Positive 
chromatin marks on Rorc in Tfh cells and Bcl6 in non-Tfh cells highlight the 
plasticity shared by these lineages. Indeed, Th17 cells can be reprogrammed 
towards the Tfh lineage by either forced expression of Bcl6 or differentiation 
under Tfh conditions. While Tfh cells isolated ex vivo can produce Th17 effector 
cytokines following repolarization in vitro. Finally, IL-17 producing Tfh cells 
(referred as “Tfh17” cells) have been shown to induce ectopic follicles in the 
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lungs of neonates following LPS-triggered pulmonary inflammation (Rangel-
Moreno et al., 2011).  
 
Bcl6 functions in Tfh cells 
Bcl6 has emerged as the master transcription factor specifying the T 
follicular helper (Tfh) cell lineage, helper T cells that provide selection signals to 
B cells, which is essential for generation of long-lived antibody responses 
(Johnston et al., 2009; Nurieva et al., 2009; Yu et al., 2009). Ectopic expression 
of Bcl6 promoted expression of hallmark Tfh molecules (CXCR5, CXCR4, PD-1, 
ICOS, IL-21R) in T cells, thereby skewing towards Tfh fate. Bcl6-deficient T cells 
fail to differentiate into Tfh cells in vivo, and mice deficient in Bcl6 lack germinal 
centers and fail to mount protective antibody responses. While Bcl6 is required 
for both GC B cells and Tfh cells, it controls Tfh differentiation program by 
regulating completely different set of genes than GC B cells (Crotty, 2011). While 
the three initial studies using elegant gain-of-function and loss-of-function 
approaches firmly established the cell-autonomous role for Bcl6 in Tfh fate 
determination, each provided unique mechanistic insight into how a 
transcriptional repressor can positively direct Tfh differentiation (Bi and Ye, 
2010). Johnston et al (Johnston et al., 2009) identified the reciprocal relationship 
between Bcl6 and BLIMP1 in Tfh cells and reported repression of the 
antagonistic Tfh transcription factor BLIMP1 by Bcl6 as essential to drive 
differentiation from effector towards Tfh lineage. Both Nurieva et al (Nurieva et 
al., 2009) and Yu et al (Yu et al., 2009) demonstrated that Bcl6 directs Tfh 
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differentiation by inhibiting differentiation to alternative non-Tfh lineages. Bcl6 
was shown to directly bind the promoters of T-bet and Rorc genes, or repress the 
transcriptional activity of Rorc. Ectopic expression of Bcl6 significantly 
suppressed Th1, Th2 and Th17 gene expression in a dose-dependent manner, 
and this effect was dependent on the DNA-binding ability of Bcl6 (Nurieva et al., 
2009). Yu et al reported an interesting aspect of Bcl6-mediated gene regulation 
in T cells, i.e. ability of Bcl6 to repress more than half of the abundantly 
expressed microRNAs in T cells by 50% or more (Yu et al., 2009). Repression of 
microRNAs that target Tfh molecules (e.g., miR-17-92 that targets CXCR5 and 
miR-101-103 that targets ICOS) was revealed as a novel mechanism by which 
Bcl6 positively induced Tfh differentiation. Bcl6 alone does not induce the entire 
Tfh signature in case of human CD4 T cells; the transcription factor cMAF 
induces IL-21 and thus collaborates with Bcl6 for optimal Tfh differentiation 
(Kroenke et al., 2012). Differentiation of naïve T cells with IL-6 and IL-21 was 
shown to up-regulate Bcl6 expression, although both the cytokines are reported 
to be dispensable for Tfh differentiation in vivo (Poholek et al., 2010). The signals 
regulating expression of Bcl6 in CD4 T cells remain relatively unknown. ICOS 
has been shown to induce Bcl6 expression and thus set an early bifurcation point 
for Tfh vs. effector T cell differentiation (Choi et al., 2011). Studies using a Bcl6 
reporter mice to track Bcl6 protein expression in vivo have shown that Bcl6 
protein gets induced in antigen-engaged CD4 T cells prior to antigen-engaged B 
cells, and its expression in CD4 T cells is further induced following cognate B cell 
interactions (Okada et al., 2012). Bcl6 protein however gets gradually lost on Tfh 
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cells, while its maintained on GC B cells. Whether these BCL6lo Tfh cells re-
differentiate towards other effector lineages, stay in GCs as memory Tfh cells or 
become a part of the circulating CD4+CXCR5+ memory T cell pool warrants 
additional studies. The presence of active chromatin marks on Bcl6 in non-Tfh 
cells and on T-bet, Gata3 and Rorc in Tfh cells highlights the potential of 
plasticity between these different helper T cell lineages (Lu et al., 2011a). Indeed, 
ectopic expression of Bcl6 or differentiation under Tfh conditions can drive Th1, 
Th2 and Th17 cells towards Tfh fate, while ex vivo isolated Tfh cells can re-
differentiate towards effector lineages under appropriate conditions.   
 
Bcl6 functions in Treg cells 
The severe Th2 inflammatory heart and lung pathology that develops 
spontaneously at an early age in majority of the Bcl6-deficient mice underscores 
the role for Bcl6 in regulatory T cell lineages. However, in comparison to the in-
depth assessment of Bcl6 functions in effector T cell subsets, not much is known 
about the role of Bcl6 in conventional CD4+Foxp3+ Treg cells. No significant 
difference in Foxp3+ Treg cell percentages derived from Bcl6-deficient and Bcl6-
sufficient cells were noted in fetal liver chimeras, suggesting that Bcl6 is 
dispensable for Treg cell development (Yu et al., 2009). Chung et al (Chung et 
al., 2011) however reported increased numbers of Foxp3+ T cells in the thymi 
and spleen, but not mesenteric lymph nodes of Bcl6-deficient mice, relative to 
wild-type mice. Bcl6-deficient T cells exhibit a reduced tendency to differentiate 
into induced Treg (iTreg) lineage following in vitro culture with TGFβ, owing to 
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their intrinsic Th2 bias, which could be restored by treatment with anti-IL-4 
(Nurieva et al., 2009). CD25hiCD4+ Treg cells from Bcl6-deficient mice express 
increased levels of effector lineage transcription factors (Gata3, Irf4, Rorc), 
increased Blimp1 and Treg cytokine Il10, and reduced Tfh markers (Cxcr5, Pd1, 
Btla, Pdcd1) and these cells maintain intact suppressor function in vitro (Chung 
et al., 2011). However, these studies by Chung et al use CD25hiCD4+ Treg cells, 
a fraction which contains high numbers of Th2 effectors that are Foxp3- and thus 
not pure Tregs. Hence a detailed assessment of phenotype and in vivo functional 
potency of pure CD25+Foxp3+ Bcl6-deficient Tregs is still lacking. Recent studies 
have focused on a specific subset of Bcl6-expressing Treg cells that are critical 
to regulate the germinal center reaction, referred as T follicular regulatory cells 
(Tfr cells) (Chung et al., 2011; Linterman et al., 2011). Bcl6-deficient mice lack 
CXCR5+Foxp3+ Tfr cells. Tcrβ-deficient mice receiving CD25hiCD4+ Bcl6-
deficient Tregs with naïve CD4+ T cells and immunized with NP-KLH in CFA 
displayed increased numbers of GL7+CD95+ germinal center B cells, increased 
titers of NP-specific global and high affinity IgG isotypes as well as increased 
numbers of NP-specific B220+ B cells and B220-CD138+ plasma cells, 
demonstrating that Bcl6-deficient Tregs have substantial defects in control of 
germinal center B cells, antibody affinity maturation and plasma cell 
differentiation (Chung et al., 2011). No obvious differences in Th1, Th2 and Th17 
responses were noted in this system for mice receiving Bcl6-deficient vs wild-
type Tregs (Chung et al., 2011). However, here again, the Treg cells used were 
not selected for Foxp3+ Tregs and the experimental design didn’t include 
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appropriate control mice receiving no Tregs. Thus, a comprehensive assessment 
of the role of Bcl6 in these different regulatory lineages and their implications in 
control of T and B cell tolerance is warranted.  
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RESEARCH AIMS 
The overall aim of this research centered on understanding the role of the 
transcription factor Bcl6 in Treg cell biology and determining how that relates to 
the inflammatory pathology that develops in the Bcl6-deficient mice. The 
inflammatory disease is mainly Th2-biased, and manifests as myocarditis and 
pulmonary vasculitis by 4-6 weeks of age. The disease is spontaneous, T cell-
dependent and resembles the pathology noted in mice with Treg-cell defects. 
Considering the central importance of Treg cells in limiting T cell proliferation and 
maintenance of immune homeostasis, the overall project focused on a detailed 
characterization of the phenotype and function of Bcl6-deficient Tregs to 
understand the molecular underpinnings underlying the control of inflammation 
by Bcl6.  
Bcl6 has gained considerable attention in recent years due to its 
identification as a master transcription factor specifying the T follicular helper cell 
lineage. Being a well-characterized transcriptional repressor, Bcl6 has been 
demonstrated to positively direct Tfh differentiation indirectly by repressing 
microRNAs that target Tfh genes and by repressing differentiation towards non-
Tfh fates by inhibiting Blimp1. In addition to directing Tfh differentiation, Bcl6 has 
also been shown to be indispensible for the differentiation of a specific Treg 
subset named T follicular regulatory cells that regulate the germinal center 
response.  
Bcl6 has previously been reported to repress Th2 differentiation and thus 
Th2 inflammation by inhibiting the Th2 transcription factor Gata3 in T cells. Apart 
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from being the key Th2 transcription factor, Gata3 has been identified to be 
essential for optimal Treg functional fitness. Since wild-type Tregs express 
Gata3, understanding the factors that regulate Gata3 expression in Tregs and 
prevent the transactivation of Th2 cytokines in Tregs has been an important 
question in the Treg field. The first aim therefore was to determine whether Bcl6 
regulation of Gata3 also operates in the Treg lineage and understanding how this 
regulation is crucial for Treg control of inflammatory Th2 responses. 
Repression of microRNAs has emerged as an important facet of Bcl6-
mediated gene regulation in T cells from studies of its role in Tfh cells. MiRNAs 
have been identified as critical players in T cell differentiation pathways and 
particularly in maintaining Treg lineage stability in inflammatory contexts. Hence, 
the second aim was to assess whether Bcl6 regulated specific miRNAs in the 
Treg lineage that can impact the Bcl6-deficient Treg phenotype and thereby 
affect Treg control of Th2 immune responses. MiRNA signatures are being 
developed as diagnostic markers for cancer detection. Hence, our third aim was 
to extend our findings of increased Bcl6 target miRNA (miR-21) in mouse models 
of Th2 inflammation to assess its relevance as a diagnostic biomarker for human 
Th2 diseases like asthma and eosinophilic esophagitis.  
Treg cells demonstrate considerable plasticity and remodeling in 
inflammatory contexts. Since the Bcl6-deficient mice exhibit Th2 inflammatory 
pathology, the Bcl6-deficient Treg phenotype, function and stability are likely to 
be modulated by the inflammatory milieu. Hence, the fourth aim focused on 
characterization of a Bcl6-deficient Foxp3 dual reporter mouse strain that allows 
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assessment of stability of Bcl6-deficient Treg phenotype. In addition to 
understanding the extent of remodeling contributed by the Th2 disease, we 
wanted to assess the effects from loss of Bcl6 specifically in the Treg lineage. 
Thus the fifth aim encompasses characterization of a Treg-specific conditional 
mutant mouse strain that could definitively differentiate the intrinsic role of Bcl6 in 
the Treg lineage and how much that impacts the overall pathology that develops 
in the Bcl6-deficient mice.  
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MATERIALS AND METHODS 
Mice  
Bcl6-deficient mice on a mixed C57BL/6-129Sv background have been 
previously described (Dent et al., 1998b; Dent et al., 1997). Bcl6-deficient mice 
were used between 5 and 10 weeks of age, and mice used were active and 
relatively healthy. Foxp3-gfp mice where an IRES element links GFP expression 
to the Foxp3 transcript were obtained from Jackson labs (strain B6.Cg-
Foxp3tm2Tch/J; Bar Harbor, ME). Bcl6-deficient mice were mated onto the 
Foxp3gfp background. Rag1-deficient, IL-10-deficient, Foxp3-gfp-cre (Foxp3cre), 
Foxp3-deficient (scurfy), Rosa26-YFP reporter and C57BL/6 congenic CD45.1+ 
(BoyJ) wild-type mice were obtained from Jackson labs. The wild-type BoyJ mice 
were also bred onto the Foxp3gfp background. Bcl6/Tcra double-deficient mice 
have been previously described (Toney et al., 2000). Wild-type and Bcl6-deficient 
Foxp3gfp mice were genotyped by PCR as previously described. Bcl6fl/fl mice 
were generated in the Indiana University School of Medicine (IUSM) Transgenic 
and Knockout facility. Bcl6fl/fl mice were mated to Foxp3cre mice to generate 
Bcl6fl/fl Foxp3cre mice. Mice were bred under specific pathogen-free conditions at 
the laboratory animal facility at IUSM and were handled according to protocols 
approved by the IUSM Animal Care and Use Committee.  
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Human patient samples 
The collection and analysis of control, EoE patient, asthma and Crohn’s disease 
patient samples were approved by the Institutional Review Board of Indiana 
University and required parental consent for samples from infants. Details on the 
patient populations have been described previously (Subbarao et al., 2011; 
Tepper et al., 2008). 
 
Murine helper T cell differentiation and Treg cell assays 
Naïve T cells (CD4+CD62L+) were purified from lymph nodes and spleen using 
magnetic beads (Miltenyi Biotech). Naïve CD4+ T cells (1x106 cells/ml in DMEM 
medium supplemented with 10% FCS (Atlanta Biologicals), 2 mM glutamine, 100 
units/ml Penicillin-Streptomycin, MEM non-essential amino acids, 25 mM HEPES 
and 55 µM 2-mercaptoethanol (Gibco) were activated with plate-bound anti-CD3 
(5 µg/ml; 145-2C11; BD Biosciences) and anti-CD28 (10 µg/ml; 37.51; BD 
Biosciences) and polarized under Th0 (with no added cytokines), Th1 (20 ng/ml 
IL-12 and 10 µg/ml anti-IL-4), Th2 (20 ng/ml IL-4 and 10 µg/ml anti-IFNγ), iTreg 
(5 ng/ml TGFβ, 10 µg/ml anti-IFNγ and 10 µg/ml anti-IL-4), Th17 (20 ng/ml IL-6, 5 
ng/ml TGFβ, 10 µg/ml anti-IFNγ and 10 µg/ml anti-IL-4), Th9 (10 ng/ml IL-4, 2 
ng/ml TGFβ, 10 µg/ml anti-IFNγ and 10 µg/ml anti-IL-4), Tfh (20 ng/ml IL-6, 20 
ng/ml IL-21, 10 µg/ml anti-IFNγ, 10 µg/ml anti-IL-4 and 10 µg/ml anti-TGFβ) 
differentiation conditions. After 5 days of culture, cells were re-stimulated with 
plate-bound anti-CD3 (10 µg/ml) for 12-16 hours prior to harvest. Recombinant 
mouse IL-4 was purchased from R&D Systems and Abs to CD3 and CD28 from 
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BD Biosciences. Recombinant human IL-2 was obtained from the Biological 
Resources Branch, Division of Cancer Treatment and Diagnosis, National 
Cancer Institute-Frederick Cancer Research and Development Center.  
 For Treg assays, CD4+CD25+ T cells were purified from wild-type and 
Bcl6-deficient Foxp3gfp mice using magnetic beads, followed by FACS sorting 
for pure GFP+ Tregs using FACSAria cell sorter (Becton Dickinson). The 
CD4+CD25- T cell fraction from magnetic bead isolation was used as responder T 
cells (Tresps). Antigen-presenting cells (APCs) were prepared from the spleens 
of Tcra-deficient mice. For Treg suppression assays, wild-type or Bcl6-deficient 
Tresps (50x103/well) were separately co-cultured with wild-type or Bcl6-deficient 
Tregs at different ratios as indicated along-with Mitomycin-C (20 µg/ml) treated 
APCs (50x103/well) plus anti-CD3 (2 µg/ml) or 10 µg/ml Ova for 72 hrs. Plates 
were pulsed with 1 µC of [3H] thymidine at 48 hrs of culture and cell proliferation 
in triplicate cultures was measured using a scintillation counter. 
 
Antibodies and FACS analysis 
Flow cytometry analysis of intracellular transcription factors and cytokines was 
performed by staining the cells with flourochrome-conjugated anti-Foxp3 (FJK-
16a; eBioscience), anti-Helios (22F6; BioLegend), anti-Gata3 (TWAJ; 
eBioscience) and anti-IL-4 (BD Biosciences) using the mouse Regulatory T cell 
staining kit (eBioscience). Cells were first stained with antibodies for the desired 
cell surface markers – CD4 (RM4-5; BD Biosciences) and CD25 (PC61.5; 
eBioscience), followed by permeabilization with Fixation/Permeabilization buffer 
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and intracellular staining in Permeabilization buffer. For the bone marrow 
chimera experiments, cells were stained for Treg markers (CD4, CD25) and 
CD45.1 (A20; BD Biosciences). For discrimination of GFP versus YFP signals in 
the BRFC mice, 510-nm/ 20-nm filters (505LP dichroic mirror, GFP) and 525-
nm/50-nm filters (535LP dichroic mirror, YFP) were used (Zhou et al., 2009c). 
For analysis of Tfh cells, spleen cells were stained for CD4 (RM4-5; BioLegend), 
CXCR5 (2G8; BD Biosciences), PD-1 (29F.1A12; BioLegend) and ICOS 
(7E.17G9; eBioscience) expression. GC B cells were stained for B220 (RA-3-
6B2; BioLegend), GL-7 (GL7; BD Biosciences) and CD95 (Jo2; BD Biosciences) 
and plasma cell were stained for CD138 (281-2; BD Biosciences). Flow analysis 
was performed on a FACSCalibur (4 color) and LSR 561 analyzer (7-8 color) and 
data analyzed using the FLOWJO software (Tree Star, Inc.). 
 
Induction of experimental colitis  
Un-fractionated CD4+ T cells (Tresps) (1x106) from Il10-deficient mice isolated 
using magnetic bead selection were adoptively transferred intra-peritoneally (i.p.) 
into Rag-deficient mice to induce a strong Th1-mediated colitogenic response in 
the recipients 4-8 wks post-transfer (Ostanin et al., 2009). Along with the transfer 
of Il10-deficient Tresps, two cohorts of Rag-deficient recipients were injected i.p. 
with FACS-sorted CD4+CD25+Foxp3+ Tregs (250x103) from Bcl6-deficient or 
wild-type Foxp3gfp mice. The recipient mice were monitored for signs of 
intestinal pathology and weight loss over a period of 4-5 wks, following which 
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mice were sacrificed to assess severity of colitis using the parameters of percent 
weight loss, changes in colon length and colon histology scores.  
Colon sections were stained with hematoxylin and eosin (H&E) and colitis 
severity was graded in a blinded fashion on a scale of 0-6 as described: 0 – 
Normal crypt architecture and occasional cell infiltration, 2 – Irregular crypt 
architecture and increasing number of cells in lamina propria (LP), 4 – Moderate 
crypt loss (10-50%) and confluence of cells extending to sub-mucosa, 6 – Severe 
crypt loss (50-90%) and transmural extension of infiltrate.  
 
Induction of experimental allergic airway inflammation 
Both wild-type B6 female mice (recipients) as well as the Bcl6-deficient and wild-
type Foxp3gfp mice (Treg donors) were sensitized intra-peritoneally (i.p.) with 
Ova (Sigma) adsorbed to alum (Sigma) at a dose of 20 µg Ova/2 mg alum on 
days 0 and 7 of the protocol (Chang et al., 2010). On day 14, CD4+CD25+Foxp3+ 
Tregs were FACS-sorted from Ova-sensitized Bcl6-deficient and wild-type 
Foxp3gfp mice and then injected i.p. (350 x 103 cells/mouse) into the sensitized 
wild-type B6 female recipients. After 3 hrs following immunization, recipient mice 
were then challenged intranasally with Ova for 5 consecutive days (100 µg/ day). 
Mice were sacrificed by i.p. injection of pentobarbital (5 mg/mouse) 48 hrs after 
the final intranasal challenge. The trachea was cannulated and lungs were 
lavaged three times with 1 ml PBS to collect the bronchoalveolar lavage (BAL). 
Cells recovered in BAL fluid and the lung mediastinal lymph nodes (MLNs) were 
counted with a hemocytometer. Eosinophils, neutrophils, T cells, B cells and 
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mononuclear cells in the BAL fluid were distinguished by cell size and by 
expression of CD3, B220, CCR3, CD11c and major histocompatibility complex 
class II, analyzed by flow cytometry as described (Chang et al., 2010; van Rijt et 
al., 2004). For quantitative PCR analysis, lung tissues were homogenized in a 
tissue lyser (Qiagen) and RNA isolated with an RNeasy kit (Qiagen) was used for 
synthesis of cDNA for subsequent analysis. Paraffin-embedded sections were 
stained with H & E for evaluation of the infiltration of inflammatory cells by light 
microscopy. 
 Airway hyper-reactivity to methacholine challenge was determined 24 hrs 
after the final intranasal challenge. Noninvasive unrestrained whole-body 
plethysmography (Buxco Research Systems) was used to record airway 
responsiveness with the dimensionless parameter 'enhanced pause' for 
estimation of total pulmonary resistance, an indicator of broncho-constriction. 
Mice were placed in whole-body plethysmographs and baseline measurements 
were recorded. Saline was administered by nebulization for 2 min, followed by 
increasing doses of methacholine, and the enhanced-pause parameter was 
recorded over 5 min. 
 
Generation of bone marrow chimeras 
Donor wild-type BoyJ (CD45.1+) and Bcl6-deficient (CD45.1–) mice on Foxp3gfp 
background and Foxp3-deficient mice were euthanized with CO2 asphyxiation 
and cervical dislocation, and femurs and tibias were removed aseptically. Bone 
marrow (BM) was flushed with DMEM complete media. Recipient Rag-deficient 
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mice were sub-lethally irradiated (350 Gy) 16-24 hrs prior to re-constitution. The 
recipients were then reconstituted with wild-type and Foxp3KO BM (WT:Foxp3KO 
chimeras), Bcl6-deficient and Foxp3KO BM (KO:Foxp3KO chimeras) or wild-type 
and Bcl6-deficient Foxp3gfp BM (WT:KO chimeras) (10x106) by intravenous 
injections (i.v.). Flow analysis was performed to assess satisfactory reconstitution 
of the lymphocyte and myeloid compartments after 4-5 months. Mice were 
immunized with OVA/Alum i.p. two weeks prior to FACS sorting of the wild-type 
(CD45.1+) and Bcl6-deficient (CD45.1–) CD25+Foxp3+ (Tregs) and CD25-Foxp3- 
(Tconv) cells for quantitative PCR analysis. 
 
Affymetrix Microarrays and qRT-PCR 
Total RNA was extracted from FACS-sorted CD4+CD25+Foxp3+ Tregs from Bcl6-
deficient and wild-type Foxp3gfp mice following 16 hr activation in vitro with 
plate-bound anti-CD3 (5 µg/ml) and anti-CD28 (10 µg/ml) using the RNeasy Mini 
kit, according to the manufacturer’s protocol (Qiagen). The microarray studies 
were carried out using the facilities of the Center for Medical Genomics at 
Indiana University School of Medicine which process the samples employing the 
protocols recommended by Affymetrix in their GeneChip® Expression Analysis 
Technical Manual (Affymetrix, Santa Clara, CA). Biotinylated cRNA was 
hybridized to Affymetrix GeneChip Mouse Genome 430 2.0 arrays. Data analysis 
was performed using the MeV software.  
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 To validate the expression array data, qPCR was performed on 
independently prepared Tregs from Bcl6-deficient and wild-type Foxp3gfp mice. 
PCR primer sequences are listed in Table 1. 
 
Gene expression analysis 
Total cellular RNA was prepared using the Trizol method (Life Technologies) and 
cDNA prepared with the Transcriptor First Strand cDNA synthesis kit (Roche). 
Quantitative PCR reactions were run by assaying each sample in triplicates using 
the Fast Start Universal SYBR Green Mix (Roche Applied Science) with a 
Stratagene Mx3000P Real-Time QPCR machine. Samples with limiting RNA 
were assessed for gene expression using Taqman assays (ABI). Levels of 
mRNA expression were normalized to β-tubulin mRNA levels, and differences 
between samples analyzed using the ΔΔCT method. PCR primer sequences and 
Taqman assay IDs are listed in Table 1.  
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Genes Taqman assay IDs 
Tubb5 Mm00495804_m1 
Spry1 Mm00839969_g1 
Pten Mm00477208_m1 
Pdcd4 Mm01266062_m1 
Btg2 Mm00476162_m1 
Il12a Mm00434169_m1 
miR-21 000397 
miR-22 000398 
miR-146b 002453 
miR-16 002489 
U6 001973 
sno202 001232 
sno234 001234 
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 Genes SYBR Green PCR primer sequences 
β-tub F: 5’-CTGGGAGGTGATAAGCGATGA-3’ 
R: 5’-CGCTGTCACCGTGGTAGGT-3’ 
Foxp3 F: 5’-CCCTGCCCTTGACCTCAA-3’ 
R: 5’-GCCTCAGTCTCATGGTTTTGG-3’ 
Il4 F: 5’-ACAGGAGAAGGGACGCCAT-3’ 
R: 5’-GAAGCCCTACAGACGAGCTCA-3’ 
Il5 F: 5’-GCAGCTGGATTTTGGAAA-3’ 
R: 5’-GTGGCTGGCTCTCATTCACA-3’ 
Il13 F: 5’-CGCAAGGCCCCCACTAC-3’ 
R: 5’AAAGTGGGCTACTTCGATT-3’ 
Il10 F: 5’-GGTTGCCAAGCCTTATCGGA-3’ 
R: 5’-ACCTGCTCCACTGCCTTGCT-3’ 
Tgfβ1 F: 5’-GCAGTGGCTGAACCAAGGA-3’ 
R: 5’-AGCAGTGAGCGCTGAATCG-3’ 
Gzmb F: 5’-CCCAGGCGCAATGTCAAT-3’ 
R: 5’-CCCCAACCAGCCACATAGC-3’ 
Ccr8 F: 5’-TGTGGCTGGCTGCTGTCA-3’ 
R: 5’-TCAGAGGCCACTTGGTAAAAAAC-3’ 
Tnfα F: 5’-CACAAGATGCTGGGACAGTGA-3’  
R: 5’-TCCTTGATGGTGGTGCATGA-3’ 
Gata3 F: 5’-GAAGGCATCCAGACCCGAAAC-3’  
R: 5’-ACCCATGGCGGTGACCATGC-3’ 
Ifnγ F: 5’-TCAAGTGGCATAGATGTGGAAGAA-3’ 
R: 5’- TGGCTCTGCAGGATTTTCATG-3’ 
Smad7 F: 5’ - CAGCACTGCCAAGCATGGT-3’ 
R: 5’- ACCGAAACGCTGATCCAAAG-3’ 
Bcl6 F: 5’ - GAAGACCCACACTCGAATTCACT-3’ 
R: 5’- CCCCACAGGTTTCACATTTGT-3’ 
Table 1: Taqman probe IDs and SYBR Green Primer sequences 
used for quantitative real time-PCR.  
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Retroviral transductions 
Naïve T cells (CD4+CD62L+) prepared from wild-type C57BL/6 or Stat6-deficient 
mice using magnetic beads were activated in vitro with plate-bound anti-CD3 (5 
µg/ml) and anti-CD28 (10 µg/ml) for 24 hrs. Cells were then transduced by spin 
infection with bicistronic retroviral vector (RV) supernatants encoding Bcl6 and 
H2Kk or Gata3 and hCD4 (Chang et al., 2005; Kusam et al., 2003). Naïve T cells 
activated similarly under Th0 and Th2 differentiation conditions were infected 
with retroviral supernatant encoding miR-21 and H2Kk. Wild-type Treg cells were 
similarly transduced with retroviral supernatant encoding miR-21 and H2Kk. 
Second or third day following transduction, cells infected with H2Kk RVs were 
stained with biotin-anti-H2Kk and streptavidin-APC, while those infected with 
hCD4 RVs were stained for anti-hCD4-PE and then FACS-sorted based on APC 
or PE expression, respectively. The sorted RV+ T cells were re-stimulated in vitro 
with anti-CD3 and anti-CD28 for 4-6 hrs for gene expression analysis or 
overnight for cytokine measurements. 
 
Reporter assays 
Jurkat T cells (10x106 cells/250ul) were electroporated as described (Vasanwala 
et al., 2002) in serum-free RPMI 1640 medium with an IL-5 promoter-driven 
luciferase reporter vector or Foxp3 promoter (10 µg) along with expression 
constructs (10 µg) for CXN, CXN-Gata3, CXN-Bcl6 or CXN-Gata3 plus CXN-Bcl6 
at the concentrations listed. Similarly, wild-type Foxp3 promoter-driven luciferase 
reporter vector and a mutated version (with the two GATA sites deleted) was 
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tested in Jurkat T cells with titrations of CXN-Gata3 (0-10 µg). After 
electroporation, cells were re-suspended in RPMI media supplemented with 10% 
FCS and rested overnight. For experiments with co-transfection of full-length, 
SB1 and SB2 miR21 promoter constructs (1 µg) and expression constructs for 
CXN or CXN-Bcl6 (1 µg), 1x106 cells Jurkat T cells were transiently transfected 
with X-tremeGENE HP DNA transfection reagent (Roche), according to the 
manufacturer’s protocol. Luciferase measurements were performed 24 hrs after 
transfection following 6 hr activation of cells with PMA (10 ng/ml) and Ionomycin 
(0.3 µM) using Luciferase Assay System (Promega).  
 
MicroRNA profiling and qRT-PCR assessment of microRNAs 
RNA was extracted from FACS-sorted CD4+CD25+Foxp3+ Tregs from wild-type 
and Bcl6-deficient Foxp3gfp mice following 16 hr activation in vitro with anti-CD3 
(5 µg/ml) and anti-CD28 (10 µg/ml) using MiRNeasy Mini kit, according to 
manufacturer’s protocol (Qiagen). The quality of the total RNA was verified by an 
Agilent 2100 Bioanalyzer profile. Total RNA (140 ng) was tagged with fluorescent 
label. The samples were hybridized to the miRCURY™ LNA array version 11.0 
(Exiqon, Denmark), which contains capture probes targeting all miRNAs for 
human, mouse or rat registered in the miRBASE version 13.0 at the Sanger 
Institute.  
 Validation of the differentially expressed microRNAs from the microarray 
dataset, assessment of microRNA expression profile of the total lungs and 
esophageal biopsies as well as from mouse and human serum was performed 
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using TaqMan microRNA assays (Applied Biosystems), according to the 
manufacturer’s protocol. Normalization was performed using sno202, sno234 
and U6 as controls, with U6 as the sole control for samples with limiting RNA. 
Quantitative real-time PCR was performed by assaying each sample in 
triplicates, including no-template controls, on a Stratagene Mx3000P real-time 
PCR system. Relative expression was calculated using the delta-delta CT (ddCT) 
method, as previously described.     
 
Cloning of mmu-microRNA-21 and miR-21 reporter vectors 
The miR-21 gene representing the primary transcript (~300 bp) was PCR 
amplified from mouse genomic DNA and cloned into retroviral vector co-
expressing H2Kk via EcoRI (restriction enzyme). The microRNA is expressed as 
a partial-primary microRNA transcript, transcribed from the retroviral LTR. 
F (miR-21): 5’-AATT-GAATTC-GGTACC-TTGGCATTAAGCCCCAGCAAACC-3’ 
R (miR-21): 5’-AATT-GAATTC-TCCAAGTCTCACAAGACATAAGGACC-3’ 
Full-length mouse miR-21 promoter region was PCR amplified from mouse 
genomic DNA and was inserted using Mlu-I and Xho-I restriction enzyme sites 
into the pGL3-basic vector (Promega). SB1 and SB2 mutations in the miR-21 
promoter region were created by insertion of restriction enzyme sites in the 
respective STAT/Bcl6 binding site by amplifying with mutated primer sequences, 
followed by insertion into the pGL3-basic vector. Primer sequences listed in table 
2. All constructs were sequenced prior to their application to confirm construct 
integrity.  
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MIR21 
PROMOTER 
CONSTRUCTS 
PRIMER SEQUENCES 
Full-length 
promoter 
Full-length Forward: 
5’-AAAAAA ACGCGT GGT TTT GTG GCA AGG TCT CCG 
TGT-3’ 
 Full-length Reverse: 
5’-AAAAAA CTCGAG TGT CAG GAG GGC GAG GCT 
AGT GCA-3’ 
SB1-mutated 
promoter 
SB-mut1 Forward: 
5’-TTAA ACCAG TTCTT GAATT CACTA GTGGT GATAA 
ATGTG GGACT TCTCA GAAGT CATTC ATTTT-3’ 
SB-mut1 Reverse: 
5’-AAAAT GAATG ACTTC TGAGA AGTCC CACAT 
TTATC ACCAC TAGTG AATTC AAGAA CTGGT TTAA-3’ 
SB2-mutated 
promoter 
SB-mut2 Forward: 
5’-TTAA ACCAG TTCTT ACAGG AACTA GTGGT GATAA 
ATGTG GGACT TAGGC CTAGT CATTC ATTTT-3’ 
SB-mut2 Reverse: 
5’-AAAAT GAATG ACTAG GCCTA AGTCC CACAT 
TTATC ACCAC TAGTT CCTGT AAGAA CTGGT TTAA-3’ 
Table 2: Primer sequences for miR-21 promoter reporter constructs 
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Overexpression and inhibition of miR-21 
Naïve T cells activated under Th0 conditions (with nothing added) were treated 
with 1 µM control (scrambled oligo), miR-21 mimic (double stranded RNA oligo) 
and antagomiR (single stranded DNA oligo) (Exiqon). The oligos were 
cholesterol linked that enabled efficient delivery into cells, without the need of 
any transfection protocol. Gene expression was assessed 12-16 hrs following 
treatment. For assessment of cytokine productions, cells were treated with the 
oligos over a 5-day period, following which the cultures were re-stimulated with 
anti-CD3 (10 µg/ml) overnight to obtain cell-free supernatants for ELISA. 
 
In situ hybridization 
In situ hybridizations were performed in 8 µM cryosections from lungs of mice in 
the airway inflammation experiment using the miRCURY LNA microRNA ISH 
Optimization kit 2 (miR-21), according to the manufacturer’s protocol (Exiqon). In 
brief, the FFPE slides were rinsed and digested with Proteinase K for 12 mins at 
37οC. After protease digestion, the digoxin-labeled LNA-scrambled control probe 
and LNA miR-21 antisense probe (Exiqon) were hybridized to the slides at 52οC 
for 6 hrs. Following post-hybridization washes with SSC buffer at 47οC, 100 µl of 
rabbit anti-digoxin (Sigma-Aldrich) Ab, diluted 1/2000 was applied to the slides 
for 1 hr at room temperature. The slides were rinsed and then incubated with 100 
ul anti-rabbit alkaline phosphatase and TNBS substrate for 2 hr at 30οC. Slides 
were counterstained with Nuclear Fast Red (Polyscientific), coverslipped, and 
mounted for viewing. 
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Assessment of myocarditis 
Heart sections from Bcl6neofl/neoflFoxp3cre and Bcl6neofl/neofl mice were stained with 
hematoxylin and eosin (H&E) and severity of myocarditis was graded in a blinded 
fashion on a scale of 0-4 as described: 0 – No cell infiltration, 1 – Sparse cell 
infiltration, 2 – Small foci of cell infiltration, 3 – Large foci of cell infiltration and 
moderate loss (10-50%) of architecture, 4 – Massive cellular infiltration and 
severe loss (50-90%) of myocardial architecture. 
 
Cytokine secretion analysis 
Cytokines were measured from 24 hr activated cell-free supernatants by ELISA. 
IL-4, IL-5, IFNγ and IL-17 ELISA reagents were purchased from BD Biosciences; 
IL-13 reagents purchased from R&D systems. To test for cytokine secretion, 100 
µl/well of 1:500 dilution of the capture antibody in Coating Buffer was used to 
coat a 96 well immunosorbent plate (Thermo Scientific). Plates were sealed and 
incubated overnight at 4ο C and then washed three times next day in ELISA wash 
buffer (PBS with 0.05% Tween-20). Plates were next blocked with 200 µl/well 
Assay Diluent (PBS with 10% FBS) for minimum 2 hours at room temperature. 
Cytokine standards, sample supernatants and controls diluted in Assay Diluent 
(100 µl/well) were added and incubated for 2 hours at room temperature or 
overnight at 4ο C. Plates were washed five times in ELISA wash buffer and 100 
µl/well of Working Detector (1:500 dilution of Detection antibody and 1:250 
dilution of Avidin-HRP reagent) was incubated for 1 hour at room temperature. 
Plates were washed seven times in ELISA wash buffer and 100 µl/well of 
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Substrate Solution (Tetramethybenzidine, TMB and Hydrogen Peroxide) was 
incubated for 5-30 mins at room temperature in dark and cytokine levels were 
determined following addition of 50 µl/well of Stop Solution (2N H2SO4) by 
measuring the absorbance at 415 nm (BIO-RAD iMarK Microplate Reader).  
The concentration of IL-4, IL-5, IL-13, IFNγ and IL-17A in samples with 
limiting cytokine levels was measured by multiplex analysis with the Milliplex 
MAP Kit according to the manufacturer's protocol (Millipore) (Chang et al., 2010). 
Cytokine concentrations were calculated with Bio-Plex Manager 2.3 software with 
a five-parameter curve-fitting algorithm applied for standard-curve calculations. 
 
Statistical analysis 
p values were calculated using Students’ T-test or One-way analysis of variance 
with Tukey’s post test (for multiple sample comparisons). All calculations were 
done using GraphPad Prism software. A p value < 0.05 was considered to show 
a significant difference. 
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RESULTS 
Part I: Bcl6 limits the Th2 inflammatory activity of Treg cells by the control 
of Gata3 function  
T cell-dependent spontaneous autoimmune disease in Bcl6-deficient mice  
Approximately 80% of the Bcl6-deficient mice develop spontaneous Th2-
type inflammatory disease, commonly manifested as severe myocarditis and 
frequently accompanied by pulmonary vasculitis (Figure 4) and most of these 
mice die by 6-12 weeks of age (Dent et al., 1998a; Dent et al., 1997; Ye et al., 
1997). Although the disease severity correlates well with the observed growth 
retardation (nearly one-third or half the body weight of wild-type littermates) and 
the apparent moribund phenotype of the Bcl6-deficient mice, a small percentage 
(~10-20%) of these mice appear grossly normal and display relatively mild 
inflammation in heart and/or lungs when assessed by histology. The 
inflammation is complex in nature, with infiltration of cells from both the lymphoid 
and myeloid compartments - T cells, macrophages and granulocytes, mainly 
eosinophils (Toney et al., 2000; Yu et al., 2005). In addition to the eosinophilic 
infiltration, the infiltrating T cells in the lesions predominantly produce the 
hallmark Th2 cytokines (IL-4, IL-5 and IL-13), demonstrating the Th2-bias of the 
inflammation (Dent et al., 1997). To assess the role of T cells in the inflammatory 
disease, Bcl6/Rag double-deficient and Bcl6/Tcrα double-deficient mice were 
bred and examined for signs of the hyper-Th2 inflammatory disease (Table 3). 
Absence of inflammation in Bcl6/Tcra double-deficient mice highlights a key role 
for αβ-T cells in mediating this spontaneous inflammation.  
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Mouse Strain Rate of Myocarditis 
Rate of Pulmonary 
Vasculitis 
Bcl6-deficient 7/8 5/5 
Bcl6/Rag 
double-deficient 
0/4 0/4 
Bcl6/Tcrα 
double-deficient 
0/8 0/8 
Figure 4: Spontaneous myocarditis and pulmonary vasculitis that 
develops in Bcl6-deficient mice. 
Heart (Left) and lung (Right) histology as assessed by hematoxylin & eosin 
(H& E) staining of sections.  
Table 3: Histological assessment of frequency of myocarditis and 
pulmonary vasculitis in Bcl6-deficient mice on different genetic 
backgrounds. 
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Inflammatory disease in Bcl6-deficient mice is reminiscent of pathology in 
mice with defects in Treg cell lineage  
The disease in Bcl6-deficient mice is spontaneous in nature, T cell-
dependent and resembles the pathology in mice with Treg defects. Mice lacking 
genes critical for Treg phenotype and suppressor function (Foxp3, Ctla-4, 
TGFβ1) develop spontaneous autoimmune diseases owing to reduced Treg 
numbers or altered function. Foxp3-deficient or scurfy mice succumb to a 
spontaneous T cell-dependent multi-organ autoimmune pathology manifested as 
diabetes, thyroiditis, hemolytic anemia, hyper-IgE syndrome, dermatitis, 
splenomegaly, lymphadenopathy and cytokine storm (Brunkow et al., 2001; 
Godfrey et al., 1994; Wildin et al., 2001). Ctla-4-deficient mice develop an 
aggressive lympho-proliferative disease manifested as splenomegaly, 
lymphadenopathy, pancreatitis and myocarditis (Tivol et al., 1995). Similarly, 
TGFβ1-deficient mice develop wasting disease by 1-2 weeks of age and 
inflammatory lesions in many organs, primarily the heart and lungs (Kulkarni and 
Karlsson, 1993). Thus, reminiscent of the pathologies noted above, the 
inflammatory disease in Bcl6-deficient mice may have an autoimmune 
component and could be ascribed to defective Treg cell numbers or activity. The 
only difference is that unlike the systemic and multi-organ nature of the pathology 
noted in Foxp3-deficient, CTLA-4-deficient and TGFβ1-deficient mice, the 
disease in Bcl6-deficient mice is restricted to the heart and the lungs. More 
recent studies demonstrate that Tregs deficient in key effector transcription 
factors like T-bet, IRF4 and STAT3 exhibit selective defects in control of Th1, 
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Th2 and Th17-type inflammatory conditions. T-bet-deficient Tregs fail to control 
Th1 responses during Mycobacterial infection (Koch et al., 2009), mice with 
IRF4-deficient Tregs develop Th2-driven inflammation in pancreas, stomach and 
lungs (Zheng et al., 2009) while mice with Stat3 deletion in Tregs succumb to a 
Th17-mediated intestinal pathology (Chaudhry et al., 2009). Considering that the 
pathology in the absence of Bcl6 is mainly Th2-biased (Dent et al., 1997), this 
may indicate that the deletion of Bcl6 results in a partial defect in Treg function, 
that manifests as a restricted heart and lung-specific pathology. Thus, Bcl6 may 
be important to regulate a sub-function of Tregs and their ability to control the 
Th2-arm of the immune response.  
 
Bcl6 deficiency does not alter the Treg cell compartment 
We initially analyzed the composition of the Treg compartment in the Bcl6-
deficient mice. CD4+CD25+ T cells from the spleen and lymph nodes of wild-type 
and healthy Bcl6-deficient mice were stained for Foxp3 expression, and 
assessed by flow cytometry. As shown in Figure 5A, we did not observe any 
obvious difference in the percentage of CD4+CD25+Foxp3+ Tregs in both types of 
mice. This is consistent with other reports showing that Bcl6 is dispensable for 
Treg cell development (Yu et al., 2009). Additionally, we tested if induced Treg 
(iTreg) development was intact in the absence of Bcl6, by staining 
CD4+CD25+Foxp3+ T cells for Helios expression. Helios, an Ikaros family 
transcription factor is preferentially expressed by thymically-derived nTregs, 
thereby differentiating iTregs as Helios-CD4+CD25+Foxp3+ T cells (Getnet et al., 
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2010; Thornton et al., 2010), although some recent reports have raised concerns 
about its validity as an nTreg marker (Akimova et al., 2011; Getnet et al., 2010; 
Gottschalk et al., 2012; Verhagen and Wraith, 2010; Zabransky et al., 2012). 
Nevertheless, we noted normal percentages of Helios-CD4+CD25+Foxp3+ T cells 
in Bcl6-deficient mice as their wild-type counterparts (Figure 5B). In vitro 
differentiation of naïve T cells to iTregs following treatment with TGFβ is reported 
to be defective with Bcl6-deficient T cells (Nurieva et al., 2009). This may be 
attributed to the intrinsic Th2 bias of Bcl6-deficient T cells that antagonistically 
inhibits iTreg differentiation in vitro. The induced Treg subset is essential for 
control of Th2 inflammatory responses at mucosal sites in mice as they age 
(Josefowicz et al., 2012b). However, the pathology noted in Bcl6-deficient mice 
develops at an early age and is specific to the heart and lungs and not observed 
at mucosal environments. Thus, the pattern of pathology and the data with Helios 
as an nTreg marker can rule out potential defects in iTregs contributing to the 
disease in Bcl6-deficient mice. 
 A B 
Figure 5: Treg numbers remain intact in the absence of Bcl6.  
Analysis of Treg cell compartment in the peripheral lymphoid organs of Bcl6-
deficient (KO) mice (black bars) and their wild-type (WT) littermates (white 
bars). The frequency of CD4+CD25+Foxp3+ Tregs (A) and Helios-
CD4+CD25+Foxp3+ (iTregs) (B) was quantified by flow analysis. N = 3 per 
group (p=0.30 (NS) for CD4+CD25+Foxp3+ T cells and p=0.67 (NS) for iTregs. 
NS = non-significant (p > 0.05, Student’s t-test). 
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Bcl6-deficient Tregs lack anergy, but are competent at suppressing T cell 
proliferative responses in vitro 
Since there was no apparent defect in Treg numbers in the absence of 
Bcl6, our next step was to perform a detailed characterization of the Bcl6-
deficient Treg phenotype and function. Treg function is classically assessed in 
vitro using a standard Treg suppression assay, wherein Tregs and responder T 
cells (Tresps) are cultured at varying ratios, in the presence of soluble anti-CD3 
and mitomycin-treated APCs. Our initial attempts to isolate Tregs for these 
assays involved using magnetic bead-based separation kits to isolate 
CD4+CD25+ Tregs from the spleen and lymph node preparations of wild-type and 
Bcl6-deficient mice. Bcl6-deficient Tregs derived from such preparations showed 
a striking segregation in suppressor function, based on the disease severity. 
Thus, Tregs isolated from the healthy Bcl6-deficient mice retained normal 
suppressor function, while Tregs derived from sick Bcl6-deficient mice (assessed 
by growth retardation and organ histology) were severely defective in controlling 
T cell proliferative responses in vitro (Figure 6A). This suggested that the 
magnetic bead-based isolation strategy allows purification of Tregs based on 
CD25 expression and does not control for the percentage of Foxp3+ cells within 
the CD25+ fraction. Any contaminating CD25+Foxp3- activated effector T cells in 
the preparations can interfere with the suppression activity of Tregs. Moreover, 
Bcl6-deficient mice are already well-characterized to have an abundance of 
spontaneously activated Th2 cells due to the ongoing Th2 inflammatory disease 
(Dent et al., 1997). Thus, the higher proportion of contaminating effectors in the 
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Treg preparations from the sick Bcl6-deficient mice can compromise their activity. 
This impairment in their function was potentially due to the inflammatory 
cytokines secreted by the contaminating effector Th2 cells (Goodman et al., 
2011; Pace et al., 2005; Pasare and Medzhitov, 2003). Indeed, consistent with 
reports in the literature wherein pro-inflammatory T cell effector cytokines (IL-4 
and IL-6) inhibit Treg suppressor function in various disease settings, we noted 
reduced suppressor function of wild-type Tregs when treated with these 
inflammatory cytokines (Figure 6B). On the other hand, IL-2 augmented Treg 
function (Barron et al., 2010), which fits with the reported role for this cytokine in 
maintaining Treg homeostasis and functional fitness (Figure 6B).    
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Figure 6: Treg function modulated by inflammatory cytokines in Bcl6-
deficient mice. 
(A) CD4+CD25+ Tregs were isolated from wild-type (WT) and 2 healthy (KO1 
& KO2) plus 2 sick (KO3 & KO4) Bcl6-deficient mice using MACS beads. 
Tregs were co-cultured with WT Tresp (CD4+CD25-) T cells induced by 
stimulation with mitomycin C-treated spleen cells plus 2 µg/ml α-CD3.           
(B) WT CD4+CD25+ Tregs were co-cultured with WT Tresp (CD4+CD25-) T 
cells in the presence of IL-2 (100 units/ml), IL-4 (50 ng/ml) and IL-6 (20 ng/ml) 
along-with mitomycin-C treated APCs plus 2 µg/ml α-CD3.            
For both (A) and (B), wells were pulsed on day 2 of the assay with tritiated 
thymidine and harvested on day 3. Results shown are normalized proliferation. 
Results representative of 2 independent experiments.   
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Therefore, in order to obtain pure CD25+Foxp3+ Tregs for functional 
analysis, we bred the Bcl6-deficient mice onto the Foxp3-gfp knock-in 
background. Foxp3-gfp mice have an IRES-linked green fluorescent protein 
(GFP) tagged in the endogenous Foxp3 locus, such that transcription of Foxp3 
coincides with that of GFP. Bcl6-deficient mice bred on this background develop 
the characteristic heart and lung-specific Th2 inflammation as the germ-line Bcl6-
deficient mice and thus these mice have been used to sort pure CD25+Foxp3+ 
Tregs, based on GFP expression for the subsequent studies (Figure 7). Two 
recent studies have reported that a previously described Foxp3gfp reporter strain 
in which the GFP is fused to the N-terminal region of Foxp3 is an hypomorph, 
leading to the development of spontaneous autoimmune pathologies (Bettini et 
al., 2012; Darce et al., 2012). However, the Foxp3gfp reporter used in our study 
is a different strain with a bi-cistronic contruct of IRES linking Foxp3 and GFP, 
thus leaving Foxp3 expression intact. Thus, any potential deviation from the 
hallmark Treg phenotype and function noted on the Bcl6-deficient background is 
unlikely to be attributable to the inherent defects in the reporter strain.  
 
 
 
 
CD4+CD25+FOXP3+ 
BCL6 WT/KO  
FOXP3gfp mice  
FACS 
GFP+ 
CD4+CD25+ 
C
D
4 
CD25 
Figure 7: Schematic for isolation of pure CD4+CD25+Foxp3+ Tregs using 
Foxp3-gfp reporter mouse model. 
CD4+CD25+ T cells from the spleen and lymph node preparations of wild-type 
(WT) and Bcl6-deficient (KO) mice on the Foxp3gfp knock-in background are 
isolated using magnetic bead isolation. These cells are further sort purified 
using GFP expression to isolate highly pure CD4+CD25+Foxp3+ Tregs (~95-
99% pure), for functional analysis.  
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 An important feature of Treg cells is their inability to produce IL-2 and 
proliferate in response to TCR stimulation; this anergic phenotype is essential for 
maintaining immune homeostasis (Thornton and Shevach, 1998; Walker, 2004). 
We analyzed the proliferative potential of the pure FACS sorted CD25+Foxp3+ 
Bcl6-deficient and wild-type Foxp3-gfp Tregs following stimulation with anti-CD3 
and anti-CD28. Bcl6-deficient Tregs display a consistent hyper-proliferative 
phenotype compared to their wild-type counterparts (Figure 8). Since Bcl6-
deficient mice have pronounced Th2-differentiation and high levels of IL-4 that is 
known to negatively impact Treg phenotype and function, we also examined Treg 
proliferation using an IL-4 blocking antibody. Although there was a slight 
reduction in proliferation of both wild-type and Bcl6-deficient Tregs with blocking 
IL-4 antibody, Bcl6-deficient Tregs still displayed a hyper-proliferative phenotype 
(Figure 8). This may imply an intrinsic role for Bcl6 in regulating Treg activation 
following TCR stimulation.  
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Figure 8: Bcl6-deficient Tregs lack anergic phenotype in vitro. 
Purified CD4+CD25+Foxp3+ Tregs were FACS sorted from wild-type (WT) and 
Bcl6-deficient (KO) Foxp3-gfp mice and activated in vitro with 5 α-CD3 and 2 
α-CD28 Abs with and without α-IL-4 (10 µg/ml). Wells were pulsed on day 2 of 
the assay with tritiated thymidine and harvested on day 3. Cell proliferation 
was determined based on thymidine incorporation. Similar results were 
observed in 2 independent experiments. 
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We then tested the functionality of the FACS-sorted CD25+Foxp3+ Bcl6-
deficient and wild-type Foxp3-gfp Tregs using the standard in vitro Treg 
suppression assay. We found that Bcl6-deficient Tregs consistently displayed 
enhanced capacity to suppress wild-type T cell proliferation compared to wild-
type Tregs at both the ratios of Tregs/Tresps tested (1:2 and 1:4) (Figure 9A). In 
certain contexts, Treg cells fail to function due to cytokine-mediated resistance 
acquired by responder T cells towards Treg suppression (Walker, 2009). In 
addition, similar to the hyper-proliferative phenotype of Bcl6-deficient Tregs, 
conventional CD25- T cells (Tresps) from Bcl6-deficient mice also exhibit a 
several fold-increase in proliferative potential than their respective wild-type 
counterparts (Figure 9B). Interestingly, Bcl6-deficient Tregs were also capable of 
suppressing the increased proliferation of Bcl6-deficient CD4+CD25- (Tresps) 
comparable to wild-type Tregs (Figure 9C), thus demonstrating that Bcl6-
deficient Tresps were not resistant to Treg-mediated suppression. Thus, these in 
vitro experiments indicate that despite lacking an anergic phenotype, Bcl6-
deficient Foxp3+ Tregs retain intact suppressor function in vitro. Intact in vitro 
suppressor function of Bcl6-deficient Tregs was also recently demonstrated by 
another group (Chung et al., 2011), which concurs with our results. However, this 
group used CD4+CD25+ Tregs, which as we have noted above are a mixed 
population containing activated Foxp3- Th2 effectors. Thus, our results using 
Tregs from Foxp3-gfp mice provide a more refined analysis of the intact 
functional potency of Bcl6-deficient Tregs in vitro.  
 
	   100 
 
 
 
 
 
 
 
 
Figure 9: Bcl6-deficient Tregs retain intact suppressor function in vitro. 
(A) Suppression of wild-type T cell proliferative responses by 
CD4+CD25+Foxp3+ Tregs sorted from Bcl6-deficient (KO) (black bars) and wild-
type (WT) (white bars) Foxp3-gfp mice following co-culture with wild-type CD25-
Foxp3- (Tresps) cells (grey bar) at different ratios (Treg/Tresp ratios - 1:2 and 
1:4).  
(B) Proliferation of MACS isolated Bcl6-deficient (KO) (black bar) and wild-type 
(WT) (white bar) CD4+CD25- T cells (Tresps) following stimulation with anti-CD3 
for 72 hrs.        
(C) Suppression of Bcl6-deficient T cell proliferative responses by 
CD4+CD25+Foxp3+ Tregs sorted from Bcl6-deficient (KO) (black bars) and wild-
type (WT) (white bars) Foxp3-gfp mice following co-culture with Bcl6-deficient 
CD25-Foxp3- (Tresps) cells (grey bar) (Treg/Tresp ratio-1:2).  
Proliferation in the above assays was assessed as [H3] thymidine incorporation. 
Data plotted as percent proliferation is representative of three independent 
experiments (mean and s.e.m. of triplicate cultures)                                 
*p<0.05, ***p<0.001, ****p<0.0001 (One-way analysis of variance)  
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Treg function in vitro does not often correlate with their role in vivo 
In vitro functional assays wherein the Tregs are in close proximity to the 
APCs and responder T cells may not simulate the setting with pathogenic T cells 
in vivo and thereby have led to discrepancies in interpreting functional potency of 
Tregs in a variety of disease models. The Treg functional capacity in vivo is 
largely determined by appropriate localization and migratory behavior (Siegmund 
et al., 2005). Tissue-specific inflammatory diseases in mice lacking specific 
chemokine receptors (CCR4, CCR7) or adhesion molecules (LFA-1), despite the 
intact Treg functional competency in vitro, highlights the importance of 
appropriate localization of Tregs in their ability to prevent autoimmunity 
(Schneider et al., 2007; Wohler et al., 2009; Yuan et al., 2007). In addition to the 
homing requirements, the in vivo inflammatory milieu also impacts the Treg 
functional competency. The fact that the Treg transcriptional program is not 
permanently fixed and that Foxp3 gets destabilized under inflammatory settings 
to allow more regulatory flexibility complicates the situation in vivo (Zhou et al., 
2009b; Zhou et al., 2009c). Studies in vitro assessing the functional efficacy of 
Bcl6-deficient Tregs have revealed enhanced functional competency compared 
to their wild-type counterparts, indicative of no intrinsic functional defect. 
However, the fact that the Bcl6-deficient mice still exhibit pronounced Th2 
inflammatory disease of the heart and lungs suggests that a different scenario 
exists in vivo. Therefore, we tested the functional potency of Bcl6-deficient Tregs 
to control systemic and organ-specific Th1 and Th2 diseases using well-
characterized mouse models of inflammation.  
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Bcl6-deficient Tregs are competent at suppressing Th1-mediated 
colitogenic inflammation in vivo 
We tested the ability of CD4+CD25+Foxp3+ Bcl6-deficient Tregs to 
suppress Th1 inflammation in vivo in a T cell transfer model of colitis established 
following adoptive transfer of IL-10-deficient CD4+ T cells into Rag1-deficient 
mice (Ostanin et al., 2009) (Figure 10). IL-10 is critical for gut homeostasis and 
IL-10-deficient mice develop spontaneous enterocolitis due to abnormal immune 
response to enteric antigens within 2-3 mos. of age (Paul et al., 2012). The 
disease pathology in this model resembles human inflammatory bowel disease 
histologically, physiologically and biochemically. Thus, transfer of IL-10-deficient 
CD4+ T cells into immune-deficient recipients provokes a strong Th1-mediated 
colitogenic inflammation 4-8 wks post T cell transfer. This is associated with the 
characteristic signs of colitis: wasting disease, shortening and thickening of the 
colon due to the robust inflammation and infiltration of leukocytes, particularly, 
Th1 cells and their cytokine and chemokine products.  
Figure 10: Schematic for testing Treg suppression of Th1 responses in 
vivo in a T cell transfer model of colitis.  
Colitis was induced following adoptive transfer of Il10-deficient CD4+ T cells 
(Tresps) (1x106 cells/mouse) i.p. into Rag1-deficient mice. Along-with the 
Tresps, wild-type or Bcl6-deficient (KO) Tregs (250 x 103 cells/mouse) were 
injected i.p. into separate cohorts of Rag-deficient mice. Mice were assessed 
for severity of colitis 4-5 wks later based on percent weight loss, colon length 
and colon histology. 
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The experimental protocol involved transfer of IL-10 deficient CD4+ T cells 
(Tresps) i.p. into Rag-deficient mice. Along with the Tresps, wild-type and Bcl6-
deficient Tregs were injected into separate cohorts of recipients. The recipient 
mice were then monitored for signs of colitis. We noted that while the control 
mice that received IL-10-deficient Tresps alone developed weight loss starting 
from week 1 which progressed over time, the mice receiving either wild-type or 
Bcl6-deficient Tregs remained healthy and did not exhibit signs of wasting 
disease (Figure 11A). Also, the colons in the control mice were shorter and 
thicker, characteristic of severe inflammation, while the colons were relatively 
normal in mice receiving wild-type and Bcl6-deficient Tregs (Figure 11B). This 
protection conferred by the wild-type and Bcl6-deficient Tregs was also evident 
by histological assessment of colon sections and following scoring in a blinded 
fashion (Figure 11C and 11D). Together, these data demonstrate that Bcl6-
deficient Tregs are competent at suppressing Th1 inflammatory responses in 
vivo as wild-type Tregs. 
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Figure 11: Bcl6-deficient Tregs are capable of suppressing Th1-mediated 
inflammatory responses in vivo.  
(A) Bcl6-deficient Foxp3-gfp Tregs (KO, black line) or their wild-type 
counterparts (WT, light grey line) were co-transfered i.p. along with Il10-
deficient Tresps to separate cohorts of Rag1-deficient mice to assess reversal 
of disease. Data represents percent weight change relative to initial weight 
averaged for 3-4 mice per cohort and assessed over a 4-wk time period 
(*p<0.05 and **p<0.01 for cohorts receiving Tresps alone relative to cohorts 
receiving Tresps with either wild-type or Bcl6-deficient Tregs, p=NS between 
cohorts receiving wild-type and Bcl6-deficient Tregs).          
(B) Severity of colitis assessed by changes in colon length 4 wks post-transfer 
to Rag1-deficient mice as described in (A).  
(C) Representative colon histopathology for the 3 cohorts of Rag1-deficient 
mice as described in (A) assessed by hematoxylin and eosin (H&E) staining 4 
wks post-transfer (Original magnification - 200X for Rag1-deficient mice 
receiving Il10-/- Tresps alone and 400X for those receiving Il10-deficient 
Tresps plus either Bcl6-deficient or wild-type Tregs).  
(D) Colon sections from the 3 cohorts of Rag1-deficient mice were scored 4 
wks post-transfer in a blinded-fashion on a scale of 0-6.  
(B,D) *p<0.05,**p<0.01,***p<0.001 (One-way analysis of variance)                
(error bars=s.e.m.) 
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Bcl6-deficient Tregs promote rather than suppress Th2-driven allergic 
airway inflammation 
Since Bcl6-deficient mice develop spontaneous Th2-type inflammation, we 
next tested whether Bcl6-deficient Tregs were defective in their ability to 
suppress Th2 responses. We used a model where Th2 airway inflammation is 
induced by repeated intranasal administration of Ovalbumin (Ova) following initial 
i.p. priming with Ova (Chang et al., 2010; Presser et al., 2008) (Figure 12). Prior 
to the Ova challenge, CD4+CD25+Foxp3+ Tregs from wild-type or Bcl6-deficient 
mice were injected to test their ability to suppress airway inflammation. Tregs 
were isolated from Ova primed mice, in order to obtain Ova-specific Tregs as 
shown (Figure 12). After the last Ova challenge, the mice were analyzed for 
airway hyper-reactivity by plethysmography (Figure 14).  
SENSITIZATION 
OVA-alum i.p. 
0                          7 
WT B6 recipients 
&  
Treg donors 
(WT & Bcl6 KO 
Foxp3gfp mice) 
CHALLENGE 
 OVA aerosol 
intranasal Lung function 
 test 
Harvest BAL & lungs 
for flow analysis and 
histology 14  15  16 17  18          20   21 
OVA-primed WT/KO Tregs 
injected i.p.  
(350 x 103) 
!  Mice receiving PBS alone  
!  Mice receiving WT Tregs 
!  Mice receiving KO Tregs  
Figure 12: Schematic for testing Treg suppression of Th2 responses in 
vivo in an Ova-induced allergic airway inflammation model.  
Both the Treg donor (Bcl6-deficient,KO and wild-type, WT Foxp3gfp mice) and 
recipients (WT B6 female mice) were sensitized intra-peritoneally (i.p.) with 
Ova/Alum on days 0 and 7. On day 14, OVA-primed Tregs were then injected 
i.p. (350 x 103 cells/mouse) into the sensitized wild-type B6 female recipients. 
The recipient mice were then challenged intranasally with Ova for 5 
consecutive days following which the mice were tested for lung function on 
day 20 and sacked for analysis of Th2 inflammation parameters. 
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We first tested the suppressor function of the OVA-primed Tregs from wild-type 
and Bcl6-deficient mice in vitro in the standard Treg suppression assay. Here, 
the isolated OVA-primed wild-type and Bcl6-deficient Tregs were co-cultured 
separately with wild-type Tresp cells activated in the presence of OVA-antigen. 
We noted that OVA-primed Bcl6-deficient Tregs were equally effective as wild-
type Tregs in suppressing the proliferation of OVA-primed T cell responses in 
vitro (Figure 13). Thus, this indicated that Bcl6-deficient Tregs maintain their 
suppressor function after in vivo priming with OVA/Alum.  
 
 
 
 	   APC+ OVA + WT Tresps APC+ OVA + WT Tresps + WT Tregs 	  	   APC+ OVA + WT Tresps + KO Tregs 
Figure 13: Bcl6-deficient Tregs maintain intact suppressor function after 
priming with antigen.  
Suppression of Ova-primed T cell proliferative responses by 
CD4+CD25+Foxp3+ Tregs sorted from Bcl6-deficient (KO) (black bars) and 
wild-type (WT) (white bars) Foxp3-gfp mice sensitized with Ova following co-
culture with wild-type CD25-Foxp3- (Tresps) cells (grey bar) activated with Ova 
(10 µg/ml) plus mitomycin-C treated APCs for 72 hrs (Treg/Tresp ratios - 1:2 
and 1:4). Proliferation assessed as [H3] thymidine incorporation. Data plotted 
as percent proliferation is representative of two independent experiments 
(mean and s.e.m. of triplicate cultures). *p< 0.05, **p<0.01 (One-way analysis 
of variance). 
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Allergic airway inflammation is associated with increased eosinophilic infiltration, 
pulmonary obstruction and airway hyper-responsiveness (Nials and Uddin, 
2008). We therefore assessed lung function in the different cohorts of recipient 
mice subject to airway inflammation protocol by whole-body plethysmography 
(Figure 14). This entails exposure of the recipient mice to increasing doses of 
aerosolized methacholine and assessment of the enhanced pause response. As 
shown in Figure 14, wild-type Tregs suppressed the increased Penh response 
induced by methacholine, compared to control mice that did not receive Tregs. In 
contrast, mice receiving Bcl6-deficient Tregs displayed a similar Penh response 
as the control mice with inflammation, and at the highest dose of methacholine, 
showed a higher Penh reading than the control mice. These data indicate that 
Bcl6-deficient Tregs were not functioning to suppress airway responsiveness.  
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Figure 14: Bcl6-deficient Tregs fail to control airway hyper-
responsiveness in vivo in allergic airway inflammation model. 
Assessment of lung function in Ova-sensitized and intranasally challenged 
wild-type recipient mice immunized i.p. with or without Bcl6-deficient (KO) or 
wild-type (WT) Tregs or left non-challenged (NC) (n = 5 per group). Airway 
hyper-reactivity was measured by the enhanced pause value by whole body 
plethysmography of the recipient mice 24 hrs after the final intranasal 
challenge, tested at baseline (B), and following inhalation of increasing doses 
of aerosolized methacholine (horizontal axis). *p<0.05 (Student’s t-test) 
between mice receiving Bcl6-deficient vs. wild-type Tregs. 
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To further analyze the airway inflammatory response, we measured the cellularity 
of the bronchoalveolar lavage (BAL) and of the draining mediastinal lymph nodes 
(MLN) for the three treatment groups. Strikingly, whereas wild-type Tregs 
suppressed BAL and MLN cell counts compared to control mice with 
inflammation, Bcl6-deficient Tregs promoted a several fold increase in BAL and 
MLN cellularity compared to control mice (Figure 15A). Analysis of the specific 
cell types in the BAL revealed that the bulk of the increase in cellularity was due 
to eosinophils, a cell type characteristic of Th2 mediated allergic airway 
responses (Figure 15B). This was also evident following histological examination 
of lung inflammation and blinded scoring of the inflammation by differential cell 
counts (Figure 15C and 15D). As shown in the figure, whereas wild-type Tregs 
clearly suppressed inflammatory cell accumulation around the airways, Bcl6-
deficient Tregs failed to suppress the inflammation. These data indicate that 
Bcl6-deficient Tregs are not just severely defective in controlling inflammatory 
cell infiltration in the inflamed lungs, but that Bcl6-deficient Tregs actively 
exacerbate the lung inflammation, leading to greater recruitment of eosinophils 
and other inflammatory cell-types. 
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Figure 15: Bcl6-deficient Tregs fail to control inflammatory cell 
accumulation in vivo in allergic airway inflammation model.  
(A) Cellularity in the bronchoalveolar lavage (BAL) and the lung mediastinal 
lymph nodes (MLNs) for the Ova-sensitized and challenged recipient mice 
immunized with or without Bcl6-deficient (KO) or wild-type (WT) Tregs.  
(B) Cellular composition of the BAL for the mice challenged as in (A) assessed 
by flow cytometry (Eos=Eosinophils, Neu=Neutrophils, Mac=Macrophages, 
DC=Dendritic cells).  
(C) Lung histopathology assessed by H & E staining of paraffin-embedded 
lung sections for mice challenged as in (A) or left non-challenged (NC). 
Original magnification, 100 X (left) and 400 X (right). 
(D) Differential cell counts of specific inflammatory cell types in 10 different 
fields of H & E-stained lung sections of the mice treated as in (A).  
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We next analyzed gene expression in the lungs by quantitative PCR anaylsis. 
We tested Foxp3 expression as a marker for Tregs, and found the highest Foxp3 
expression in the lungs from mice injected with Bcl6-deficient Tregs (Figure 16A). 
This ruled out the possibility of defective homing of the Bcl6-deficient Tregs to the 
inflamed lungs. More importantly, we found that the Th2 cytokines Il4, Il5 and Il13 
were most strongly expressed in the lungs of mice that received Bcl6-deficient 
Tregs (Figure 16A). The increased Th2 cytokines can account for the increased 
eosinophilic infiltration, impaired lung function and elevated levels of total IgE in 
the sera of mice receiving Bcl6-deficient Tregs than the other groups (Figure 
16B). Overall, all these data demonstrated that Bcl6-deficient Tregs are severely 
defective in their ability to suppress the Th2 inflammatory responses in vivo. This 
selective failure to suppress Th2 responses can explain the severe Th2-mediated 
inflammatory disease that develops in Bcl6-deficient mice.  
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Figure 16: Bcl6-deficient Tregs augment Th2 responses in vivo in allergic 
airway inflammation model.  
(A)Quantitative PCR analysis of Th2 cytokine genes (Il4, Il5, Il13) and Foxp3 
in the total lung RNA of Ova-sensitized and intranasally challenged wild-type 
recipient mice (grey bars) or immunized i.p. with Bcl6-deficient (KO) Tregs 
(black bars) or wild-type (WT) Tregs (white bars). Results are normalized to 
β2-microglobulin.  
(B) ELISA of total IgE and OVA-specific IgE in the serum of Ova-sensitized 
and intranasally challenged wild-type recipient mice (grey bars) or immunized 
i.p. with Bcl6-deficient Tregs (black bars) or wild-type Tregs (white bars). n = 5 
mice per group. 
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Bcl6-deficient Tregs are selectively impaired in controlling systemic Th2 
responses 
Since the Bcl6-deficient Tregs demonstrated a selective impairment in the 
control of Th2 responses in the airway challenge model, but retained intact 
function in the Th1 colitis model, we next tested their ability to control systemic 
inflammatory T cell responses in another in vivo setting. Foxp3-deficient or scurfy 
mice lack functional Tregs and develop a severe multi-organ autoimmune 
pathology that manifests as wasting disease, diabetes, pancreatitis, hyper-IgE, 
exfoliative dermatitis and cytokine storm. This fulminant autoimmunity is 
associated with exacerbated Th1 and Th2 responses in the absence of Tregs 
(Koch et al., 2009; Liston et al., 2008; Singh et al., 2007). Therefore, taking 
advantage of this model to tease the functional competency of Bcl6-deficient 
Tregs to control Th1 vs. Th2 responses, we set up mixed bone marrow chimeras 
where bone marrow from Foxp3KO (scurfy) mice was injected into irradiated 
Rag1-deficient recipient mice along with bone marrow from wild-type Foxp3-gfp 
mice (WT:Foxp3KO chimeras) or Bcl6-deficient Foxp3-gfp mice (KO:Foxp3KO 
chimeras) (Figure 17).  
Rag1 KO 
Foxp3KO 
Bcl6 WT  
Foxp3-gfp 
WT:Foxp3KO chimera 
Rag1 KO 
Foxp3KO 
Bcl6 KO  
Foxp3-gfp 
KO:Foxp3KO chimera 
Figure 17: Schematic for setting up Foxp3KO BM chimeras.  
Scheme depicting the two types of bone marrow (BM) chimeras generated 
with Rag1 KO mice as recipients: wild-type (WT) BM mixed with Foxp3KO BM 
(WT:Foxp3KO) and Bcl6-deficient (KO) BM mixed with Foxp3KO BM 
(KO:Foxp3KO). 
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WT:Foxp3KO chimeric mice have a mixture of wild-type and Foxp3-deficient 
conventional T cells (Tconv cells) and a functional wild-type Treg subset, while 
KO:Foxp3KO chimeric mice have a mixture of Bcl6-deficient and Foxp3-deficient 
conventional T cells (Tconv cells) and complete deficiency of Bcl6 in the Treg 
subset. After 16-20 weeks of immune reconstitution, both types of chimeric mice 
were immunized with Ova-Alum to promote a Th2-type immune response, and 
Tconv cells were purified and tested for gene expression, following activation 
with anti-CD3 and anti-CD28 Abs in vitro. As shown in Figure 18A and 18B, 
Tconv cells from KO:Foxp3KO chimeras showed a striking increase in the 
expression of Th2 cytokines, compared to Tconv from WT: Foxp3KO chimeras, 
while Ifng and Il17a levels were not significantly different between the two 
chimera types. Also the Th2 transcription factor, Gata3 was increased in Tconv 
cells from KO:Foxp3KO chimeras, relative to WT:Foxp3KO chimeras (Figure 18A). 
Thus, considering the abnormal development of Th1 and Th2 cells in Foxp3-
deficient mice (Koch et al., 2009; Liston et al., 2008; Singh et al., 2007), the 
specific increase in Th2 cytokines but not Th1 cytokines with the KO:Foxp3KO 
chimeras further confirms the selective failure of Bcl6-deficient Tregs to control 
Th2 responses but not Th1 and Th17 responses. Thus, our results with the 
KO:Foxp3KO chimeras and the Th1 and Th2 disease models clearly demonstrate 
a critical role for Bcl6 in Treg-mediated control of Th2 inflammatory responses in 
vivo.  
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Figure 18: Bcl6-deficient Tregs are selectively impaired in the control of 
systemic Th2 inflammatory responses in vivo. 
Quantitative PCR analysis of Th2 genes (Il4, Il13, Il5, Gata3, Il10) (A) and 
(Ifng, Il17a, Foxp3) (B) in Foxp3KO bone marrow chimera-derived wild-type 
(WT) and Bcl6-deficient (KO) Tconv cells with expression normalized to tubb5. 
Data show average expression from 4 mice for (WT: Foxp3KO) group and 3 
mice for (KO:Foxp3KO) group. **p<0.01, ****p<0.0001 (Student’s t-test) (error 
bars=s.e.m.)    
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Bcl6 represses the expression of both Treg and Th2 genes in Treg lineage 
Next, to understand the functional defect that can explain the selective failure of 
Bcl6-deficient Treg cells to control Th2 immune responses, we performed a gene 
expression microarray using mRNA from highly purified CD4+CD25+Foxp3+ Tregs 
from wild-type and Bcl6-deficient mice, activated in vitro with anti-CD3 and anti-
CD28 Abs. We found a large number of gene differences between wild-type and 
Bcl6-deficient Tregs, with 833 genes being up-regulated more than 1.5-fold in 
Bcl6-deficient Treg cells in a statistically significant manner. Several of the 
hallmark Treg suppressor genes, such as Foxp3, Il2rα, Ctla4 and Tgfβ1 were up-
regulated in Bcl6-deficient Tregs, relative to their wild-type counterparts (Figure 
19A, 19B). Il10 and Granzyme B (Gzmb), two important components of the Treg 
genetic program were strikingly up-regulated in Bcl6-deficient Tregs (Figure 
19A). Both these genes have previously been reported as Bcl6 targets in T cells 
(Kusam et al., 2003; Yoshida et al., 2006), confirming that Bcl6 is a critical 
repressor of gene expression in Treg cells. Many of these Treg suppressor 
genes are also increased in CD4+CD25hi Bcl6-deficient Tregs (Chung et al., 
2011), however we have noted that this Treg population can also include 
activated CD25hiFoxp3- Th2 effectors. Therefore, our microarray analysis with 
CD25+Foxp3+ Tregs identifies direct targets of Bcl6 in Tregs. The up-regulation of 
Treg suppressor genes in Bcl6-deficient Treg cells can explain the enhanced 
ability of Bcl6-deficient Tregs to suppress T cell proliferation in vitro. Also, the 
significant up-regulation of Il10 and Tgfβ1 can explain their ability to effectively 
maintain gut homeostasis in the Th1-mediated colitis model.  
A 
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Interestingly, in addition to the increased Treg suppressor genes, Bcl6-
deficient Tregs also displayed increased expression of multiple Th2 lineage 
genes (Figure 19A, 19B), most notably the Th2 transcription factors (Gata3, Maf), 
Th2 cytokines (Il4, Il5 and Il13) as well as Th2-associated chemokine receptors 
like Ccr8. The increased Treg and Th2 gene expression of Bcl6-deficient Tregs 
indicated that Bcl6-deficient Tregs acquire a hybrid Treg-Th2 phenotype and this 
may contribute to their failure in control of Th2 immune responses. Thus, Bcl6 
may be essential for repression of Treg and Th2 gene expression in Tregs. Irf4, 
another Th2-associated transcription factor has been demonstrated to be critical 
for Treg control of Th2 inflammatory responses (Zheng et al., 2009). However, 
the expression of Irf4 was not significantly different between wild-type and Bcl6-
deficient Tregs, suggesting that Bcl6 regulates Th2 gene expression in Tregs 
independent of Irf4. Importantly, Th1 and Th17 lineage genes, were not 
significantly different between wild-type and Bcl6-deficient Tregs (Figure 19A, 
19B), further highlighting the specific de-regulation of the Th2 gene expression 
program in Tregs in the absence of Bcl6. In addition, several chemokine receptor 
genes were up-regulated in the Bcl6-deficient Tregs, as well as other genes with 
important immune system functions such as Csf1, Batf, Il1rl1 and Klrg1. These 
data indicate that Bcl6 expression in Tregs is also critical for limiting the effector 
profile of Treg cells.  
In the microarray, “KO2” showed a much higher expression of both Treg 
genes and Th2 genes than “KO1”, consistent with KO2 having a greater severity 
of Th2 inflammation than KO1 as assessed by histology of the heart and lungs 
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(D.V.S., A.L.D., data not shown). Th1 and Th17 genes were also modestly up-
regulated in KO2, but not KO1. This increase can be explained by the reported 
role for Bcl6 in inhibiting Th1 and Th17 differentiation (Nurieva et al., 2009; Yu et 
al., 2009). However, the role of Bcl6 in inhibiting Th2 responses is more 
dominant for the inflammatory phenotype of Bcl6-deficient mice, as Tregs from 
both the healthy and sick Bcl6-deficient mice show an increase in Th2 gene 
expression. This indicates that, in addition to an intrinsic role for Bcl6 in 
regulating Th2 gene expression in Tregs (as shown by healthier KO1), the Th2 
inflammatory disease further contributes to “remodeling” of the Treg cells (as 
shown by sicker KO2) and both these effects underlie the defective control of 
Th2 responses by Bcl6-deficient Tregs. 
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Figure 19: Bcl6-deficient Tregs exhibit a hybrid Treg-Th2 phenotype. 
(A) Heat map depiction of gene transcripts differentially expressed with 
statistical significance between sorted Tregs from Bcl6-deficient (KO) or wild-
type (WT) Foxp3-gfp mice, analyzed by expression microarrays. Gene 
expression represented as Log2 transformed values with red color 
representing expression greater than mean and green color representing 
expression less than the mean as shown in the color scale on the right (n= 2 
mice per group, with 2 replicates each mouse represented as an average, 
KO1 – healthy, KO2 - sick).  
(B) Quantitative PCR validation of differentially expressed genes between 
Bcl6-deficient (KO) Tregs (black bars) and wild-type (WT) Tregs (white bars) 
selected from the microarray analysis following activation for 16 hrs with anti-
CD3 and anti-CD28 (Treg genes - Foxp3, Il10, Tgfβ1 and Gzmb) and Th2 
genes (Il4, Il5, Il13 and Ccr8), with expression normalized to β-tub. Data are 
average expression from at least 3 different mice per group. 
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Bcl6 represses Th2 genes in Tregs, independent of Foxp3 expression 
Treg cells can down-regulate expression of Foxp3 in inflammatory 
environments and gain the potential to produce effector cytokines (IFNγ and IL-
17) (Pasare and Medzhitov, 2003; Wan and Flavell, 2007; Zhou et al., 2009c). 
Studies using elegant dual reporter mice to monitor Foxp3 expression and Treg 
stability have identified a small population of “exTregs” (Tregs that had 
expressed Foxp3 at an earlier time-point) that expand in autoimmune settings 
and secrete pro-inflammatory cytokines (Zhou et al., 2009c). Therefore, in order 
to confirm if the increased Th2 genes noted by microarray analysis was not due 
to any contaminating Th2 effectors, we stained Bcl6-deficient Tregs for Foxp3 
and Th2 genes. The percentage of Gata3+ T cells was higher in Foxp3- Tconv 
cells in Bcl6-deficient mice relative to wild-type (Figure 20), consistent with the 
established role for Bcl6 in repressing Gata3 expression in T cells (Kusam et al., 
2003). Treg cells are reported to exhibit an intrinsic Th2 bias (Wang et al., 2010), 
with increased Gata3 expression in ex vivo isolated wild-type Tregs than Tconv 
cells (Wang et al., 2011; Wohlfert et al., 2011). Importantly, we noted increased 
percentages of Foxp3+Gata3+ Tregs as well as elevated Gata3 expression in the 
Foxp3+ Tregs in Bcl6-deficient mice (Figure 20A, 20B). Correspondingly, there 
was also a significant increase in the percentage of IL-4+Foxp3+ Tregs in Bcl6-
deficient mice relative to wild-type (Figure 20C). Thus, in agreement with the 
gene expression array data, we noted increased Th2 gene expression in the 
Foxp3+ Tregs in Bcl6-deficient mice. Thus, Bcl6-deficient Tregs acquired a novel 
hybrid Treg-Th2 phenotype, that could contribute to defective Th2 regulation.   
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Figure 20: Bcl6 represses Th2 genes in Tregs, independent of Foxp3 
expression.  
(A) (Left) Representative FACS plot depicting expression of Gata3 in freshly 
isolated Foxp3+ and Foxp3- CD4+CD25+ fractions from Bcl6-deficient (KO) and 
wild-type (WT) mice. (Right) Bar graph representing % Gata3+Foxp3+ Treg 
cells in Bcl6-deficient (black bar) and wild-type (white bar) mice (n = 3 per 
group). 
(B) (Left) Representative histogram depicting expression of Gata3 on freshly 
isolated Bcl6-deficient and wild-type cells gated on CD4+CD25+Foxp3+ T cells.     
(Right) Mean fluorescence intensity (MFI) for Gata3 staining in the Bcl6-
deficient (black bar) and wild-type (white bar) Foxp3+ fraction is quantified (n = 
3 per group).  
(C) (Left) Representative FACS plot depicting expression of IL-4 on Bcl6-
deficient and wild- type CD4+CD25+Foxp3+ fraction following stimulation with 
PMA and Ionomycin (Right) Scatter plot represents % IL-4+Foxp3+ Treg cells 
in Bcl6-deficient and wild-type mice (n = 5 per group).  
*p<0.05 (Student’s t-test) (error bars=s.e.m.)  
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Th2 genes are intrinsically repressed by Bcl6 in Tregs 
The critical next step was to definitively address if the up-regulated Th2 
genes in Bcl6-deficient Tregs was due to intrinsic regulation by Bcl6 in the Treg 
lineage, or from an indirect effect from the ongoing Th2 inflammatory disease in 
the Bcl6-deficient mice. To test this, we generated mixed bone marrow chimeras 
where bone marrow from CD45.1+ wild-type Foxp3-gfp mice was injected into 
sub-lethally irradiated Rag1-deficient recipient mice along with bone marrow from 
CD45.1– Bcl6-deficient Foxp3-gfp mice (WT:KO chimeras) (Figure 21). After 16-
20 weeks of immune reconstitution, chimeric mice were immunized with Ova-
Alum to promote a Th2-type immune response, and CD45.1+ wild-type Foxp3-gfp 
and CD45.1– Bcl6-deficient Foxp3-gfp Tregs and Tconv cells were purified as 
shown in Figure 21 and tested for gene expression following activation in vitro.  
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Figure 21: Schematic for setting up WT:KO BM chimeras.  
Representative FACS sorting scheme for isolating Bcl6-deficient (KO) 
(CD45.1-) and wild-type (WT) (CD45.1+) Tregs and Tconv cells from mixed 
bone marrow chimeras; with Tregs gated as CD4+CD25+Foxp3+ (GFP+) T cells 
and Tconv cells gated as CD4+CD25- Foxp3– (GFP–) T cells, prior to gating 
based on CD45.1 expression.  
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As shown in Figure 22A and 22B, Gata3 expression was increased 
specifically in Bcl6-deficient Treg cells but not Bcl6-deficient Tconv cells. Since 
Gata3 can auto-activate its own expression (Ouyang et al., 2000), an intrinsic 
increase of Gata3 in chimeric Bcl6-deficient Treg cells is consistent with the 
augmented Gata3 expression noted in Treg cells from Bcl6-deficient mice as 
shown in Figures 19 and 20. Il4 and Il10 were up-regulated 2-fold in Bcl6-
deficient Tregs from the chimera compared to wild-type Tregs in the same 
chimera (Figure 22A), indicating that these genes are intrinsically repressed by 
Bcl6 in Tregs. We also observed increased intrinsic expression of Il4, Il13 and 
Il10 in Bcl6-deficient conventional T (Tconv) cells from the chimeric mice relative 
to wild-type Tconv cells, validating our previous work demonstrating Bcl6 as an 
inhibitor of Th2 responses (Kusam et al., 2003) (Figure 22B). Overall, the up-
regulation of Th2 genes in the Bcl6-deficient Treg and Tconv cells derived from 
mixed bone marrow chimeras was less dramatic compared to Th2 responses 
noted in germline Bcl6-deficient mice. This is potentially due to the presence of 
functional wild-type Treg counterparts in the chimeras that reduce the severity of 
overall Th2 inflammation. Indeed, Bcl6-deficient Tregs derived from KO:Foxp3KO 
chimeras showed several fold increase in Th2 genes, similar to germline Bcl6-
deficient mice, since these chimeras lack functional wild-type Tregs due to Foxp3 
deficiency (Figure 23). Nevertheless, the significant up-regulation of Th2 genes in 
the Bcl6-deficient Tregs in the chimeras strongly support an intrinsic role for Bcl6 
in repressing Th2 gene expression in Tregs and their conversion to pro-
inflammatory Th2 effector-like Tregs.  
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Figure 22: Bcl6 intrinsically represses Th2 genes in Tregs. 
(A) Quantitative PCR analysis of Gata3, Il4, Il10, Il5, Ifng and Foxp3 in sorted 
bone marrow chimera-derived Bcl6-deficient (KO) (CD45.1-) and wild-type 
(WT) (CD45.1+) Tregs with expression normalized to tubb5. Data show 
average expression from 6 different mice per group. *p<0.05, ***p<0.001 
(Student’s t-test) (error bars=s.e.m.)  
(B) Quantitative PCR analysis of transcripts for Gata3, Il4, Il13, Ifng, Il5, Il10, 
Il17a and Foxp3 in sorted bone marrow chimera-derived Bcl6-deficient (KO) 
Tconv cells (CD45.1-) and wild-type (WT) Tconv counterparts (CD45.1+) with 
expression normalized to tubb5. Data show average of 6 different mice per 
group. **p<0.01,  ***p<0.01 (Student’s t-test) (error bars=s.e.m.)    
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Figure 23: Greater Th2 remodeling of Bcl6-deficient Tregs in KO:Foxp3KO 
chimeras than WT:KO chimeras.  
Quantitative PCR analysis of Gata3, Il4, Il5, Il10, Ifng and Il17a in Foxp3KO 
bone marrow chimera-derived wild-type (WT) and Bcl6-deficient (KO) Treg 
cells with expression normalized to tubb5. Data show average expression from 
4 mice for (WT:Foxp3KO) group and 3 mice for (KO:Foxp3KO) group.  
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Bcl6 represses transcriptional activity of Gata3 
Bcl6 is well-established as an inhibitor of Th2 cell differentiation and Th2-
type inflammation. This Th2 inhibition by Bcl6 is IL-4/STAT6 independent and 
has been demonstrated to involve post-transcriptional repression of Gata3 
protein expression, although the exact mechanism is not yet clear (Dent et al., 
1998a; Kusam et al., 2003). However, whether Bcl6 can also block the 
transactivation of Th2 cytokines by Gata3 is not yet explored. Increased Gata3 
expression as well as augmented Gata3 transcriptional activity in the absence of 
Bcl6 can explain the Th2-dominated phenotype of Bcl6-deficient mice. To 
address this, we tested the effect of Bcl6 on Gata3 transcriptional activity in two 
different functional assays. First, we induced Th2 cytokine expression in Stat6-
deficient T cells by infecting with a Gata3-expressing retrovirus and tested the 
ability of Bcl6 to repress the Gata3-induced Th2 cytokine expression. As shown 
in Figures 24A and 24B, while Gata3 potently induced Th2 cytokine expression 
(both transcript and protein), Bcl6 essentially ablated the induction of Il4 and Il5 
by Gata3, showing that Bcl6 could strongly repress Gata3 function in T cells. 
However, Bcl6 did not repress Tnfa, indicating that Bcl6 does not globally repress 
cytokine gene expression. 
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Figure 24: Bcl6 represses Th2 cytokine-inducing ability of Gata3. 
(A) Quantitative PCR analysis of relative cytokine gene expression (Il4, Il5, 
Tnfa) for Stat6-deficient T cells retrovirally transduced with control RV, hCD4-
Gata3 RV alone and double transduction of hCD4-Gata3 RV and H2Kk-Bcl6 
RV. Transduced cells were sorted using RV markers - hCD4 and H2Kk and 
then re-stimulated with anti-CD3 and anti-CD28 for 4 hrs for analysis of gene 
expression. Expression normalized to β-tub. **p<0.01 (One-way analysis of 
variance)  
(B) Levels of Th2 cytokines (IL-4, IL-5, IL-13 and IL-10) in samples treated as 
in (A) quantified by multiplex analysis.  
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As a second approach to further examine the repression of Gata3 function by 
Bcl6, we utilized a transient transfection assay in Jurkat T cells wherein 
luciferase expression is under the control of the Il5 promoter. As shown in Figure 
25A, Gata3 alone strongly activates the Il5 promoter, and Bcl6 alone weakly 
represses Il5 promoter activity. When co-transfected together, Bcl6 potently 
represses Gata3-induced Il5 promoter activity, showing that Bcl6 can directly 
target and inhibit the transcriptional activity of Gata3. Similar repressive effects 
were also noted in M12 B cells (Figure 25B), thus showing that Bcl6 inhibits 
Gata3 function independent of endogenous Gata3 and does not require other T 
cell specific factors. Both these approaches demonstrate the critical role of Bcl6 
in repressing Gata3 transcriptional function. Thus, the increased levels of Gata3 
and increased Gata3 transcriptional activity in the absence of Bcl6 would lead to 
increased auto-activation of Gata3 (Ouyang et al., 2000), thus amplifying the 
effects of loss of Bcl6, and strengthening Th2 lineage gene expression in Bcl6-
deficient T cells.  
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Figure 25: Bcl6 represses trans-activation of Th2 cytokines by Gata3. 
Luciferase activity in Jurkat T cells (A) and M12 B cells (B) co-transfected with 
IL-5 promoter driven luciferase reporter and expression constructs for CXN, 
CXN-Gata3, CXN-Bcl6 and CXN-Gata3 plus CXN-Bcl6. Following 
electroporation, cells were stimulated with PMA and Ionomycin for Jurkat T 
cells or PMA plus dibutyryl cAMP 24 hrs prior to harvest and luciferase 
measurement. Results representative of 5 and 2 independent experiments, 
respectively. **p<0.01, ***p<0.001 (Student’s t-test) (error bars=  s.e.m.). 
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Repression of Gata3 function by Bcl6 is critical in the Treg lineage  
We next wanted to understand if the regulation of Gata3 transcriptional 
activity by Bcl6 is functional in the Treg lineage and how it relates to the Th2-bias 
of Bcl6-deficient Tregs and their failure to control Th2 responses. Gata3 and Th2 
cytokines are known to antagonistically regulate Treg fate determination. At a 
mechanistic level, several lines of evidence support this long-standing premise in 
the field. IL-4 induces Stat6 that can bind to a silencer element in the Foxp3 
promoter and repress TGFβ-induced Treg differentiation (Takaki et al., 2008). IL-
4 can also function by Gata3 induction via the canonical Stat6 signaling pathway, 
and enforced expression of Gata3 is sufficient to block Foxp3 induction (Wei et 
al., 2007). Gata3 can directly bind to palindromic Gata site (located ~303 bp 
upstream of TSS) in the Foxp3 promoter and inhibit Foxp3 expression in Th2 
cells (Mantel et al., 2007). Foxp3 promoter activity was reported as significantly 
reduced in Jurkat T cells that constitutively express Gata3 (Mantel et al., 2007). 
We however noted strikingly opposite results in performing similar tests to assess 
Gata3 regulation of Foxp3. We generated two different Foxp3 promoter 
constructs – wild-type promoter with the palindromic Gata site intact and a 
mutant promoter with both the Gata sites deleted by site-directed mutagenesis 
(Figure 26A). Both these promoter constructs were functional in Jurkat T cells. In 
contrast to the results in the Mantel study, we noted that co-transfection of Gata3 
activated Foxp3 promoter activity, independent of the palindromic Gata site 
(Figure 26B). In agreement with our data, two recent studies have identified an 
indispensible role for Gata3 in the Treg lineage (Wang et al., 2011; Wohlfert et 
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al., 2011). This is mainly attributed to a positive role for Gata3 in inducing Foxp3 
expression and thus maintaining the hallmark Treg gene signature and functional 
fitness. In this study, Gata3 was shown to bind CNS2 element in the Foxp3 
locus, while minimal binding was detected at the promoter, CNS1 and CNS3 
elements in Treg cells. Reporter assays in Jurkat T cells identified that Gata3 
positively enhanced Foxp3 promoter activity, although the effect was significantly 
stronger for promoter plus CNS2 construct. CNS2 is important for maintenance 
of Foxp3 expression in thymic Tregs, thus suggesting that Gata3 plays a role in 
this process (Zheng et al., 2010). Although minimal Gata3 binding was detected 
in the promoter, CNS1 and CNS3 elements in the Foxp3 locus, the presence of 
functional Gata binding sites in the promoter and CNS1 may imply that Gata3 
may be involved in regulating Foxp3 in other contexts as well.  
Thus, the increased Gata3 noted in Bcl6-deficient Tregs can explain their 
increased expression of Foxp3 and Treg suppressor genes. The functional role 
of Gata3 in Foxp3 induction can explain increased Gata3 expression in wild-type 
Treg cells relative to conventional T cells as well as high Gata3 expression in 
Tregs at mucosal sites (Josefowicz et al., 2012b). However, considering that 
Gata3 is the Th2 master lineage-specifying factor, it is important to understand 
what signals limit the transactivation of Th2 cytokines by Gata3 in Tregs, unlike 
conventional T cells. Gata3 induction in Tregs is guided by IL-2 and TCR signals, 
and is independent of IL-4/STAT6 signaling (Wohlfert et al., 2011). Thus, our 
data with increased Th2 gene expression in Tregs in the absence of Bcl6 and the 
ability of Bcl6 to block transcriptional function of Gata3 indicates that Bcl6 is 
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essential to limit Gata3 expression in Tregs and their conversion to Th2-biased 
Tregs, defective in control of Th2 responses. 
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Figure 26: Gata3 activation of Foxp3 promoter, independent of the 
palindromic Gata sites. 
(A) Schematic of transcription factor binding sites in the Foxp3 promoter 
depicting the palindromic GATA sites and the Foxp3 promoter constructs 
generated (WT Promoter with the GATA sites intact, Mut Promoter with the 
GATA sites deleted). 
(B) Luciferase activity in Jurkat T cells co-transfected with the WT and Mut 
Foxp3 promoter driven luciferase reporters and expression constructs for CXN 
and CXN-Gata3. Following electroporation, cells were stimulated with PMA 
and Ionomycin 24 hrs prior to harvest and luciferase measurement. Results 
representative of 5 independent experiments. 
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Part II: Bcl6 repression of microRNA-21 is essential for stability of the Treg 
functional program 
Bcl6 represses expression of microRNAs in the Treg lineage 
MicroRNAs function as important regulators of T cell development and 
differentiation at the post-transcriptional level and are dysregulated in a number 
of autoimmune and inflammatory diseases (Cho, 2007; Jeker and Bluestone, 
2010; O'Connell et al., 2010). Treg cells exhibit a distinct Foxp3-depedent 
microRNA profile, with a number of miRNAs differentially expressed in Tregs 
compared to Tconv cells (Cobb et al., 2006; Zhou et al., 2008b). Mice deficient in 
the miRNA-processing enzymes, Dicer and Drosha in the Treg lineage, develop 
a severe multi-organ pathology, resembling Foxp3-deficient scurfy mice, 
highlighting the importance of miRNAs in Treg function (Liston et al., 2008; Zhou 
et al., 2008b). Dicer/Drosha-deficient Tregs exhibit developmental and functional 
defects and lack lineage stability, thus indicating that different miRNAs may 
regulate different aspects of Treg cell biology (Zhou et al., 2008b). Indeed, miR-
155 is important for Treg cell homeostasis (Lu et al., 2009a), miR146a is critical 
for Treg control of Th1 responses (Lu et al., 2010), miR-142-3p regulates cAMP 
production in Tregs (Huang et al., 2009), and miR-10a marks stable Tregs (Jeker 
et al., 2012). Thus, identifying the transcriptional control of these differentially 
expressed miRNAs in Tregs and their relevant target genes will help delineate 
the functional relevance of miRs in Tregs. MiR-146a targets STAT1 in Tregs; 
thus miR-146a-deficient Tregs exhibit a Th1-bias with increased STAT1 
phosphorylation, secrete the Th1 cytokine IFNγ and fail to suppress Th1 
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inflammatory responses (Lu et al., 2010). Analogous to this situation, we have 
noted that in the absence of Bcl6, Tregs exhibit a profound Th2-bias, secrete Th2 
cytokines and fail to control Th2 responses. We thus wondered if Bcl6 regulated 
Treg lineage stability by repressing micro-RNAs in Tregs. Importantly, studies on 
Bcl6 in Tfh cells have highlighted repression of miRNAs as an important aspect 
of Bcl6-mediated gene regulation in T cells (Yu et al., 2009). Therefore, to 
identify miRNAs regulated by Bcl6 in Treg cells, we utilized a micro-RNA 
microarray approach, using RNA prepared from highly purified 
CD4+CD25+Foxp3+ Tregs from wild-type and Bcl6-deficient mice, activated in 
vitro. As shown in Figures 27A and 27B, three micro-RNAs were increased 
significantly in Bcl6-deficient Tregs, although only microRNA-21 (miR21) was 
increased more than 2-fold in the Bcl6-deficient Treg microRNA microarray. MiR-
21 has previously been reported as increased in Treg cells compared to Tconv 
cells (Cobb et al., 2006) and also linked to Foxp3 up-regulation in human Tregs, 
via unknown mechanisms (Rouas et al., 2009). MiR-21 is also one of the most 
extensively studied micro-RNAs in the cancer field (Jung and Calin, 2010). In 
addition, it has been shown to promote heart disease (Thum et al., 2008), which 
could be relevant to the myocarditis observed in Bcl6-deficient mice. Interestingly 
and highly relevant to our findings was its increased expression in Th2-mediated 
allergic airway inflammation (Lu et al., 2009b). Two other micro-RNAs (miR-22 
and miR-146b) were also increased in Bcl6-deficient Tregs relative to wild-type.  
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Figure 27: Bcl6 represses miR-21 in Treg cells.  
(A) The heat map represents the miRs differentially expressed between sorted 
Bcl6-deficient (KO) and wild-type (WT) Tregs with statistical significance 
analyzed by expression microarrays. The color scale shown at the bottom 
illustrates the relative expression level of a miR across all samples: red color 
represents an expression level above mean, blue color represents expression 
level lower than the mean. n = Tregs from 3 wild-type mice and 2 Bcl6-
deficient mice.               
(B) Quantitative PCR validation of the selected set of miRs in Bcl6-deficient 
(KO) Tregs (black bars) relative to wild-type (WT) Tregs (white bars) following 
activation for 16 hrs with anti-CD3 and anti-CD28, normalized using sno202, 
sno234 and U6 as controls. Data are average expression from at least 3 mice 
per group.  
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Bcl6 intrinsically represses miR-21 in the Treg lineage 
In order to obtain a more definitive understanding of the regulation of miR-
21 and Th2 genes in Bcl6-deficient Tregs by intrinsic and extrinsic mechanisms, 
we generated mixed bone marrow chimeras. Bone marrow from CD45.1+ wild-
type Foxp3-gfp mice was injected into irradiated Rag1-deficient recipient mice 
along with bone marrow from CD45.1– Bcl6-deficient Foxp3-gfp mice (Figure 
28A). After 16-20 weeks, the chimeric mice were immunized with Ova-Alum to 
promote a Th2-type immune response, and CD45.1+ wild-type Foxp3-gfp and 
CD45.1– Bcl6-deficient Foxp3-gfp Tregs were purified and tested for gene 
expression following activation in vitro. As shown in Figure 28B, miR-21 was 
significantly increased in Bcl6-deficient Tregs from the chimera compared to wild-
type Tregs in the same chimera, confirming that miR-21 is an intrinsic target of 
Bcl6 in Tregs. MiR-22 and miR-146b were not increased in chimeric Bcl6-
deficient Tregs and thus are not likely to be directly regulated by Bcl6 in Tregs. 
MiR-21 was specifically increased in Bcl6-deficient Tregs and not Tconv cells, 
suggesting that Bcl6 specifically represses miR-21 in the Treg lineage. 
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Figure 28: Intrinsic regulation of miR-21 by Bcl6 in the Treg lineage. 
(A) Representative FACS sorting scheme for isolating Bcl6-deficient (KO) 
(CD45.1-) and wild-type (WT) (CD45.1+) Tregs from mixed bone marrow 
chimeras; with Tregs gated as CD4+CD25+Foxp3+ T cells, prior to gating based 
on CD45.1 expression.  
(B) Quantitative PCR (QPCR) analysis of miR transcripts in sorted bone 
marrow chimera-derived Bcl6-deficient (KO) Tregs (CD45.1-) and their 
respective wild-type Treg counterparts (CD45.1+), following activation for 16 hrs 
with anti-CD3 and anti-CD28. MiR21, miR22 and miR146b expression 
normalized to U6. Data are average expression from 6 different mice per 
group. *p<0.05 (two-tailed Student’s t-test) (error bars, s.e.m.) 
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MiR-21 is a novel Bcl6 target gene in T cells 
To further test the regulation of miR-21 by Bcl6 in T cells, we infected 
activated wild-type CD4+ T cells, which have low levels of Bcl6, with a Bcl6-
expressing retrovirus and tested repression of the miRNAs up-regulated in Bcl6-
deficient Tregs (miR-21, miR-22 and miR-146b). As shown in Figure 29, Bcl6 
specifically repressed miR-21 but not miR-22 or miR-146b, supporting the idea 
that miR-21, is a direct target of Bcl6 in T cells. This result is consistent with the 
miRNA regulation by Bcl6 reported by the Yu et al study (Yu et al., 2009), which 
also noted miR-21 as one of the most strongly down-regulated miRNA by Bcl6 in 
T cells (~3.9 fold). Minimal effects were noted for the other two miRs (miR-146a 
was down-regulated ~1.1 fold while miR-22 was up-regulated ~1.2 fold). Thus, 
this result confirms miR-21 as a novel Bcl6 target gene in T cells, thereby 
warranting a functional assessment of miR-21 in Bcl6-mediated gene regulation 
in Tregs and T cells in general. 
 
 
 
 
 
Figure 29: MiR-21 is a novel Bcl6 gene target in T cells. 
Quantitative PCR analysis of expression of miRs – 21, 22 and 146b following 
ectopic expression of Bcl6 in T cells, normalized using sn0202, sno234 and 
U6 as controls. Naïve T cells were transduced with control RV and Bcl6 RV 
and the sorted RV+ T cells were re-stimulated for 4-6 hrs to assess its effect 
on miR expression. Data are average expression from at least 3 different 
experiments. *p<0.05, **p<0.01 (two-tailed Student’s t-test) (error bars=s.e.m.) 
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MiR-21 is up-regulated in Stat3-activating conditions 
The miR-21 gene promoter has binding sites for several transcriptional 
regulators - AP-1, Ets/PU.1, C/EBPα, NFI, SRF, p53 and STAT3 (Fujita et al., 
2008). These enhancer elements are also conserved in the human miR-21 gene, 
indicating common transcriptional regulatory mechanisms for miR-21. AP-1 and 
Stat3 positively regulate miR-21 transcription via direct binding to the 3 AP-1 and 
2 STAT3 binding sites in the miR-21 promoter (Fujita et al., 2008; Loffler et al., 
2007). MiR-21 induction via Stat3 contributes to the oncogenic role of miR-21 in 
multiple myeloma and also links the role of miR-21 in cancer and inflammation 
(Iliopoulos et al., 2010). Indeed, IL-21 acting via Stat3 up-regulates miR-21 in 
CD4 T cells as well as Sezary cells (T cell lymphoma) (van der Fits et al., 2011). 
Consistent with a positive role for Stat3, we noted increased miR-21 in Th2 cells, 
as well as in Th17 and Tfh cells (Figure 30A), all cell types that are dependent 
upon Stat3 for their complete differentiation (Crotty, 2011; Ivanov et al., 2007; 
Stritesky et al., 2011). Treatment of wild-type, Stat3-deficient and Bcl6-deficient 
naïve CD4+ T cells with increasing dose of IL-6 demonstrated the defective miR-
21 induction of Stat3-deficient T cells. IL-6 induced miR-21 up to 5.5-fold in wild-
type CD4 T cells, whereas in Bcl6-deficient CD4 T cells, basal miR-21 was 
increased about 3-fold and IL-6 titration further augmented it to almost 30-fold 
(Figure 30B). Thus, overall these results identify miR-21 as a Stat3 regulated 
factor in CD4 T cells and suggest potential counter-regulation of miR-21 
transcription via Stat3 and Bcl6. 
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Figure 30: MiR-21 is up-regulated in Stat3-activating Thelper conditions. 
(A) Quantitative PCR analysis of miR-21 expression during different time-
points (24h, 72h and 120h) following culture of wild-type naïve T cells 
(CD4+CD62L+) into different T helper subset differentiation conditions (Th1, 
Th2, iTreg, Th17, Th9 and Tfh), with expression normalized to U6. Data 
representative of 2 different mice.  
(B) Quantitative PCR analysis of miR-21 expression following culture of WT, 
Bcl6-deficient and Stat3-deficient naïve T cells (CD4+CD62L+) in response to 
increasing doses of IL-6 (0, 0.1, 1, 10 ng/ml) for 16-24 hrs, with expression 
normalized to U6. Data representative of 2 independent experiments. 
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Antagonistic regulation of miR-21 transcription by Bcl6 and Stat3 
The Bcl6 recognition motif resembles binding sites for the cytokine-
induced STAT family of transcription factors and Bcl6 has been shown to repress 
STAT-induced cytokine transcription (Shaffer et al., 2000). Since our results 
identify miR-21 as a target gene for Bcl6, we next wanted to assess if Bcl6 
counter-regulated miR-21 via competing with Stat3 for the two well characterized 
Stat3-binding sites in the miR-21 promoter. To test this regulation, we generated 
three different miR-21 promoter constructs – full-length (WT) construct with the 
two Stat3-binding sites intact, SB1 mutant with the 5’ Stat-3 binding site mutated 
and an SB2 mutant with the 3’ Stat3-binding site mutated by site-directed 
mutagenesis (Figure 31). These constructs were tested in a transient transfection 
assay in Jurkat T cells, with or without Bcl6 expression plasmids. We found that 
Bcl6 potently repressed the wild-type miR-21 promoter. Mutation of the 5’ Stat3-
binding site (SB1) had no effect on repression by Bcl6, whereas mutation of the 
3’ Stat3-binding site (SB2), completely abolished repression by Bcl6 (Figure 31). 
By comparing the sequence of the two Stat3 binding sites, we found that the SB2 
site has better consensus to the core Bcl6 recognition motif than SB1, thus 
contributing to the differential effect of Bcl6 in regulating miR-21 via the two sites. 
These data suggest that Bcl6 and Stat3 may compete for binding to the miR-21 
promoter, and that each opposes the function of the other factor. Thus, Bcl6 and 
Stat3 have opposing effects on the transcription of miR-21 in T cells.  
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Figure 31: Bcl6 directly targets miR-21 via binding sites in its promoter. 
Luciferase activity in Jurkat T cells co-transfected with full-length or SB1 and 
SB2 mutated miR21 promoter driven luciferase reporters and expression 
constructs for CXN and CXN-Bcl6. Cells were stimulated with PMA and 
Ionomycin for 24 hrs prior to harvest and luciferase measurement. Results 
averaged from 5 independent experiments, where the basal activity of each 
promoter construct is set to 100 relative units. *p<0.05, **p<0.01 (two-tailed 
Student’s t-test) (error bars=s.e.m.)  
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Inflammatory signals contribute to miR-21 up-regulation in Tregs  
Since Stat3 induces miR-21 during inflammation (Iliopoulos et al., 2010), 
and miR-21 induction is associated with Th2 inflammation (Lu et al., 2009b), we 
next wondered if some of the increase in miR-21 noted in Bcl6-deficient Tregs 
was due to the Th2 inflammatory disease that occurs in Bcl6-deficient mice. 
Therefore, to address the potential extrinsic regulation of miR-21 by the 
inflammatory cues in Bcl6-deficient mice, we transferred wild-type Foxp3-gfp 
Tregs into wild-type or Bcl6-deficient mice, immunized with HEL/Alum to induce a 
Th2 response, then after 3 days, isolated the Tregs by sorting for GFP 
expression (Figure 32A). As shown in Figure 32B, in comparison to transfers into 
wild-type mice, wild-type Tregs that were transferred into Bcl6-deficient mice 
showed a significant increase in miR-21. However, Gata3 mRNA was not 
increased in the wild-type Tregs in the Bcl6-deficient background, and Th2 
cytokines were not detected in the wild-type Tregs in either the wild-type or Bcl6-
deficient background (Figure 32B, data not shown). These data indicate that in 
addition to being a Bcl6 target, miR-21 expression in Tregs is also regulated 
extrinsically by inflammation. At the same time, failure of wild-type Tregs to up-
regulate Th2 genes in the Bcl6-deficient environment highlights the Treg-intrinsic 
role of Bcl6 in controlling Gata3 and Th2 cytokines.   
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Figure 32: Extrinsic regulation of miR-21 in Tregs by inflammatory cues in 
Bcl6-deficient mice.       
(A) Representative FACS sorting scheme for isolating WT CD25+Foxp3+ 
(GFP+) Tregs 3 days following adoptive transfer i.p. into Bcl6-deficient (KO) 
(black bars) and wild-type (white bars) recipients and immunized next day.  
(B) Quantitative PCR analysis of miR-21 and Gata3 transcript in FACS-sorted 
wild-type CD25+Foxp3+ Tregs isolated from WT and Bcl6-deficient mice, 
following activation for 16 hrs with anti-CD3 and anti-CD28 with miR expression 
normalized to U6, and Gata3 expression normalized to tubb5. Data are 
average of 3-4 mice/group. 
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MiR-21 can promote Th2 differentiation in a T cell-autonomous manner 
Although miR-21 has been linked to Th2 inflammation, it was reported as 
primarily elevated in cells of the myeloid lineage (Lu et al., 2011b; Lu et al., 
2009b). MiR-21 was demonstrated to promote Th2 differentiation indirectly via 
inhibition of the myeloid cell derived Th1 polarizing cytokine, IL-12. Thus, 
whether miR-21 regulates Th2 differentiation in a T cell intrinsic manner has not 
been ascertained. To test this idea, we constructed a miR-21-expressing 
retrovirus, and used it to infect “naïve” CD4+CD62L+ T cells from wild-type mice, 
with the hypothesis that over-expression of miR-21 in T cells by retrovirus could 
recapitulate the elevated levels of miR-21 observed in Bcl6-deficient Tregs. As 
shown in Figure 33A, the retrovirus promoted a greater than 3-fold increase in 
miR-21 when expressed in T cells, which was comparable to the increased miR-
21 level observed in Bcl6-deficient Tregs. We then tested whether miR-21 could 
induce Th2 differentiation in cells cultured under “Th0” conditions, where no 
cytokines were added. As shown in Figure 33A, miR-21 promoted increases in 
Th2 genes (Gata3, Il4 and Il13), whereas expression of the Th1 cytokine Ifng 
was mildly repressed by miR-21. We also found that miR-21 could augment Th2 
but not Th1 cytokine expression when over-expressed in Th2 cells (Figure 33B). 
To further assess miR-21 activity in promoting Th2 differentiation, we tested a 
synthetic miR-21 “mimic” as well as an anti-sense miR-21 inhibitor “antagomiR-
21” in Th0 differentiation cultures. As shown in Figure 33C, the mimic 
significantly promoted Th2 differentiation whereas the antagomiR-21 inhibited 
Th2 differentiation, as measured by IL-4 and IL-5 secretion. The mimic and 
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inhibitor did not significantly affect IFNγ, although there was a trend towards 
decreased IFNγ with both treatments. These data show for the first time that 
miR-21 can promote Th2 differentiation by a T cell intrinsic mechanism. Thus, 
increased miR-21 in Bcl6-deficient Tregs may thus be a causal factor for the 
abnormal expression of Th2 genes in these cells. Reduced Th2 differentiation 
and allergic airway inflammation and heightened Th1 responses were reported 
for miR-21-deficient mice (Lu et al., 2011b). Our results with a positive role for 
miR-21 in promoting Th2 differentiation are consistent with the observations by 
Lu et al. Importantly, our results identify a novel T cell autonomous regulation of 
Th1 vs. Th2 bias by miR-21, that fits with the post-transcriptional control of Th2 
differentiation by Bcl6 and can also mechanistically explain the observed Th2-
bias noted for Bcl6-deficient Treg cells. 
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Figure 33: MiR-21 promotes Th2 differentiation of naïve T cells in a T cell-
intrinsic manner.  
(A) Quantitative PCR analysis of miR-21 and Gata3, Il4, Il13 and Ifng following 
ectopic expression of miR-21 RV in non-polarized (Th0) T cells, relative to 
control RV transduced cells. Sorted RV+ cells were re-stimulated with anti-CD3 
and anti-CD28 for 4-6 hrs for gene expression analysis. MiR expression 
normalized to U6, and expression of other genes normalized to β-tub.  Data are 
averaged from at least 3 independent experiments.  
(B) ELISA for cytokines assayed from supernatants of miR-21 transduced Th2 
cells (IL-4 – 20 ng/ml plus anti-IFNγ - 10 µg/ml), relative to control RV 
transduced cells. Cells were re-stimulated with anti-CD3 and anti-CD28 for 24 
hrs following sorting of RV+ Th2 cells for cytokine measurements. *p<0.05, 
(two-tailed Student’s t-test) (error bars=s.e.m.) 
(C) ELISA for cytokines assayed from supernatants of scrambled control, miR-
21 mimic and antagomiR-21 treated naïve T cells. Cells were cultured with the 
oligos (1 µM) over a 5-day period, then re-stimulated with anti-CD3 and anti-
CD28 overnight for cytokine measurements. Data are representative of 3 
independent experiments. 
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MiR-21 up-regulates Treg and Th2 genes in the Treg lineage 
Since ectopic expression of miR-21 augments Th2 gene expression in T 
cells, we next wanted to address if miR-21 over-expression can induce a similar 
Th2 bias in Treg cells. MiR-21 is one of the miRNAs up-regulated in Tregs 
compared to Tconv cells (Cobb et al., 2006) and miR-21 is reported to positively 
regulate Foxp3 expression in human Tregs, although the mechanism is yet 
unknown (Rouas et al., 2009). We overexpressed miR-21 using a retroviral 
approach in wild-type Tregs and noted a similar up-regulation of Treg genes 
(Foxp3 and Il10) and Th2 cytokine (Il4) expression with miR-21 RV compared to 
control RV (Figure 34). Interestingly, when these miR-21 RV transduced wild-
type Tregs were tested in a standard Treg suppression assay with wild-type 
CD25- Tresp cells and APCs, the miR-21 RV Tregs exhibited a trend towards 
increased suppressor function compared to control RV Tregs (data not shown). 
Thus, ectopically expressed miR-21 up-regulates both Treg and Th2 genes in the 
Treg lineage. This indicates that the increased miR-21 may serve as a causal 
factor for the increased Th2 genes, and also contribute to the up-regulated Treg 
genes and enhanced suppressor function in vitro, noted for the Bcl6-deficient 
Treg cells. 
 
 
 
Figure 34: MiR-21 augments Treg and Th2 genes in Treg cells.  
Quantitative PCR analysis of miR-21, Foxp3, Il10 and Il4 in miR-21 RV and 
control RV transduced wild-type (WT) Tregs, following 4-6 hrs activation with 
anti-CD3 and anti-CD28. MiR-21 expression normalized to U6 and other genes 
normalized to tubb5 as control. 
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MiR-21 target genes in T cells that relate to its role in promoting Th2 
immune responses 
The advantage of using the synthetic oligos to overexpress or inhibit miR-
21 is that we could better control the timing of miR21 expression, and thus we 
treated naïve wild-type CD4 T cells with miR-21 mimic, antagomiR-21 or 
scrambled control, and assessed downstream miR-21 targets after 12-16 hrs of 
expression. A large number of miR-21 target genes have been described (Jung 
and Calin, 2010), and we analyzed six of the most well-known target mRNAs 
(Figure 35A). Of these six genes, only Sprouty1 (Spry1), a negative regulator of 
the MAP kinase pathway (Thum et al., 2008), was consistently decreased by 
mimic treatment (Figure 35B). At the same time, the miR-21 mimic augmented 
Gata3 mRNA (Figure 35B). Since the MAP kinase pathway has been linked to 
promoting Gata3 protein stability (Yamashita et al., 2005), and that Gata3 can 
auto-activate its own expression (Ouyang et al., 2000), these data indicate that 
miR-21 might augment Gata3 expression by decreasing Spry1 and increasing 
MAP kinase activity.  
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Figure 35: MiR-21 gene target in T cells (Spry1) linked to its role in 
promoting Th2 differentiation.  
(A) Quantitative PCR analysis of miR-21 gene taregts (Spry1, Il12a, Smad7, 
Pten, Pdcd4, Btg2) following 12-16 hrs treatment of naïve T cells with 
scrambled control, miR-21 mimic and antagomiR-21 oligos (1 µM), normalized 
to tubb5 as control. 
(B) Quantitative PCR analysis of miR-21, Spry1 and Gata3 following 12-16 hrs 
treatment of naïve T cells with scrambled control and miR-21 mimic (1 µM). 
MiR expression normalized to U6, and expression of other genes normalized to 
tubb5. Data are averaged from at least 3 independent experiments.      
*p<0.05, **p<0.01(two-tailed Student’s t-test) (error bars, s.e.m.) 
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MiR-21 target genes in Treg cells 
To validate these miR-21 targets in Treg cells, we next tested miR-21 
target genes in wild-type versus Bcl6-deficient Tregs (Figure 36). We observed a 
decrease of Spry1 mRNA in Bcl6-deficient Tregs compared to the wild-type 
Tregs. In addition, we observed a strong decrease in Il12a mRNA in Bcl6-
deficient Tregs compared to the wild-type Tregs. Il12a is a component of the key 
Treg suppressive cytokine IL-35, in conjunction with Ebi3 (Collison et al., 2007). 
Our results suggest that the decrease in Il12a mRNA in Bcl6-deficient Tregs may 
lead to less production of IL-35, which could contribute to the inability of Bcl6-
deficient Tregs to suppress Th2 inflammation. IL-35 has been reported to control 
Th2 inflammatory responses in a house-dust mite allergen challenge model in 
vivo (Huang et al., 2011). Thus, a critical target of miR-21 in Tregs appears to be 
an important immuno-suppressive cytokine.  
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Figure 36: Spry1 and II12a are miR-21 gene targets in Treg cells. 
Quantitative PCR analysis of Spry1 and Il12a in sorted Tregs from Bcl6-
deficient (KO) (black bars) and wild-type (WT) (white bars) Foxp3-gfp mice, 
with expression normalized to β-tub. n = 3 mice per group.  
*p<0.05, **p<0.01(two-tailed Student’s t-test) (error bars, s.e.m.) 
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Increased miR-21 associated with exacerbated Th2 inflammatory 
responses in lungs of mice in the airway inflammation model 
Since miR-21 is up-regulated in mouse models of allergen-driven Th2-type 
inflammation (Lu et al., 2009b), we next tested if miR-21 was up-regulated in the 
lungs of the mice in which we induced Th2 airway inflammation. While miR-21 
expression was not different between control and the wild-type Treg-treated 
mice, miR-21 was significantly increased in the total RNA of lungs taken from the 
Bcl6-deficient Treg-treated mice (Figure 37A). These data are consistent with 
previous results that Bcl6-deficient Tregs promote severe Th2 inflammation, 
rather than repress inflammation. While miR-146b was also seen up-regulated in 
Th2 inflammation, changes in miR-22 were not observed (Garbacki et al., 2011; 
Lu et al., 2009b). Strikingly, miR-22 and miR-146b followed a similar pattern of 
expression in the lungs as miR-21 (Figure 37A), indicating expression of miR-21, 
miR-22 and miR146b might be a unique micro-RNA signature induced by Bcl6-
deficient Tregs in Th2-type inflammation. We wondered if the increase in miR-21 
in the lungs that received Bcl6-deficient Tregs correlated with circulating levels of 
miR-21, as has been seen in cancer (Asaga et al., 2011; Tomimaru et al., 2012; 
Wei et al., 2011). Indeed, in mice that received Bcl6-deficient Tregs, we detected 
significantly elevated levels of miR-21 in serum (Figure 37B). We also observed 
elevated serum levels of miR-22 and miR-146b, though to a lesser degree than 
for miR-21. Nonetheless, these results indicate that increased serum miR-21 
may represent a novel biomarker for Th2-type inflammatory diseases. 
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Figure 37: Increased miR-21 in lungs and sera of mice receiving Bcl6-
deficient Tregs in the airway inflammation model. 
Quantitative PCR analysis of the 3 miRs up-regulated in Bcl6-deficient (KO) 
Tregs in the total lung RNA (A) and sera (B) of Ova-sensitized and intranasally 
challenged wild-type (WT) recipient mice (grey bars) or immunized i.p. with 
Bcl6-deficient Tregs (black bars) or wild-type Tregs (white bars) normalized 
using U6 as control.  
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Cell-types expressing miR-21 in allergic airway inflammation model 
We next tested whether cell types other than Tregs expressed the high 
levels of miR-21 seen in mice that received Bcl6-deficient Tregs. A previous 
study analyzing allergic airway inflammation showed that miR-21 was primarily 
expressed in myeloid cells in the inflamed lung (Lu et al., 2009b). As shown in 
Figure 38, we used in situ hybridization to analyze miR-21 expression in the 
lungs of mice in our allergic airway inflammation model. While we observed miR-
21 expression in myeloid cells in the inflammatory lesions of the lungs, we 
observed the strongest expression of miR-21 in airway epithelium. The elevated 
expression of miR-21 in the total lungs of mice receiving Bcl6-deficient Tregs 
therefore correlated with more myeloid cells as well as higher expression of miR-
21 in airway epithelium. These results indicate that an interplay between the 
Bcl6-deficient Tregs and the airway epithelium leads to greater microRNA 
expression, which further correlates with increased amounts of circulating miR-
21. The increased circulating microRNA may be due to exosomes shed from 
miR-expressing cells (Hunter et al., 2008; Taylor and Gercel-Taylor, 2008). 
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Figure 38: Increased miR-21 expression in the lung epithelial cells in mice 
receiving Bcl6-deficient Tregs. 
(Top) Expression of miR-21 in the paraffin-embedded lung sections of Ova-
sensitized and intranasally challenged wild-type recipient mice or immunized 
i.p. with Bcl6-deficient Tregs or wild-type Tregs as determined by LNA-based in 
situ hybridization. (Left, 100X; Right, 400X). Sections are representative of 
hybridization results from at least 3 different experiments.   
(Bottom) Expression of scrambled control probe and miR-21 probe in the 
paraffin-embedded lung sections of Ova-sensitized and intranasally challenged 
wild-type recipient mice immunized i.p. with Bcl6-deficient Tregs in 2 
representative sections as determined by LNA-based in situ hybridization.  
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MiR-21 target genes associated with exacerbated Th2 inflammatory 
responses in the airway inflammation model 
Next, we wanted to validate the miR-21 gene targets in the airway 
inflammation model where the Bcl6-deficient Tregs promoted increased miR-21 
and exacerbated Th2 responses. Strikingly, we found that both Spry1 and Il12a 
mRNAs were significantly decreased in lungs of mice that received Bcl6-deficient 
Tregs, whereas other miR-21 target mRNAs were not significantly decreased 
(Figure 39). This confirms that Spry1 and Il12a are relevant target genes that 
provide a potential mechanism for miR-21 in promoting Th2 inflammatory 
responses in vivo.  
 
 
 
 
 
 
 
 
Figure 39: Spry1 and Il12a are relevant miR-21 gene targets in the airway 
inflammation model. 
Quantitative PCR validation of Spry1, Il12a, Pdcd4 and Pten in the total lung 
RNA of Ova-sensitized and intranasally challenged wild-type recipient mice 
(grey bars) or immunized i.p. with Bcl6-deficient (KO) Tregs (black bars) or 
wild-type (WT)  Tregs (white bars) normalized using tubb5 as control.  
n = 8-10 mice per group. *p<0.05, **p<0.01, ***p<0.001  (two-tailed Student’s 
t-test) (error bars, s.e.m.)  	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Part III: MiR-21 as a clinically relevant non-invasive biomarker for human 
Th2 inflammatory conditions 
MiR-21 is strongly elevated in biopsies of pediatric patients with 
Eosinophilic Esophagitis (EoE) 
MiR-21 is one of the most commonly dysregulated miRNA in a wide 
variety of cancers (Hatley et al., 2010; Jung and Calin, 2010). It is also reported 
as increased in heart diseases (Thum et al., 2008), lung fibrosis (Liu et al., 2010), 
type 1- diabetes (Ruan et al., 2011), T cell lymphoma (van der Fits et al., 2011), 
lupus (Garchow et al., 2011; Pan et al., 2010), and psoriasis (Meisgen et al., 
2012; Zibert et al., 2010). Relevant to the role of miR-21 in promoting Th2 
responses, miR-21 is up-regulated in three different mouse models of allergic 
inflammation (OVA, IL-13 transgenic and Aspergillus fumigatus) (Lu et al., 
2009b). Further, we have also noted a strong induction of miR-21 in our airway 
inflammation studies, particularly for mice receiving Bcl6-deficient Tregs that 
developed severe Th2 inflammation. While inhibition of the Th1 cytokine IL-12 
has been demonstrated as one mechanism for the association of miR-21 in Th2 
diseases (Lu et al., 2011b; Lu et al., 2009b), our studies highlight a novel T cell 
intrinsic role for miR-21 in Th2 differentiation. Thus overall these studies suggest 
that miR-21 may not just be a passive marker up-regulated in Th2 diseases, but 
serves a functional role in augmenting Th2 responses via its role in myeloid cells 
and T cells. Thus, miR-21 may be part of a positive feedback loop amplifying the 
Th2 inflammatory responses.  
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MiRNAs are being used as diagnostic biomarkers for cancer and a 
number of autoimmune and inflammatory pathologies (O'Connell et al., 2012; 
Sonkoly and Pivarcsi, 2009; Tricoli and Jacobson, 2007). Thus, to pursue the 
idea of miR-21 as a novel biomarker for Th2-type inflammatory diseases, we 
wondered if miR-21 was up-regulated in human allergic diseases. Eosinophilic 
esophagitis (EoE) is an increasingly prevalent allergic disease where the 
esophagus becomes highly inflamed, frequently in response to food allergens 
(Liacouras et al., 2011; Noel and Rothenberg, 2005; Rothenberg, 2009). Further, 
EoE is a Th2-type inflammatory disease characterized by high eosinophil 
infiltration into the esophageal epithelium, with the hallmark Th2 cytokines 
implicated in the pathology. We therefore obtained esophageal biopsies from 
pediatric EoE patients (Subbarao et al., 2011). Our controls in the study were 
patients who had undergone esophagogastroduodenoscopy (EGD) for a variety 
of non-specific reasons but had normal histology of biopsies from the upper 
gastro-intestinal tract. MiR-21 was elevated an average of 50-fold in EoE 
biopsies over control biopsy levels, with statistical significance. In contrast, miR-
22 and miR-146b were not elevated in EoE biopsies (Figure 40A). To assess the 
specificity of miR-21 induction in Th2 diseases, we also tested biopsies from 
human patients with Crohn’s disease, a Th1-mediated disease (Dalal and Kwon, 
2010). MiR-21 levels were unchanged in the biopsies of Crohn’s patients 
compared to controls, while miR-146b was undetected (Figure 40B). These 
results indicate that miR-21 is specifically elevated in human Th2 inflammatory 
diseases and could serve as a potential biomarker for Th2 conditions.  
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Figure 40: Increased miR-21 in the biopsies of pediatric patients with 
Eosinophilic Esophagitis (EoE). 
(A) Quantitative PCR analysis of miR-21, miR-22 and miR-146b expression in 
esophageal biospsy RNA from healthy controls and eosinophilic esophagitis 
(EoE) patients, normalized using U6 as control. n = 18-20 subjects per group. 
(B) Quantitative PCR analysis of miR-21 expression in colon biopsy RNA from 
healthy controls and Crohn’s disease (CD) patients, normalized using U6 as 
control. n=2 controls, 7 CD patients. ***p<0.001 (two-tailed Student’s t-test) 
(error bars, s.e.m.)  
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Circulating miR-21 can serve as a non-invasive biomarker for human Th2 
inflammatory diseases 
Circulating miRNAs are being used as non-invasive biomarkers in the 
cancer field (Cho, 2007). Since we noted increased circulating miR-21 in the sera 
of mice receiving Bcl6-deficient Tregs that correlated with a striking increase in 
miR-21 in the lungs and Th2 exacerbation, we tested sera of EoE patients. 
Indeed, consistent with the increase in miR-21 in the EoE biopsies, we noted an 
almost 30-fold increase in circulating miR-21 in the sera of EoE patients 
compared to controls (Figure 41). The other control miRs – 22 and 146b were not 
detected in the sera samples. This suggested that circulating miR-21 can be 
used as a non-invasive biomarker for Th2-type inflammation. Another report also 
noted increased miR-21 in the biopsies of EoE patients (Lu et al., 2012a; Lu et 
al., 2012b), although they noted only a 4-fold increase and reported little to no 
levels of circulating miR-21 in EoE (Lu et al., 2012b).  
  
 
Figure 41: Increased miR-21 in the sera of pediatric patients with 
Eosinophilic Esophagitis (EoE). 
Quantitative PCR analysis of miR-21 expression in serum RNA from healthy 
controls and eosinophilic esophagitis (EoE) patients, normalized using U6 as 
control. n = 18-20 subjects per group. 
*p<0.05, **p<0.01, ***p<0.001 (two-tailed Student’s t-test) (error bars, s.e.m.)  
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Increased circulating miR-21 in the sera of asthmatic patients, however, 
miR-21 does not correlate with atopy  
Some explanations for the differences between our results and the other 
studies (Lu et al., 2012a; Lu et al., 2012b) assessing miR-21 levels in EoE are                
1) possible differences in disease severity between patients in the two studies, 2) 
differences in assay sensitivity in detecting miR-21 and 3) differences in control 
patients between the two studies. Notably, for the serum analysis, the Lu et al 
study compared circulating miR-21 in EoE patients to healthy atopic patients. In 
contrast, our controls in the EoE study were patients with normal histology of the 
upper GI tract who underwent EGD for non-specific reasons, but were not 
enriched for atopy. To better understand the relationship between atopy, allergic 
inflammatory disease and miR-21, we analyzed serum miR-21 levels in pediatric 
patients recruited into a study on the development of asthma. The patients were 
recruited as infants, based on a diagnosis of dermatitis, and subsequently 
characterized for atopic status and the development of asthma (Tepper et al., 
2008). Atopic status was defined as the presence of specific IgE to at least 1 out 
of 10 allergens tested. We found that in a randomly selected set of 16 patients, 
tested at 5 years of age, serum miR-21 increased in the asthma patients by 4-
fold, with a p value of 0.018 (Figure 42A). MiR-22 showed no increase in patients 
with asthma (Figure 42A). In our selected patients, 8 out of 16 patients were 
atopic, however atopy was randomly distributed between asthmatic and non-
asthmatic patients. While asthmatic patients had on average a two-fold increase 
in serum IgE over non-asthmatic patients (130 IU/ml versus 60 IU/ml), the 
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difference in average IgE level was not significant (p=0.24). MiR-21 levels did not 
associate positively or negatively with atopy in this set of patients (Figure 42B). 
Thus, serum miR-21 is a novel biomarker for asthma, independent of atopy. 
Further research will be required to determine if serum miR-21 levels are a useful 
predictor of the development of asthma, EoE or other allergic inflammatory 
diseases.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 42: Increased miR-21 in the sera of pediatric patients with asthma. 
Q     (A) Quantitative PCR (QPCR) analysis of miR-21 and miR-22 expression in 
serum samples prepared from 5 year old patients presenting at 1 year of age 
with dermatitis and then monitored for allergy symptoms and the development 
of asthma. Relative miR expression with U6 as control miR. 
 P     (B) Pearson correlation analysis between IgE levels and miR21 levels (fold 
change from average non-asthmatic control). N = 16 total patients, 8 with 
asthma and 8 without asthma. *p<0.05 (two-tailed Student’s t-test) (error bars, 
s.e.m.) 
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Part IV: Role of Bcl6 in Treg lineage stability in the context of the Th2 
inflammatory disease in Bcl6-deficient mice 
Generation of dual reporter mice to assess stability of Foxp3 expression of 
Bcl6-deficient Tregs in vivo 
Despite the central role of Tregs in maintaining immune tolerance, less is 
known about stability of the Treg phenotype in vivo. Most Tregs maintain high 
Foxp3 levels following adoptive transfer in a non-pathogenic setting (Floess et 
al., 2007; Gavin et al., 2007). However, recent reports employing Foxp3 reporter 
mice reveal that Foxp3 expression gets de-stabilized in inflammatory settings 
and these Tregs, termed “exTregs”, acquire cytokine production capabilities of 
effector T cells (Zhou et al., 2009c). CD4+CD25-Foxp3+ Tregs can convert to 
Bcl6-expressing Tfh cells in the mouse peyer’s patches (Tsuji et al., 2009). 
Recently, TGFβ and retinoic acid present in the gut was shown to induce miR-
10a, that targets Bcl6, thus maintaining Treg stability and preventing Treg 
conversion to Tfh cells (Takahashi et al., 2012). Although our gene expression 
profiling of Bcl6-deficient Tregs did not show any reduction or loss of classical 
Treg gene signature, Bcl6-deficient Tregs exhibited a strong Th2-bias. One 
possible explanation is that the hyper-Th2 inflammation in Bcl6-deficient mice 
leads to destabilization of the Treg phenotype and reprogramming of the cells to 
Th2 fate. Therefore to perform genetic lineage tracing of Bcl6-deficient Foxp3+ 
Tregs in the context of the hyper-Th2 inflammation in vivo, we crossed Bcl6-
deficient mice with Foxp3-GFP-Cre x R26-YFP mice (designated as RFC strain). 
In the RFC mice, the Foxp3-GFP-Cre+ Tregs excise the loxP-flanked stop codon 
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allowing for constitutive YFP expression from the R26 promoter, thus 
permanently labeling the Foxp3+ T cells and their progeny (Zhou et al., 2009c). 
This dual reporter mouse strain enables effective tracing of Foxp3 induction and 
down-regulation concurrently by two-color flow analysis of GFP and YFP 
expression (Figure 43). Due to a delay between Foxp3 transcription (GFP 
expression) and excision of the loxP-flanked stop cassette in the R26-YFP 
transgene by Cre, the GFP+YFPlo-neg population represents cells that recently up-
regulated Foxp3 expression, GFP+YFP+ cells represents the stable Tregs and 
the GFP-YFP+ Treg population represents the exTregs. Monitoring the 
percentages of stable Tregs and exTregs in the peripheral lymphoid organs and 
the inflamed heart and lungs in Bcl6-defient mice (KO RFC) relative to the wild-
type counterparts (WT RFC) will provide useful insights into the impact of the Th2 
inflammatory environment on Bcl6-deficient Treg stability as well as the 
contribution of these exTregs to the Th2 disease. 
Foxp3-GFP-Cre mice 
x 
R26 –YFP mice 
YFP 
GFP 
Tconv 
GFP-YFP- 
Transient Treg 
GFP+YFP- 
Stable Treg 
GFP+YFP+ 
exTreg 
GFP-YFP+ 
Figure 43: Schematic for isolating stable Tregs and exTregs using the 
Foxp3 lineage tracing mouse model. 
Stable Tregs (GFP+YFP+) and exTregs (GFP-YFP+) populations from WT and 
KO RFC mice will be assayed by flow analysis of YFP/GFP expression 
following surface staining of thymus and (SPL+LN) CD4+CD25+ T cells. Cell 
populations will also be sorted for characterization of phenotype and function. 
	   164 
Bcl6-deficient mice exhibit increased exTregs in the periphery 
Bcl6-deficient mice on the Foxp3-GFP-Cre x R26-YFP background (KO 
RFC) developed myocarditis and lung vasculitis at an accelerated rate compared 
to the germ-line Bcl6-deficient mice. While the germ-line Bcl6-deficient mice die 
about 6-12 weeks of age, most of the KO RFC mice die by 3-5 weeks of age. 
Histology of the heart and lungs demonstrated severe inflammation in the heart 
and lungs (data not shown) compared to germ-line Bcl6-deficient mice that can 
explain their accelerated death rate. We predict that the increased inflammatory 
response in this strain is likely due to effects from the NOD background of the 
Foxp3-GFP-Cre mice or a genetic drift effect. ExTregs have been shown to 
down-regulate expression of the classical Treg surface marker, CD25 (Zhou et 
al., 2009c). However, we noted either increased or intact percentages of 
CD4+CD25+ T cells in the thymus and (SPL+LN) preparations (Figure 44). 
 
 
 
 
 
 
%
 C
D
4+
C
D
25
+  
T 
ce
lls
WT KO
0
2
4
6
8
10 **p < 0.01
(Thymus)
%
 C
D
4+
C
D
25
+  
T 
ce
lls
WT KO
0
1
2
3
4
5
NS
(SPL & LNs)
Figure 44: Increased percentages of CD4+CD25+ T cells in the thymus and 
similar percentages in the periphery of WT and KO RFC mice. 
Cell preparations from wild-type (WT) and Bcl6-deficient (KO) RFC mice were 
stained for classical Treg surface markers – CD4 and CD25 and the assessed 
by flow analysis. N=10-15 mice per group. **p<0.01 (two-tailed Student’s t-test) 
error bars = s.e.m.)   
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About 10% of peripheral CD4+ T cells are reported to be GFP+YFP+ 
(stable Tregs) and about 15-20% of the peripheral YFP+ cells can convert to 
GFP-YFP+ exTregs (Zhou et al., 2009c). Analysis of the thymus in the WT and 
KO RFC mice demonstrated a comparable percentage of both stable Tregs and 
exTregs, thereby suggesting that the KO Tregs are not intrinsically biased 
towards losing Foxp3 expression (Figure 45A). On the other hand, analysis of 
these populations in the peripheral lymphoid organs (spleen and lymph nodes) 
demonstrated a significant increase in the percentage of exTregs and a 
corresponding decrease in stable Treg numbers in the KO RFC mice relative to 
WT RFC (Figure 45B). This indicated that the Th2 inflammatory environment in 
the Bcl6-deficient mice de-stabilizes Tregs and favors the loss of Foxp3 
expression. While we did not detect any obvious difference in the percentages of 
CD4+CD25+Foxp3+ Tregs in the peripheral lymphoid organs of WT and Bcl6-
deficient mice on the Foxp3-gfp background (as shown in Figure 5), the 
heightened proliferative potential of the Bcl6-deficient Tregs (as shown in Figure 
8) may contribute to their high turnover rate, thus necessitating the use of dual 
reporters to track their stability in vivo. The increased inflammatory background in 
the KO RFC may accelerate the down-regulation of Foxp3 in the Bcl6-deficient 
Tregs. While the exact reason for the increased exTreg generation on the KO 
RFC background remains unclear, this data suggests that the absence of Bcl6 
exacerbates the instability of Foxp3 under the inflammatory setting. 
 
  
	   166 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
  
 
Figure 45: Increased percentages of exTregs and reduced stable Tregs in 
peripheral lymphoid organs of KO RFC mice. 
Cell preparations from wild-type (WT) and Bcl6-deficient (KO) RFC mice from 
the thymus (A) and (SPL+LN) (B) were stained for CD4 and assessed by flow 
analysis for YFP/GFP. Cells were gated as CD4+ T cells to assess percentages 
of stable (GFP+YFP+) and exTregs (GFP-YFP+) populations. N=10-15 mice per 
group. *p<0.05 (two-tailed Student’s t-test) error bars = s.e.m. 
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GFP+YFP+ stable Tregs and GFP-YFP+ exTregs exhibit a strong Th2-bias in 
the absence of Bcl6 
ExTreg (GFP-YFP+) cells have been reported to exhibit an activated-
memory phenotype with reduced (CD25, GITR) or heterogeneous (CTLA-4, FR4, 
CD103) expression of Treg signature genes, heterogeneous CD62L, high CD44 
and also acquire effector cytokine-producing ability (IFNγ or IL17A) based on the 
microenvironment (Zhou et al., 2009c). In order to assess the effect of the Th2 
inflammatory environment on the Treg and exTreg phenotype in Bcl6-deficient 
mice, we sorted CD25- Tconv cells, GFP+YFP+ stable Tregs and GFP-YFP+ 
exTregs from WT and KO RFC mice, activated them in vitro and assessed their 
gene expression and cytokine secretion signature. Consistent with the well-
demonstrated role for Bcl6 in inhibiting Th2 differentiation (Kusam et al., 2003), 
we noted increased expression of Th2 genes (Gata3, Il4, Il5, Il13) in KO Tconv 
cells, relative to WT (Figure 46). This translated into increased secretion of Th2 
cytokines by KO Tconv cells as represented in Table 4. Although IL-17A 
expression was increased in KO Tconv cells, IFNγ was not significantly different. 
Importantly, the stable Tregs from the KO RFC mice also exhibited a selective 
Th2-bias, consistent with our gene expression array data with Bcl6-deficient 
Foxp3gfp Tregs (Figure 46). Specifically Th2 genes were strongly elevated in KO 
Tregs, confirming that Bcl6 also represses Th2 gene expression in Treg cells. 
The overall levels of Th2 gene expression in the Treg fraction was reduced in KO 
Tregs compared to KO Tconv cells, consistent with a role of Foxp3 in limiting 
effector cytokine expression in Tregs. On the other hand, the KO exTregs 
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acquired a Th2-bias, suggesting that the exTregs were remodeled in the context 
of the Th2 inflammatory environment in the RFC mice (Figure 46). Although Il17a 
was increased in KO exTregs, the induction was not as potent as the Th2 genes, 
while Ifng remained unchanged. Interestingly, the induction of Th2 genes in the 
KO exTregs was comparable to the levels in the KO Tconv cells, indicating that 
the Tregs that lose Foxp3 under inflammatory contexts acquire effector cytokine-
producing abilities similar to effector T cells. Thus the Th2-biased exTregs in KO 
RFC mice may contribute to the exacerbation of the inflammatory Th2 responses 
and thus the heart and lung-specific pathology in Bcl6-deficient mice. Thus, while 
the increased Th2 gene signature in the KO stable Tregs strongly confirms an 
intrinsic Th2-bias of Tregs in the absence of Bcl6, the potent Th2 gene induction 
in the KO exTregs suggests that the Th2 inflammatory disease strongly favors 
loss of Foxp3 expression and remodeling of Tregs to Th2 effectors. Thus, these 
studies suggest that the Th2-biased stable Tregs and environmentally re-
programmed exTregs can contribute to the increased Th2 polarization and 
exacerbated inflammatory disease in the Bcl6-deficient mice. 
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Figure 46: Potent Th2-bias of Tconv, stable Tregs and exTregs derived 
from KO RFC mice. 
Tconv (CD4+CD25-), stable Tregs (CD4+CD25+GFP+YFP+) and exTregs 
(CD4+CD25+GFP-YFP+) populations from spleen and lymph node preparations 
of wild-type (WT) and Bcl6-deficient (KO) RFC mice were FACS-sorted and 
then stimulated with anti-CD3 and anti-CD28 for 12-16 hours for gene 
expression analysis. Data represent average gene expression normalized 
using tubb5 as endogenous control. N= 5 WT and 4 KO RFC mice. 
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Mice 
Cytokine 
            WT RFC                     KO RFC 
 
(pg/ml) 
Tconv 
GFP-YFP- 
ExTreg 
GFP-YFP+ 
Stable 
Treg 
GFP+YFP+ 
Tconv 
GFP-YFP- 
ExTreg 
GFP-YFP+ 
Stable 
Treg 
GFP+YFP+ 
IL-4 
229 
± 122 
5 
± 2 
3 
± 1 
9713 
± 3614 
7498 
± 3650 
895 
± 424 
IL-5 
27 
± 5 
23 
± 1 
6 
± 1 
6054 
± 2597 
3929 
± 1692 
904 
± 196 
IL-13 
14 
± 4 N.D. N.D. 
4663 
± 2815 
2460 
± 1220 
310 
± 128 
IL-10 
114 
± 14 
388 
± 116 
271 
± 31 
1822 
± 1279 
3626 
± 1470 
3670 
± 353 
IFNγ 
978 
± 2 
108 
± 34 
71 
± 28 
1348 
± 609 
120 
± 28 
150 
± 86 
IL-17 
219 
± 58 
107 
± 33 
65 
± 1 
1680 
± 521 
1094 
± 183 
880 
± 67 
Table 4: Cytokine levels in Tconv, exTreg and stable Treg subsets from 
WT and KO RFC mice. 
Supernatants harvested from overnight-activated FACS sorted Tconv cells 
(CD4+CD25-), exTregs (CD4+CD25+GFP-YFP+) and stable Tregs 
(CD4+CD25+GFP+YFP+), assessed by multiplex analysis. Data represented is 
an average from 2 WT and 3 KO RFC mice. 	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Part V: Characterization of Treg-specific Bcl6 conditional knockout mice  
Generation of Treg-specific Bcl6 conditional mutant (Bcl6neofl/neoflFoxp3Cre) 
mice (Stage I) 
 To test whether the promotion of Th2 inflammation by the Bcl6-deficient 
Tregs was an intrinsic effect of loss of Bcl6 within the Treg lineage, we generated 
Treg specific Bcl6 conditional mutant mice. A conditional KO allele for Bcl6, 
where the zinc finger-encoding exons of Bcl6 were flanked by loxP sites (Bcl6fl//fl), 
was constructed and used to target ES cells (Figure 47). After generation of 
chimeric mice, the Bcl6fl//fl allele was transmitted to offspring mice (Stage I). 
These Stage I mice carry the Bcl6fl//fl allele containing the neomycin gene flanked 
by loxP sites, hence referred as Bcl6neo/fl/ neo/fl mice (Stage I). These mice were 
mated to Foxp3-gfpCre mice to generate mice with Treg-specific deletion of Bcl6 
(Bcl6neofl/neoflFoxp3Cre mice). Bcl6neofl/neoflFoxp3Cre mice exhibit almost 90% loss of 
Bcl6 expression in Treg cells, whereas Bcl6 expression was increased in 
conventional CD4 T cells (Tconv) from the conditional mutant mice, indicating 
specific loss of Bcl6 in the Treg lineage (Figure 47).  
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Figure 47: Treg-specific deletion of Bcl6 (Stage I). 
(Top) Targeting construct for the generation of Bcl6neofl/neofl mice. These mice 
were mated to Foxp3-gfpCre mice to generate Bcl6neofl/neoflFoxp3Cre mice. 
(Bottom) QPCR analysis of Bcl6 transcript between Bcl6neofl/neoflFoxp3Cre (black 
bars) and Bcl6neofl/neofl (white bars) in FACS-sorted CD4+CD25+Foxp3+ (Tregs) 
and MACS-isolated CD4+CD25- (Tconv) cells, following activation for 16 hrs 
with anti-CD3 and anti-CD28. Relative gene expression normalized to tubb5. 
N=3 (Bcl6neofl/neofl) and n=6 (Bcl6neofl/neoflFoxp3Cre) groups, respectively. 
*p<0.05, **p<0.01, ***p<0.001 (two-tailed Student’s t-test) (error bars, s.e.m.)  
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Heart-specific inflammatory disease in the Bcl6neofl/neoflFoxp3cre (Stage I) 
mice, similar to germ-line Bcl6 knockout mouse 
Strikingly, deletion of Bcl6 expression specifically in the Treg lineage led to 
a high rate of spontaneous and severe myocarditis (Figure 48). Like the 
myocarditis observed in germ-line Bcl6-deficient mice, the myocarditis in 
Bcl6neofl/neoflFoxp3cre mice was associated with eosinophils (Fig 48, inset) and was 
observed at a high frequency (10/16 mice = 63%). Further investigation of the 
Stage I Bcl6neofl/neofl mice revealed that these mice also develop myocarditis, but 
at a lower frequency and with less severity. While the Bcl6neofl/neoflFoxp3cre mice 
exhibit a 90% loss of Bcl6 expression in the Treg lineage, we suspect that the 
neo gene down-regulates Bcl6 expression to a significant but lesser extent in 
other lineages. The Bcl6neofl gene may represent a “hypomorphic” Bcl6 allele, 
with expression of functional Bcl6 protein but overall decreased Bcl6 expression 
compared to wild-type. Thus, the severe myocarditis in Bcl6neofl/neoflFoxp3cre mice 
may be a combination of decreased Bcl6 expression in lymphoid and myeloid 
cells, with the Treg defects from full loss of Bcl6 leading to failure to control the 
Th2 pathology, in a manner similar to germ-line Bcl6-deficient mice.   
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Figure 48: Treg-specific Bcl6 conditional mutant mice (Stage I 
Bcl6neofl/neoflFoxp3cre ) develop spontaneous myocarditis. 
(Left) Heart histopathology assessed by H & E staining of paraffin-embedded 
sections for Bcl6fl/fl (top panel) and Bcl6fl/fl Foxp3Cre (bottom panel). Original 
magnification, 40X (left) and 400X (right). Inset in 400X in Bcl6fl/flFoxp3Cre 
shows high power view of eosinophils. (Right) Heart sections from 
Bcl6fl/flFoxp3Cre (black bars) and Bcl6fl/fl (white bars) mice were scored in a 
blinded-fashion on a scale of 0-4 to assess the severity of myocarditis. N=14 
(Bcl6fl/fl) and N=16 (Bcl6fl/fl Foxp3Cre) groups. (**p =0.0096)  
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Intrinsic regulation of Th2 gene expression in Tregs by Bcl6 
To obtain FoxP3+ Tregs from control Bcl6neofl/neofl mice, we bred the 
FoxP3-gfp allele used in our earlier studies to this strain. Foxp3+ Tregs from 
Bcl6neofl/neoflFoxp3cre mice displayed a significant increase in Th2 cytokines (Il4, 
Il5, Il13) but not an increase in the Th1 cytokine, Ifng (Figure 49), when 
compared to FoxP3+ Tregs from Bcl6neofl/neofl mice. Our results were consistent 
with our microarray analysis of Tregs from germline Bcl6-deficient mice. Tconv 
from Bcl6neofl/neoflFoxp3cre mice did not show a significant increase in Th2 
cytokines (Figure 49), showing specific effects of loss of Bcl6 in the Treg lineage. 
These results from the Stage I Bcl6neofl/neoflFoxp3cre mice strongly support the idea 
that Bcl6-deficient Tregs have an intrinsic defect that results in increased Th2 
cytokine expression and further allows them to promote, instead of suppress 
Th2-type inflammation. 
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Figure 49: Bcl6 intrinsically represses Th2 gene expression in Treg cells. 
Quantitative PCR analysis of Th2 genes (Il4, Il5, Il13) and Ifng transcripts 
between Bcl6neofl/neoflFoxp3cre (black bars) and Bcl6neofl/neofl (white bars) FACS-
sorted CD4+CD25+Foxp3+ (Tregs) and MACS-isolated CD4+CD25- (Tconv) 
cells following activation for 16 hrs with anti-CD3 and anti-CD28. Relative gene 
expression is shown, where expression is normalized to tubb5. Data are 
average expression from n=3 (Bcl6neofl/neofl) and n=6 (Bcl6neofl/neoflFoxp3cre) 
groups, respectively. 
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Generation of Bcl6 conditional mutant (Bcl6fl/flFoxp3cre) mice (Stages II and 
III)  
The next step was to assess the ability of Bcl6-deficient Tregs from the 
conditional mutant mice to control Th2 inflammatory responses in vivo. While we 
do note an intrinsic increase in Th2 cytokine expression from Tregs derived from 
the Bcl6neofl/neoflFoxp3cre mice, these mice still retain the neo gene that affects 
Bcl6 expression in other lineages and develop a Th2-baised inflammatory 
pathology in their hearts. Thus, to definitively assess control of Th2 responses by 
Bcl6-deficient Tregs, we generated the neo-deleted Bcl6fl//fl (Stage II) mice by 
mating Bcl6neofl/neofl mice to mice expressing EIIa-Cre (Figure 50). These neo-
deleted Bcl6fl//fl (Stage II) mice were then mated to Foxp3gfp Cre to generate the 
final Treg-specific conditional mutant (Bcl6fl/flFoxp3cre) Stage III mice (Figure 50). 
(Stage II) 
Mate to Foxp3gfp-Cre mice 
Bcl6fl/flFoxp3cre conditional mutant mice  
Bcl6neofl/neofl mice  
Figure 50: Treg-specific deletion of Bcl6 (Stages II & III). 
Bcl6neofl/neofl mice (Stage I) were mated to mice expressing EIIa-cre 
recombinase. The resultant neo-gene deleted Bcl6 floxed mice (Stage II) were 
mated to Foxp3gfp Cre mice to generate the final Treg-specific Bcl6 conditional 
mutant (Bcl6fl/flFoxp3cre) mice (Stage III). 
 
	   178 
Tregs derived from Bcl6 conditional mutant (Bcl6fl/flFoxp3cre) mice acquire 
a Th2-bias and fail to suppress Th2 allergic airway inflammation in vivo 
The final Stage III Treg-specific Bcl6 conditional mutant (Bcl6fl/flCre+) mice 
appear grossly normal and in preliminary assessments showed no development 
of myocarditis (not shown). To further characterize these mice, Bcl6fl/flCre+ mice 
and their littermate controls (Bcl6fl/flCre-) mice were tested for induction of allergic 
airway inflammation using the same sensitization and challenge protocol as 
shown in Figure 12. We noted that the Bcl6fl/flCre+ mice exhibited increased 
inflammatory cell accumulation in the lung airways, particularly T cells, as 
assessed from flow analysis of the bronchoalveolar lavage (BAL) fluid (Figure 
51A). The Bcl6fl/flCre+ Tregs demonstrated a significant increase in expression of 
the Th2 transcription factor, GATA-3 (Figure 51B). This is consistent with a Th2-
biased phenotype noted with germline Bcl6-deficient Tregs. Interestingly, these 
Bcl6fl/flCre+ Tregs also failed to suppress Th2 allergic responses as shown by 
increased percentages of IL-4+ T cells in the periphery for Bcl6fl/flCre+ mice, 
compared to controls, while the percentage of IFN-γ+ T cells remained 
unchanged in the two groups (Figure 51C). Thus, these results validate our 
results with Tregs derived from the germline Bcl6-deficient mice and confirm an 
intrinsic role for Bcl6 in Treg control of Th2 inflammatory responses in vivo. 
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Figure 51: Bcl6 conditional mutant (Bcl6fl/flFoxp3cre) Tregs fail to suppress 
Th2 allergic airway inflammation in vivo. 
(A) Flow analysis of different cell types (T cells, B cells, Eos, Macrophages and 
DCs) from the BAL fluid from sensitized and challenged Treg-specific Bcl6 
conditional mutant (Bcl6fl/flCre+) mice and their littermate controls (Bcl6fl/flCre-) 
mice. (B) ICS depicting percentage of GATA-3+Foxp3+ Tregs derived from the 
spleens of Treg-specific Bcl6 conditional mutant (Bcl6fl/flCre+) mice and their 
littermate controls (Bcl6fl/flCre-) following activation with PMA and Ionomysin. 
(C) ICS depicting percentage of IL-4+ and IFN-γ+ T cells derived from the 
spleens of Treg-specific Bcl6 conditional mutant (Bcl6fl/flCre+) mice and their 
littermate controls (Bcl6fl/flCre-) following activation with PMA and Ionomysin. 
N=6 (Bcl6fl/flCre+) mice and 8 (Bcl6fl/flCre-) mice, respectively.                  
*p<0.05 (two-tailed Student’s t-test) (error bars, s.e.m.)  
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Bcl6 and BAZF (Bcl6b) induce differentiation of naïve CD4+ T cells to Tfh 
fate in vitro 
Bcl6 is the master transcription factor for T follicular helper cells, subset of 
T cells that help germinal center B cells in the production of high affinity plasma 
cells and memory B cells (Johnston et al., 2009; Nurieva et al., 2009; Yu et al., 
2009). Bcl6-deficient mice fail to form Tfh cells and germinal centers. Importantly, 
Bcl6 over-expression alone is sufficient to induce Tfh differentiation of naïve 
CD4+ T cells and as shown in Figure 52A. We note induction of the Tfh signature 
genes (CXCR5, ICOS, IL-21, PD-1) in Bcl6 RV transduced T cells under both 
resting and activated conditions. Expression of a known Bcl6 homologue, BAZF 
(Bcl6b) is increased to the same extent as Bcl6 in antigen-primed Tfh cells 
(Fazilleau et al., 2009; Pelletier et al., 2010). This prompted us to test the 
functional relevance of BAZF in the Tfh differentiation program. We note that 
similar to retroviral transduction of Bcl6, BAZF RV transduced T cells also 
demonstrated an increased in Tfh genes (CXCR5, IL-21, PD-1) relative to control 
RV (Figure 52B). Thus, this suggests that BAZF may also contribute to the Tfh 
developmental program. Being a well-characterized transcriptional repressor, 
Bcl6 probably positively directs Tfh differentiation by repressing miRNAs that 
target key Tfh genes (Yu et al., 2009). Bcl6 represses miR-17-92 that targets the 
chemokine receptor, CXCR5. MiR-21 is one of the most strongly down-regulated 
miRNA by Bcl6 in T cells as shown (Figure 52C), although its functional 
relevance to Tfh differentiation is unknown. 
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Figure 52: Bcl6 and Bazf direct Tfh differentiation in vitro. 
(A) Quantitative PCR analysis of Tfh genes (Cxcr5, Icos, Il21, Pd1) in Bcl6 RV 
transduced CD4 T cells, with their expression in control RV transduced cells    
set to 1. Fold induction (Bcl6 RV/Control RV) of Tfh genes reported in FACS-
sorted RV transduced resting cells (white bars) and following activation for 6-
12 hrs with anti-CD3 and anti-CD28 (black bars). Data are averaged from at- 
least 3 independent experiments. 
(B) Quantitative PCR analysis of Tfh genes (Cxcr5, Icos, Il21, Pd1) in Bazf RV 
transduced CD4 T cells, with their expression in control RV transduced cells    
set to 1, following activation for for 6-12 hrs with anti-CD3 and anti-CD28. 
(C) Quantitative PCR analysis of miRNAs (21, 17, 92) in Bcl6 RV transduced 
CD4 T cells, with their expression in control RV transduced cells set to 1. Fold 
repression (Bcl6 RV/Control RV) of miRNAs reported following activation of RV 
transduced cells for 6-12 hrs with anti-CD3 and anti-CD28.  Data are averaged 
from at-least 3 independent experiments. 
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Bcl6 specifies development of T follicular regulatory cells, specialized in 
control of germinal center response  
T follicular regulatory cells (Tfr) are a sub-population of Tregs that co-
express Bcl6 and CXCR5 and localize to the germinal centers in mice and 
humans (Chung et al., 2011; Linterman et al., 2011). These cells up-regulate the 
hallmark Tfh markers (CXCR5, BTLA, PD-1, ICOS) in a Bcl6-dependent manner. 
Thus, Bcl6-deficient CD4+CD25hi Tregs exhibit decreased expression of Cxcr5, 
Pdcd1 and Btla (Chung et al., 2011). Similar decreases in Tfh markers was also 
noted in our Bcl6-deficient CD4+CD25+Foxp3+ Tregs derived from Foxp3gfp mice 
(data not shown). Foxp3-deficient scurfy mice lack Tfr cells and exhibit moderate 
increases in Tfh cell numbers, but marked increase in GC B cells, indicating that 
these cells are indispensible for regulating the germinal center B cell response. 
Since Bcl6-conditonal mutant mouse strains were unavailable, earlier reports by 
Linterman et al (Linterman et al., 2011) and Chung et al (Chung et al., 2011) 
relied on indirect methods to assess the functional relevance of Tfr cells – fetal 
liver chimeras of Bcl6+/+: Bcl6-/- and Sh2d1a-/- or Sh21a+/+: Foxp3DTR, or 
adoptive transfers of Bcl6-deficient and CXCR5-deficient Tregs to Tcrβ-deficient 
mice.  
Thus, the Treg-specific Bcl6 conditional knockout mouse strain we have 
generated is ideal to define the functional implications of Tfr cells in regulating 
both the magnitude and quality of the germinal center reaction. We note that un-
immunized Bcl6neofl/neofl Foxp3cre (Stage I) mice exhibit spontaneous increase in 
Tfh cells, GC B cells and plasma cells, compared to Bcl6neofl/neofl control mice 
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(Figure 53). Similar results were obtained comparing unimmunized Stage III 
Treg-specific Bcl6 conditional mutant (Bcl6fl/flCre+) mice, relative to controls 
(Bcl6fl/flCre-). This confirms that defects in Tfr cell development lead to 
uncontrolled Tfh and germinal center activity.  
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Figure 53: Bcl6neofl/neoflFoxp3Cre mice have increased spontaneous Tfh, GC 
B and plasma cells. 
Spleen cell preparations from un-immunized Bcl6neofl/neoflFoxp3Cre and control 
Bcl6neofl/neofl (Cre negative) mice were stained for the indicated Tfh 
(CD4+CXCR5+ICOS+PD-1+) (A), GC B (B220+GL-7+CD95+) (B) and plasma 
cell (B220lowCD138+) (C) surface markers. N=2/group.  
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DISCUSSION 
Bcl6-deficient Treg cells exhibit a selective failure to suppress Th2 immune 
responses in vivo 
In the past few years, Bcl6 has gained a great deal of attention as a 
master regulator of T follicular helper (Tfh) cells, and has been shown to inhibit 
differentiation towards Th1, Th2 and Th17 fates (Dent et al., 1998a; Dent et al., 
1997; Johnston et al., 2009; Kusam et al., 2003; Nurieva et al., 2009; Yu et al., 
2009). Lack of germinal centers and failure to mount protective secondary 
antibody responses are the key observations underlying its role as a master 
transcription factor for Tfh and GC B cells. In addition, the absence of Bcl6 
manifests as a spontaneous and severe Th2-mediated inflammatory disease, 
affecting the heart and lungs, early in life. The inflammatory disease in Bcl6-
deficient mice is complex and involves multiple cell types, however, the disease 
is completely dependent upon T cells (Table 3). While the Bcl6-deficient APC-
derived pro-Th17 cytokines also contribute to the disease severity (Mondal et al., 
2010), the Th2 inflammatory response is dominant to the pathology. These 
observations underscore the well-characterized role for Bcl6 in inhibiting Th2 
differentiation, but may also suggest that Th2 inflammatory responses increase in 
severity due to defective Treg responses in the absence of Bcl6. Very recent 
work has shown that Bcl6 is involved in the formation of a novel Foxp3+ subset of 
follicular T helper cells referred as “Tfr” cells that regulate the germinal center 
response (Chung et al., 2011; Linterman et al., 2011). However, the function of 
Bcl6 in Treg-mediated control of inflammatory T cell responses has not been 
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studied, despite the organ-specific Th2 pathology in germ-line Bcl6-deficient 
mice. In this work, we have undertaken the first in-depth analysis of Bcl6-
deficient Treg cells to gain insights into the regulation of this inflammation. 
Our studies have employed Bcl6-deficient Tregs derived from Foxp3-gfp 
reporter mice that ensure isolation of highly purified CD4+CD25+Foxp3+ Tregs. In 
a previous report, Chung et al reported a dispensable role for Bcl6 in control of T 
cell responses by testing CD4+CD25hi Tregs in vivo (Chung et al., 2011). 
However, we have observed that these CD4+CD25hi Treg preparations also 
include contaminating activated Foxp3- Th2 effectors; thus our studies with 
Foxp3+ Tregs provide a more definitive assessment of Treg phenotype and 
function in the absence of Bcl6. 
Defects in Treg cell development were not observed with Bcl6 deficiency, 
as we noted normal numbers of CD4+CD25+Foxp3+ Tregs and Helios-
CD4+CD25+Foxp3+ iTregs in the periphery in Bcl6-deficient mice. This is 
consistent with other reports in the literature indicating a dispensable role for Bcl6 
in Treg development (Chung et al., 2011; Yu et al., 2009). In vitro assessment of 
Treg functionality also indicated intact suppression of T cell proliferative 
responses by Bcl6-deficient Tregs. In fact, Bcl6-deficient Tregs displayed 
augmented ability to suppress increased proliferation of Bcl6-deficient T cells, 
thereby also ruling out resistance of the Bcl6-deficient T cells to Treg-mediated 
suppression. We further noted that the Bcl6-deficient Tregs were capable of 
controlling Th1-mediated colitogenic responses in vivo when tested in the T cell 
transfer model of colitis. This indicated that their potent suppressor function 
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noted in vitro also translated in vivo with their observed competency to control 
Th1 responses. However, our studies in the Th2-driven allergic airway disease 
model showed the opposite effect. Mice receiving Bcl6-deficient Tregs displayed 
reduced lung function and striking increases in cellular infiltration in the BAL and 
the lungs, with predominance of eosinophils. The inflammatory response in the 
lungs was strongly Th2-biased with augmented levels of Th2 cytokines in the 
mice receiving Bcl6-deficient Tregs, even higher than the levels in the control 
group. Thus, our studies in the Th2 disease model highlighted that Bcl6-deficient 
Tregs were not simply defective in control of inflammatory Th2 responses; they 
actually augmented Th2 responses in vivo. Similar failure to control systemic Th2 
responses was also noted with mixed chimeras of Foxp3-deficient (scurfy) bone 
marrow with Bcl6-deficient bone marrow. Foxp3 expression limits effector Th1, 
Th2 and Th17 production in Treg cells, resulting in a fulminant mixed T cell-
driven pathology in scurfy mice (Koch et al., 2009; Liston et al., 2008; Singh et 
al., 2007). Considering that chimeras of Bcl6-deficient BM with scurfy BM led to 
increased Th2-type T cell responses again highlights the selective failure of Bcl6-
deficient Tregs to control Th2 responses in vivo.  
An important issue is how Bcl6-deficient Tregs selectively fail and 
exacerbate Th2 responses in the airway inflammation and the Foxp3-deficient 
scurfy chimera models. Key to these questions was the Th2-bias noted for Bcl6-
deficient Tregs by gene expression profiling. Bcl6-deficient Foxp3+ Tregs 
expressed increased Th2 cytokines (Il4, Il5, Il13), Th2 transcription factors 
(Gata3, Maf) and chemokine receptor (Ccr8), while Th1 and Th17-associated 
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genes were not significantly different compared to wild-type Treg counterparts. 
Importantly, this observed increase in Th2 genes was not associated with down-
regulation of Foxp3 or other Treg genes. Bcl6-deficient Tregs retained either 
intact or increased expression of Treg suppressor molecules (particularly, Il10 
and Gzmb). Thus, unlike other reports in the literature, wherein Treg cells lose 
Foxp3 expression in inflammatory contexts and acquire effector cytokine-
producing abilities (Kitoh et al., 2009; Wan and Flavell, 2007; Wang et al., 2010), 
Foxp3+ Tregs in the Bcl6-deficient mice up-regulated Th2 genes, indicative of 
their acquisition of a hybrid Treg-Th2 phenotype. This also suggested that Bcl6 
regulates Th2 gene expression in Tregs, via Foxp3-independent mechanisms.  
One obvious explanation for the exacerbated Th2 responses promoted by 
Bcl6-deficient Tregs could be their down-regulation of Foxp3 expression in the 
inflamed Th2 environment in the Th2 model. However, since we note higher 
Foxp3 expression in lungs of mice receiving Bcl6-deficient Tregs than wild-type 
Tregs (Figure 16), this possibility seems unlikely. Further, we have noted that the 
Foxp3+ Bcl6-deficient Tregs secrete Th2 cytokines. Thus, the more interesting 
possibility is that Bcl6-deficient Tregs promote Th2 inflammation by secreting Th2 
cytokines that mimic Th2 effector activity and/or amplify further Th2 
differentiation, and that in vivo this effect over-rides the suppressive functions. 
While we have observed that supernatants from Bcl6-deficient Tregs can 
promote Th2 differentiation of naïve CD4+ T cells, the amount of IL-4 and IL-5 
secreted by Bcl6-deficient Treg cells is much less than what is made by activated 
Th2 cells in vitro (D.V.S., A.M., A.L.D., data not shown) and is unlikely to be 
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higher than what is produced by activated Th2 cells in vivo. Another possibility is 
that Bcl6-deficient Tregs migrate more efficiently to the inflamed organ than other 
cell types, due to increased expression of several chemokine receptors (Figure 
19). Once in the lungs, the increased Th2 cytokines made by the Bcl6-deficient 
Tregs are likely to upset the normal regulatory balance. For instance, IL-4 can 
desensitize effector T cells to the inhibitory effects of Tregs (Pillemer et al., 
2009). Bcl6-deficient Tregs may produce other factors besides IL-5 that promote 
eosinophil recruitment, however neither eotaxin-1 (Ccl11), eotaxin-2 (Ccl24) nor 
eotaxin-3 (Ccl26) mRNAs were significantly increased in the Bcl6-deficient Tregs 
(D.V.S., A.L.D., data not shown).  
Nevertheless, these experiments assessing the phenotype and function of 
Bcl6-deficient Tregs highlighted the critical role for Bcl6 in repressing Th2 gene 
expression in the Treg lineage, similar to conventional T cells. Thus, in the 
absence of Bcl6, Tregs develop a Th2-type pro-inflammatory phenotype, 
showing that Bcl6 is a key transcriptional regulator of Treg function. The selective 
failure to control Th2 responses in vivo can explain the hallmark Th2-mediated 
heart and lung pathology that develops spontaneously in Bcl6-deficient mice. 
Indeed, our attempts to characterize Tregs isolated from the heart and lungs of 
Bcl6-deficient mice revealed their potent Th2-bias associated with secretion of 
Th2 cytokines and an increase in the numbers of IL-4+Foxp3+ Tregs relative to 
wild-type counterparts (data not shown). Thus, these hybrid Th2-Tregs may 
offset the regulatory balance in these organs and contribute to the exacerbations 
to the disease phenotype noted in the absence of Bcl6. Thus, expression of Bcl6 
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in Tregs is essential for Treg-mediated control of Th2 inflammatory responses 
and to limit excessive pro-Th2 activity of this regulatory subset in vivo. 
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Bcl6 limits the Th2 inflammatory activity of Tregs by repressing the 
transcriptional activity of Gata3  
While Foxp3 is central to the Treg phenotype and function, Foxp3 alone 
does not explain the complete transcriptional landscape of this crucial regulatory 
subset (Chatila, 2007; Hill et al., 2007). Several other transcription factors have 
emerged that regulate Treg cell development, homeostasis and suppressor 
function (Campbell, 2011; Rudensky, 2011). The variegated expression of 
transcription factors, chemokine receptors, and suppressor modules allow for 
phenotypic and functional specialization of Treg cells that enable optimal control 
of diverse immune challenges. The current dogma in the Treg field indicates that 
Treg cells undergo functional specialization in the periphery by co-opting the 
transcriptional program of the effector T cells they suppress. Thus, many 
transcription factors have been identified that control the ability of Tregs to 
suppress a specific type of immune response (T-bet for Th1 responses, Irf4 for 
Th2 responses, Stat3 for Th17 responses and Bcl6 for Tfh and GC B cell 
responses) (Chaudhry et al., 2009; Chung et al., 2011; Koch et al., 2009; 
Linterman et al., 2011; Zheng et al., 2009). Most relevant to our observations is 
the requirement of Irf4 in Tregs for effective control of Th2 responses. However, 
the expression of Irf4 was unaltered in the absence of Bcl6 in Tregs. The 
pathology in Irf4-deficient mice was localized to pancreas, lungs and stomach, 
unlike the heart and lung-specific disease noted in Bcl6-deficient mice. Also, 
while Irf4-deficient Tregs fail to suppress autoimmune Th2 responses, Irf4-
deficient Tregs do not express elevated Th2 genes (Gata3 or Th2 cytokines), as 
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noted for Bcl6-deficient Tregs. Irf4-deficient Tregs however, display reduced 
expression of Treg suppressor genes (particularly Il10 and Gzmb) and also 
reduced chemokine receptor, Ccr8 expression. Thus, the reduced expression of 
Treg suppressor genes has been proposed to contribute to the observed Th2 
pathology in Irf4-deficient mice. Thus, these differences in the observed 
pathology and the Treg phenotype in the absence of Bcl6 (increased Th2 genes, 
increased Treg suppressor genes like Il10 and Gzmb as well as increased Ccr8 
expression) are consistent with Bcl6 and Irf4 operating through distinct 
mechanisms in Tregs.  
Tregs cells have previously been reported to exhibit an intrinsic Th2-bias, 
associated with higher expression of the Th2 transcription factor, Gata3 in Tregs, 
compared to conventional T cells (Wang et al., 2010). The inherent Th2 bias is 
partially attributed to the ability of Foxp3 to up-regulate Gata3, but not the Th1 
transcription factor, T-bet. Two recent reports reported a functional role for the 
Treg-specific Gata3 expression using Treg-specific Gata3 mutant mice (Wang et 
al., 2011; Wohlfert et al., 2011). Both mouse and human Tregs express Gata3, 
particularly at mucosal surfaces. Wang et al noted that mice with Gata3-null 
Tregs develop spontaneous inflammation at multiple sites, even under 
homeostatic conditions, while Wohlfert et al indicated that Gata3 played a critical 
role in Treg physiology during inflammation. Nevertheless, both these studies 
demonstrated that Gata3-deficient Tregs have reduced expression of Foxp3 and 
Treg suppressor genes (Ctla4, Gitr, Il2ra) and expressed Th1, Th2 and Th17 
effector cytokines. Thus, unlike T-bet or Stat3 expression in Tregs, Gata3 seems 
	   193 
to play a broader role in terms of Treg-mediated control of Th1, Th2 and Th17 
immune responses. Treg-specific expression of Gata3 is induced by TCR 
stimulation and occurs independent of IL-4/STAT6 signaling, unlike conventional 
T cells. The key question that these studies pose is identifying the signals that 
regulate the expression of Gata3 in Tregs and prevents the expression of Th2 
cytokines by Gata3 in Tregs.  
Bcl6 is well established as a potent inhibitor of Th2 differentiation and Th2-
mediated inflammation. This regulation occurs via an IL-4/STAT6 independent 
mechanism and involves post-transcriptional repression of the Th2 transcription 
factor, Gata3 by Bcl6 (Kusam et al., 2003). Bcl6 over-expression has been 
demonstrated to inhibit non-Tfh fate determination by repressing the expression 
of Tbx21, Gata3 and Rorc or by blocking the transcriptional activity of T-bet and 
RORγt (Nurieva et al., 2009; Yu et al., 2009). However, while Bcl6 represses 
Gata3 protein, its ability to block transcriptional function of Gata3 has not been 
ascertained in previous reports. We observed that Bcl6 potently represses the 
Th2 cytokine-inducing ability of Gata3 in two independent assays. Similar results 
were also noted in B cells, indicative that Bcl6 represses Gata3 function 
independent of other T cell factors. Thus, these studies confirm that Bcl6 limits 
the transactivation of Th2 cytokines by Gata3 in T cells. Gata3 can auto-activate 
its own expression (Ouyang et al., 2000). Thus, the increased Gata3 expression 
noted in Bcl6-deficient Tregs may be explained by the augmented ability of 
Gata3 to auto-activate its own expression in the absence of Bcl6, but also 
probably reflects the Th2 environment and the degree of Treg stimulation through 
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the TCR. From our current findings, we propose that Bcl6 controls Gata3 
expression in Tregs independently of IL-4 and Stat6, by dampening Gata3 
transcriptional activity and modulating the ability of Gata3 to auto-activate its own 
expression.  
 Thus, our studies with Bcl6-deficient Tregs suggest that Bcl6 is one of the 
key factors regulating Gata3 function in Tregs. This limits the transactivation of 
Th2 cytokines by Gata3 in Tregs, thereby preventing the Tregs from converting 
to pro-inflammatory Th2-type Tregs, exacerbating Th2 pathologies in vivo (Figure 
54). Acquisition of specific T effector transcriptional programs allows Tregs to 
effectively curb immune responses, however this regulatory mechanism can lead 
to pathogenic consequences, due to the presence of self-reactive TCRs on 
Tregs. Thus, Treg-acquired effector features need to be under tight control, and 
here we have shown that a Bcl6-mediated brake on Gata3 activity in Tregs is 
essential for the ability of Tregs to control Th2-type inflammation. Bcl6 is unique 
among transcription factors that regulate the ability of Tregs to control Th2 
responses; in that Bcl6 represses Gata3 and Th2 responses in Tregs at the 
same time that Bcl6 is required for Tregs to properly control Th2 cell responses. 
Bcl6 thus prevents Tregs from acquiring Th2 effector-like characteristics, by 
repressing Gata3 function. 
Our study provides an interesting new facet to the Treg-transcription factor 
driven suppression model wherein expression of T helper specific transcription 
repressors such as Bcl6 is essential for Tregs to control inflammatory T cell 
responses that are inhibited by the same repressor. Whether the control of Th2 
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responses by Bcl6 in Tregs is unique or similar repressor factors exist for control 
of Th1 and Th17 responses by Tregs will definitely spark interest in the Treg field 
and call for further investigations. Also one important point that derives from this 
work is that Bcl6 control in Tregs regulates the rare autoimmune disease, 
myocarditis. Thus investigating the significance of other such transcriptional 
repressors has the potential to identify an entirely new realm of rare autoimmune 
diseases subject to Treg control mechanisms. 
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Figure 54: Repression of Gata3 function by Bcl6 limits Th2 gene 
expression in Tregs. 
Bcl6 expression in the Treg lineage limits the transcriptional activity of Gata3, 
thus controlling expression of Th2 cytokines in Tregs. Thus, wild-type Tregs 
retain normal Treg suppressor function. In the absence of Bcl6 in Tregs, Tregs 
acquire a Th2-bias due to increased Gata3 activity, produce Th2 cytokines 
and augment Th2 responses in vivo. This leads to exacerbated Th2 
inflammatory responses, that manifest as myocarditis in the absence of Bcl6.  
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Bcl6 limits the Th2 inflammatory activity of Treg cells by repressing miR-21 
MicroRNAs have emerged as critical regulators of Treg lineage stability, 
particularly under inflammatory contexts (Liston et al., 2008; Zhou et al., 2008b). 
The lack of any single Treg suppressor mechanism does not recapitulate the 
fatal autoimmunity that develops spontaneously in Foxp3-deficient scurfy mice. 
However, deletion of miRNA–processing enzymes in the Treg lineage completely 
phenocopies the disease in scurfy mice, thus highlighting the importance of 
miRNAs in Treg suppressor function. A number of miRNAs are differentially 
expressed in Tregs compared to conventional T cells in a Foxp3-dependent 
manner (Cobb et al., 2006). Recent studies are defining the contribution of 
individual miRNAs to the Treg phenotype and function that will enable fine-tuning 
Treg activity in diverse disease settings.  
Relevant to our study was the observation that miR-146a was 
preferentially expressed in Tregs and regulated Treg-mediated control of Th1 
inflammatory responses. Mice harboring miR-146a-deficient Tregs displayed 
increased activation of the target gene (Stat1) (Lu et al., 2010). Thus, the miR-
146a-deficient Tregs were Th1-biased, secreted the Th1 cytokine, IFNγ and 
failed to suppress Th1 immune responses. Our results with Bcl6-deficient Tregs 
displayed a similar paradigm for the control of Th2 responses. Bcl6-deficient 
Tregs were Th2 biased, secreted Th2 cytokines and failed to suppress Th2 
responses. In addition, Bcl6 was demonstrated to repress miRNAs in T cells to 
allow Tfh fate determination (Yu et al., 2009). These results suggested that Bcl6 
controls Treg stability by repressing miRNAs in Treg cells. Indeed, miRNA 
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profiling identified a signature of miRNAs that are differentially expressed in Bcl6-
deficient Tregs. Our studies suggest that miRNA-21 was highly expressed in 
Bcl6-deficient Tregs. MiR-21 is a Stat3-regulated miRNA and thus pro-
inflammatory cytokines such as IL-6 up-regulate miR-21 via Stat3 during 
inflammation (Iliopoulos et al., 2010; Loffler et al., 2007; van der Fits et al., 2011). 
Here we have found that Bcl6 represents a counter-balance to up-regulation of 
miR-21 by Stat3, particularly in regulatory T cells, which are necessary for 
controlling inflammation. Intriguingly, Stat3 and Bcl6 appear to bind to a common 
site in the miR-21 promoter, indicating the potential for competitive binding of 
these factors to miR-21 in cells in an inflammatory environment.  
In addition to identifying the Bcl6-Stat3 pathway that can regulate miR-21 
expression in Tregs during inflammatory settings, we also extend our study to 
identify a novel role for miR-21 in T cell differentiation. Previous reports have 
suggested that miR-21 expression in myeloid cells inhibits the Th1 cytokine, IL-
12 and indirectly promotes Th2 responses (Lu et al., 2011b; Lu et al., 2009b). 
MiR-21 positively regulates the Ras-MAPK pathway by targeting negative 
regulators of the Ras-MAPK pathway such as Spry1, Spry2, Btg2 and Pdcd4 
(Jung and Calin, 2010). Of these target genes, Spry1 mRNA was significantly 
decreased in Bcl6-deficient Tregs. Thus, we identify a T cell-intrinsic role for miR-
21 in promoting Th2 differentiation, likely by targeting the Map kinase pathway 
inhibitor (Spry1). Since the master Th2 factor Gata3 can be stabilized by Map 
kinase activity (Yamashita et al., 2005), our studies suggest that the increased 
miR-21 can decrease Spry1, thus promoting greater Map kinase activity and thus 
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increased Gata3 and Th2 differentiation. This miR-21-MAP kinase mechanism 
could account for some of the ability of Bcl6 to repress Gata3 activity in the 
retroviral and reporter assays. 
Our results imply that T cells within an inflammatory environment can 
undergo Th2 differentiation due to miR-21 up-regulation, and that this is 
enhanced in the absence of Bcl6. The deregulation of miR-21 in Bcl6-deficient T 
cells could augment Th2 differentiation, and lead to deregulated Th2 
inflammation as is seen in Bcl6-deficient mice. Thus, miR-21 may be part of a 
positive feedback loop for Th2 inflammation, which can explain the large increase 
in miR-21 in wild-type Tregs in the Bcl6-deficient environment. The deregulation 
of miR-21 in Bcl6-deficient Tregs could accelerate the positive feedback of Th2 
inflammation and lead to greater miR-21 induction within Bcl6-deficient Tregs, 
leading to higher levels of Th2 gene expression. Since miR-21 regulates Th2 
differentiation by a separate pathway than the canonical pathway of IL-4 and 
Stat6, our findings may explain why Th2-type inflammation occurs in Bcl6-
deficient mice independently of IL-4 and Stat6 (Dent et al., 1998a). Repression of 
miR-21 by Bcl6 might also explain the post-transcriptional control of Gata3 and 
Th2 differentiation by Bcl6 (Kusam et al., 2003). Stat3 is required for full Th2 
differentiation (Stritesky et al., 2011), and the failure to up-regulate miR-21 can 
explain the incomplete Th2 differentiation seen with Stat3-deficient T cells. The 
counter-regulation of miR-21 by Bcl6 and Stat3 can explain the opposing roles of 
these transcription factors in Th2 differentiation, with Bcl6 inhibiting and Stat3 
promoting Th2 differentiation, respectively.  
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Interestingly, the regulation of miR-21 by Bcl6 may also relate to the 
specific development of myocarditis in Bcl6-deficient mice, as increased miR-21 
expression in cardiac fibroblasts has been associated with cardiac hypertrophy. 
MiR-21 has been shown to regulate heart diseases by regulating the ERK-MAP 
kinase pathway in cardiac fibroblasts, impacting global cardiac structure and 
function (Thum et al., 2008). MiR21 levels are selectively increased in fibroblasts 
of failing hearts, leading to inhibition of a miR21 target gene, Spry1, that 
negatively regulates the ERK-MAP kinase-signaling cascade. Thus, a de-
regulated miR-21-Spry1 pathway in Bcl6-deficient Tregs could also contribute to 
the exacerbations of myocarditis associated with the absence of Bcl6 (Figure 55). 
MiR-21 is specifically increased in Tregs versus conventional T cells 
(Cobb et al., 2006), suggesting that miR-21 may have an important role in Treg 
biology. MiR-21 is up-regulated in human Tregs, and can positively regulate 
Foxp3 expression (Rouas et al., 2009). Since many Treg suppressor genes are 
dependent upon Foxp3 for their expression, regulation of miR-21 by Bcl6 can 
control expression of Foxp3 and thus other Treg genes. Indeed, the increased 
miR-21 can account for elevated Treg suppressor genes (Foxp3, Il10, Ctla4, 
Tgfβ) noted in Bcl6-deficient Tregs. IL-10 is a well-characterized Bcl6 target gene 
in T cells (Kusam et al., 2003) and is positively regulated by miR-21 (Sheedy et 
al., 2010). Thus Bcl6 may regulate IL-10 indirectly in Tregs via miR-21 regulation. 
Interestingly, our results also demonstrate that miR-21 can also decrease Il12α 
expression in Treg cells. Il12a (p35 subunit of IL-12) is a component of the Treg 
immune-suppressive cytokine, IL-35, in conjunction with Ebi3 (Collison et al., 
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2007). Thus, reduced Il12a expression in Bcl6-deficient Tregs may lead to less 
IL-35 secretion. IL-35 is important for control of allergic diseases in a house-dust 
mite allergen challenge model (Huang et al., 2011). Thus, the reduced IL-35 
secretion from Bcl6-deficient Tregs may further contribute to their failure to 
control Th2 responses (Figure 55). Overall, the constellation of gene changes 
mediated by increased expression of miR-21 can potentially explain the unusual 
gene signature exhibited Bcl6-deficient Tregs with augmented Treg and Th2 
genes resulting in potent suppression of T cell proliferation in vitro yet 
exacerbated Th2 inflammation in vivo. 
MiR-21 is increased in a large number of different pathologic conditions, 
typically on the order of 2- to 6-fold (Liu et al., 2010; Pan et al., 2010; Si et al., 
2007; Stagakis et al., 2011; Thum et al., 2008; van der Fits et al., 2011; Wu et al., 
2008). In previous studies on Th2-type airway inflammation, miR-21 was up-
regulated 3- to 6-fold (Lu et al., 2012a; Lu et al., 2009b; Lu et al., 2012b).  In our 
work, we observed a 9-fold increase in miR-21 in the severe Th2-type airway 
inflammation induced with Bcl6-deficient Treg cells. In ulcerative colitis, a Th2-
type inflammatory disease of the colon, miR-21 was elevated up to 20-fold in 
actively inflamed disease tissue (Wu et al., 2008). While two other studies report 
an increase in miR-21 in biopsies of patients with EoE, the fold induction reported 
was about 4-fold (Lu et al., 2012a; Lu et al., 2012b), while miR-21 was reported 
as undetectable in the patient sera (Lu et al., 2012b). The 50-fold average 
increase in miR-21 in EoE biopsies and 30-fold average increase in circulating 
miR-21 in EoE in our study represents one of the greatest elevations of miR-21 in 
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diseases reported in the literature. We reason that differences in the type of 
control individuals selected in our study may account for the discrepancy in the 
two studies. Since the controls used in the Lu et al study were enriched for atopy 
(Lu et al., 2012b), unlike our study, we tested miR-21 levels in the sera of 
asthmatic individuals and noted a 4-fold induction of miR-21. We thus propose 
that high levels of miR-21 are a novel biomarker for severe Th2-inflammation, 
and that highly elevated serum miR-21 may be useful for diagnosis of Th2-
inflammatory disease. While miR-21 is a well-known “oncomir” due to its over-
expression in multiple types of cancer (Hatley et al., 2010), miR-21 is also 
commonly de-regulated in inflammatory diseases, and thus could also be termed 
as an “inflamir”. 
While miR-21 function has been extensively studied in cancer, the function 
of miR-21 in T cells and inflammation has not been well characterized. To our 
knowledge, this is the first study identifying miR-21 as a novel target gene for 
Bcl6 in Treg cells, and reporting a T cell autonomous role for miR-21 in 
promoting Th2 differentiation. Finally, we have identified miR-21 target genes 
that shed light on the role of miR-21 in conventional T cells and Tregs. In addition 
to defining a functional role for miR-21 in Th2 inflammatory conditions, we also 
extend our study to characterize miR-21 as a non-invasive biomarker for human 
Th2 diseases (like EoE and asthma). Thus, repression of miR-21 by Bcl6 in 
Tregs adds another important facet to the Treg-mediated control of inflammatory 
Th2 responses.  
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Figure 55: Repression of miR-21 by Bcl6 limits Th2 gene expression in 
Tregs. 
Bcl6 expression of miR-21 in the Treg lineage limits Gata3 expression via 
Spry1-Mapk pathway, thus controlling expression of Th2 cytokines in Tregs. 
Il12a levels are also maintained, allowing for optimal secretion of IL-35, that 
permits effective control of Th2 inflammation. In the absence of Bcl6 in Tregs, 
the increased miR-21 promotes increased Gata3 and Th2 gene expression, 
promoting a Th2-bias in the Tregs and failure to control Th2 responses in vivo. 
Also reduced Il12a levels with increased miR-21 lead to less IL-35 secretion, 
that further exacerbates Th2 inflammatory responses in vivo. 
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Intrinsic and extrinsic regulation of Th2 gene expression by Bcl6 in Tregs 
and their contributions to the Th2 inflammatory disease in Bcl6-deficient 
mice 
Bcl6 is expressed in multiple cell types to different extents (including B, T 
and myeloid cells), although its expression is particularly high in GC B and Tfh 
cells. Thus, the inflammatory disease in germ-line Bcl6-deficient mice is complex 
in nature and involves contributions from diverse cell lineages (Toney et al., 
2000; Yoshida et al., 1999). The disease is primarily T cell-dependent as 
Bcl6/Tcrα double-deficient mice fail to develop spontaneous myocarditis and 
pulmonary vasculitis. The ability of Bcl6 to inhibit Th2 differentiation by 
repressing the Th2 factor, Gata3, can explain the strong Th2-bias of the 
inflammatory disease noted in Bcl6-deficient mice (Kusam et al., 2003). In 
addition, functions of Bcl6 in the myeloid lineage also contribute to the excessive 
eosinophilic infiltration and hyper-IgE phenotype (Toney et al., 2000; Yu et al., 
2005). Deregulated chemokine expression by macrophages in Bcl6-deficient 
mice also promotes the Th2 inflammation (particularly since MCP-1, MRP-1, 
MCP-3 favor Th2 polarization via effects on APCs) (Toney et al., 2000). Bcl6 also 
seems important to protect mature cardiac myocytes from degeneration (Yoshida 
et al., 1999). Since the disease develops spontaneously, is T cell-dependent and 
resembles the inflammation noted in mice with defects in Treg suppressor 
molecules like CTLA-4 or TGFβ (Kulkarni and Karlsson, 1993; Tivol et al., 1995), 
our study investigated the contributions of defects in the Treg lineage to the 
disease in Bcl6-deficient mice. Our results extend the role of Bcl6 in inhibiting 
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Th2 differentiation in T cells to Treg cells. Thus, we demonstrate a critical role for 
Bcl6 in repressing Th2 gene expression in Treg cells and preventing their 
conversion to pro-inflammatory Th2 effectors. We have identified two different 
mechanisms that can explain the Th2-bias exhibited by Bcl6-deficient Tregs and 
their selective failure to control Th2 inflammatory responses: (1) Increased Gata3 
transcriptional activity in the absence of Bcl6 can account for the increased Th2 
cytokine expression and also increased Gata3 expression noted in Bcl6-deficient 
Tregs, (2) Increased miR-21 expression in the absence of Bcl6 can explain the 
Th2-bias, since miR-21 can polarize T cells to Th2 fate, potentially via our 
proposed Spry1-Mapk-Gata3 pathway (Figure 56).  
 
 
 
 
 
 
 
 
 
Figure 56: Control of Th2 gene expression and Th2 inflammatory activity 
of Treg cells by Bcl6. 
Bcl6 functions in Treg cells by 2 different mechanisms to limit their acquisition 
of a pro-Th2 inflammatory phenotype: (1) Inhibits Gata3 function, thus 
preventing secretion of Th2 cytokines by Tregs, and (2) Competes with Stat3 
for repression of miR-21. MiR-21 can target Spry1 and Il12a, and thus 
promote Th2 differentiation of naïve T cells. Inflammatory cues (IL-6 acting via 
Stat3) up-regulate miR-21 and this combined with Bcl6 deficiency exacerbates 
Th2 differentiation and Th2 inflammation.  
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Treg cells get remodeled in inflammatory environments; they lose Foxp3 
expression and/or acquire effector T cell features (Zhou et al., 2009b). Thus, 
considering the hyper-Th2 inflammatory milieu in Bcl6-deficient mice, it is 
essential to delineate the intrinsic effects due to absence of Bcl6 in Treg cells 
and assess indirect contributions from extrinsic inflammatory signals. One 
approach we took in this regard included evaluating Bcl6-deficient Treg 
phenotype from mixed chimeras (WT BM:KO BM) (Figure 21). Increased 
expression of Gata3, IL-4 and miR-21 in Bcl6-deficient Tregs derived from the 
chimeras relative to their wild-type Treg counterparts validates the intrinsic role of 
Bcl6 in repressing Th2 genes and miR-21 in Treg cells (Figures 22 and 27). 
However, we observed that the overall expression of Th2 genes in chimera-
derived Bcl6-deficient Tregs was significantly reduced compared to Tregs from 
germ-line Bcl6-deficient mice (Figure 19). This can be explained by the presence 
of functional wild-type Tregs in the mixed WT:KO chimeras that dampen the 
overall severity of Th2 inflammation. Indeed, the Bcl6-deficient Tregs derived 
from KO:Foxp3KO chimeras were strongly Th2-polarized similar to those in 
germ-line KOs, as compared to Tregs from WT:Foxp3KO chimeras (Figure 23). 
The Th2-bias noted in the Stage I conditional knockout Tregs and increased 
percentages of GATA-3+Foxp3+ Tregs in the allergic airway inflammation model 
with the final Stage III conditional mutant mice provides a definitive validation to 
the intrinsic role of Bcl6 in limiting Th2 gene expression and Treg control of Th2 
responses (Figures 49 and 51). Overall, the Th2-bias noted for the conditional 
knockout Tregs was reduced compared to germ-line Bcl6-deficient mice. Taken 
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together the bone marrow chimera and the conditional Bcl6-knockout Treg data 
validate the intrinsic role of Bcl6 in the Treg lineage in repressing Th2 genes and 
miR-21. 
At the same time, relatively reduced Th2 polarization in both the chimera-
derived and the conditional Bcl6-deficient Tregs suggests that the Th2 
inflammatory disease in Bcl6-deficient mice also contributes to the remodeling of 
the Treg phenotype. Indeed, the observation that the stable Tregs and the 
exTregs in Bcl6-deficient mice (KO RFC) acquire a potent Th2-bias does 
highlight the effect of the Th2 inflammatory environment on Bcl6-deficient Treg 
phenotype (Figure 46). In addition, we noted increased exTregs (loss of Foxp3) 
and reduced stable Tregs in KO RFC mice, relative to WT RFC (Figure 45). 
Presence of the NOD background in the BRFC mice can account for their more 
severe Th2 disease compared to germ-line Bcl6-deficient mice, and can 
accelerate exTreg generation in the absence of Bcl6. However, the striking Th2-
bias noted in the exTregs and even the stable Tregs does validate the influence 
of the environment on Bcl6-deficient Treg phenotype and subsequent suppressor 
function. Also, we note acquisition of miR-21 expression by wild-type Tregs 
transferred to Bcl6-deficient mice, relative to wild-type mice (Figure 32). Thus, in 
inflammatory settings, Tregs can acquire miR-21 expression and its expression is 
further up-regulated in Tregs in the absence of Bcl6. Thus, overall we have 
demonstrated that the Bcl6-deficient Treg phenotype is a composite effect of loss 
of intrinsic regulation by Bcl6 and extrinsic effects from the inflammatory Th2 
disease. Both of these effects amplify the Th2 gene and miR21 expression and 
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thereby contributes to the failure of Bcl6-deficient Tregs to control Th2 
responses.  
The observation that the hypomorphic stage I Treg-specific conditional 
mutant mice also develop heart inflammation similar to the germ-line Bcl6-
deficient mice validates defective control of Th2 responses by Bcl6-deficient 
Tregs. However, since the final Stage III Treg-specific conditional mutant mice do 
not develop heart pathology indicates that the pro-Th2 Bcl6-deficient Tregs do 
not initiate the heart inflammation, but fail to suppress abberant Th2 responses 
that develop from absence of Bcl6 in diverse cell lineages. Thus we propose that 
the absence of Bcl6 in cardiac myocytes initiates degenerative changes in the 
cardiac myocardium. These changes trigger infiltration of inflammatory Th2 cells 
and eosinophils. The Th2 cytokines and the toxic eosinophil granule components 
exacerbate the heart inflammation. Bcl6-deficient Tregs get recruited to the 
inflamed hearts, but these Th2-biased Tregs undergo further remodeling in the 
inflammatory Th2 milieu and their expression of Th2 genes and miR-21 offsets 
the regulatory balance and contributes to their failure to suppress myocarditis. 
Also the fact that the conditional knockout mice do not develop lung inflammation 
as the germ-line Bcl6-deficient mice, indicates that loss of Bcl6 in the other 
lineages (particularly the myeloid lineage) is likely a key factor for the lung 
vasculitis. Thus assessing the phenotype of the myeloid, T and B cell-specific 
conditional Bcl6 knockout mice strains will provide further insights into the 
contributions of individual cell types to the myocarditis and pulmonary vasculitis 
in germ-line Bcl6-deficient mice.  
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FUTURE DIRECTIONS 
Analyze the role of miR-21 in Th2-type inflammation   
We will use gain-of-function and loss-of-function approaches to perform an 
in-depth assessment of the role of miR-21 in Th2-type inflammation. Our studies 
so far have demonstrated that miR-21 can prime de novo differentiation of naïve 
T cells to Th2 fate and that increased levels of miR-21 are observed in Th2 
pathologies in both mice and human. One of the key questions to be addressed 
includes determining whether increased miR-21 is a passive marker associated 
with Th2 diseases or actively responsible for the initiation and exacerbations of 
the Th2 pathologies. Thus, to better understand the role of miR-21, we will 
analyze the signals that control miR-21 expression, cell types that express miR-
21 in Th2 inflammation, and miR21 target genes that can provide mechanistic 
insights into its function. Finally, we should analyze miR-21 in a Th1 model of 
inflammation to test whether miR-21 is increased to a greater extent in Th2 
inflammation than other inflammatory conditions. We also want to delineate the 
contributions of increased miR-21 to Bcl6-deficient Treg phenotype and their 
failure to suppress Th2 responses in vivo. We have already obtained miR-21 
transgenic (miR-21 Tg), miR-21 knock-out (miR-21 KO) and miR-21 floxed and 
conditional miR21 Tg mice from Dr. Eric Olson at UT Southwestern, and these 
mouse models will be ideal tools to gain definitive insights into the function of 
miR-21 in Th2 inflammatory settings in vivo. 
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Assess effects of miR21 over-expression and knock-down in mouse model 
of allergic airway inflammation  
Here we will use cohorts of wild-type and miR-21 Tg mice and assess 
induction of Th2 inflammation in the Ova-induced airway inflammation model 
(Figure 12). Additionally, unchallenged mice of each type will be assessed to see 
whether basal lung inflammation is altered in the miR-21 Tg mice. Parameters to 
be analyzed are BAL cell counts, BAL cell analysis by flow cytometry, cytokine 
levels in lung and draining lymph node by QPCR (Il4, Il5, Il13, Il17, Ifng, Tnfα, 
Ccl2, Ccl3, Ccl11), lung histology, serum IgE levels, and enhanced pause (Penh) 
measurements following methacholine challenge by whole body 
plethysmography. We predict that overexpression of miR-21 would promote 
augmented Th2 allergic responses with increased inflammation and airway 
hyper-reactivity. A similar set of experiments will also be performed using cohorts 
of wild-type and miR-21 KO mice, which would develop reduced Th2 responses 
compared to controls, thus confirming that miR-21 is functionally implicated in 
Th2 pathologies in vivo. 
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Assess cell types that express miR-21 in allergic inflammatory settings 
MiR-21 expression in myeloid cells was reported to inhibit the Th1 
cytokine, IL-12 and indirectly prime for Th2 responses (Lu et al., 2011b; Lu et al., 
2009b). However, our studies have identified a T-cell intrinsic role for miR-21 in 
promoting Th2 differentiation. In addition, our studies show significant miR-21 
expression in the lung epithelial cells. Hence, understanding the cell-types that 
contribute to its effects in allergic settings would be important for developing 
strategies to inhibit miR-21. The conditional miR-21 Tg and KO mice, that allow 
for over-expression and deletion of miR-21 in specific cell-types by mating to 
tissue-specific cre mice, would provide useful insights into the functional 
relevance of miR-21 in different cell types. We can therefore generate CD4 T 
cell, Treg, myeloid and epithelial cell type-specific miR-21 Tg and KO mice by 
crossing to CD4-cre, Foxp3-cre, lysM-cre and surfactant protein C (SP-C) Cre, 
respectively. These mice would be tested for induction of allergic airway 
inflammation. Alternatively, BM chimeras could be produced with miR-21 Tg and 
KO BM into wild-type mice, to assess the effect of miR-21 in hematopoietic cells 
versus lung stromal cells. These experiments will provide clear understanding of 
the cell-type specific role of miR-21 that can aid in developing strategies targeting 
this miRNA to attenuate allergic responses in vivo. 
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Assess relevance of miR-21 to the exacerbations of allergic inflammatory 
responses promoted by Bcl6-deficient Tregs in vivo 
 Our studies with the airway inflammation model demonstrated that transfer 
of Bcl6-deficient Treg cells promoted exacerbated Th2 responses that were 
associated with almost 10-fold induction of miR-21 in both the lungs and the sera 
of the recipient mice. Therefore, to define the contribution of miR-21 in the 
increased Th2 inflammatory responses promoted by Bcl6-deficient Tregs, we will 
generate Bcl6/miR-21 double KO (dKO) mice. These dKO Tregs will be tested in 
the airway inflammation model (as shown in Figure 12). In addition, we will 
transfer Bcl6-deficient Tregs into whole body miR-21 KO mice, and test induction 
of lung inflammation alongside wild-type mice that receive Bcl6-deficient Tregs. 
These experiments will determine if expression of miR-21 in non-Treg cells 
contributes to the disease exacerbations promoted by Bcl6-deficient Tregs.  
 
Assess effect of miR-21 inhibitors in allergic inflammatory diseases 
To assess if inhibition of miR-21 has therapeutic implications in the 
treatment of allergic diseases, we will administer miR-21 inhibitors during the 
airway inflammation experiments. Locked nucleic acid (LNA)-based cholesterol 
tagged antisense miR-21 oligos that are effective at sequestering miR-21 by 
forming duplexes with miR-21 will be used for miR-21 inhibition in vivo (Liu et al., 
2010). A scrambled non-specific oligo will be used as a control for these 
experiments. These oligos will be instilled either during the initial OVA priming or 
the aerosol challenges by administration intra-tracheally that ensure delivery to 
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the lungs. Assessment of airway induction and Th2 inflammatory responses in 
mice receiving the anti-sense miR-21 and control probes will advance 
development of specific targeting strategies for miR-21 to treat allergic 
inflammation.  
 
Assess miR-21 gene targets that offer mechanistic insights into its role in 
promoting Th2 responses 
MiR-21 has been demonstrated to target the myeloid cell-derived Th1 
cytokine component, Il12a, in a previous report (Lu et al., 2011b; Lu et al., 
2009b). Our studies in the airway inflammation model with Bcl6-deficient Tregs 
associated with increased miR-21 have validated Il12a as a target gene for miR-
21 in myeloid cells. In addition, we have also identified the Mapk pathway 
inhibitor, Spry1, as miR-21 gene target, in the context of its role in promoting Th2 
differentiation intrinsically in T cells. Lungs from miR-21 Tg mice tested for airway 
inflammation will be useful to validate miR-21 target genes. In addition, similar 
validation of cell-type specific miR-21 gene targets can be performed on lung 
tissue isolated from CD4, Foxp3, LysM and SpC-miR21 Tg mice following 
induction of airway inflammation. Biochemical analysis of our proposed miR-21-
Spry1-Mapk-Gata3 pathway could be performed using approaches to 
overexpress miR-21 and Spry1 and assess activation of Map kinases (phospho 
ERK1/2) and Gata3 protein levels. We expect that miR-21 overexpression in T 
cells would lead to reduced Spry1 protein and increased phosphoERK and thus 
increased Gata3 and Th2 differentiation. On the other hand, overexpression of 
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Spry1 will induce the opposite trend – reduced phosphoERK and thus decreased 
Gata3 and Th2 genes. These experiments using miR-21 Tg mouse strains and 
dissection of the miR-21-Spry1 signaling pathway will provide mechanistic 
insights into its function, that can help in the development of therapeutic 
strategies.  
 
Assess the effect of Treg-specific miR-21 expression on the immune 
suppressive cytokine, IL-35 and its role in control of Th2 responses 
We have noted reduced Il12a expression in Bcl6-deficient Tregs that 
exhibit increased levels of miR-21. Hence we proposed that Il12a is a miR-21 
gene target in Treg cells. Thus, increased miR-21 would lead to decreased levels 
of the Treg suppressive cytokine, IL-35 (composed of Ebi3 and Il12a subunits) 
(Collison et al., 2007). This observation can be validated by testing Treg 
supernatants from miR-21 Tg and KO mice, particularly, the Foxp3 Cre miR21 Tg 
and KO. These studies will identify a novel regulator for the Treg cytokine, IL-35. 
In addition, IL-35 has been implicated in the control of Th2 responses in the 
house dust-mite allergen challenge model in vivo (Huang et al., 2011). Thus, 
testing the levels of IL-35 in our airway inflammation model with miR21 Tg and 
KO mice will determine the contributions of IL-35 to the Th2 responses. It is likely 
that the highly elevated miR-21 levels with the transfer of Bcl6-deficient Tregs in 
the Th2 model leads to reduced IL-35 levels, that further promotes exacerbated 
Th2 inflammation in vivo. This hypothesis can be validated by experiments 
testing miR-21/Il12a double knockout mice in the airway inflammation model. 
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Taken together, these experiments will help delineate a novel regulator of IL-35 
and assess the relevance of miR-21/IL-35 regulatory circuitry in Treg control of 
Th2 inflammatory responses.  
 
Assess signals that regulate miR-21 expression in Th2 inflammatory 
settings 
IL-6 acting via Stat3 induces miR-21 expression in inflammatory contexts 
(Iliopoulos et al., 2010; Loffler et al., 2007). However, a large number of other 
cytokines produced during inflammation can also activate Stat3. A critical 
question is whether there is one specific cytokine that directly promotes miR-21 
transcription and up-regulation during inflammation, or if miR-21 is induced by 
multiple cytokines and other factors. Our results have indicated that wild-type 
Tregs transferred to Bcl6-deficient mice up-regulate miR-21. However, in vitro 
studies following treatment of wild-type Tregs with cytokines abundantly present 
in the Bcl6-deficient Th2 inflammatory environment (IL-4, IL-6 or a combination of 
IL-4 and IL-6) fail to induce miR-21 (data not shown). Thus, identifying the 
inflammatory signal/signals that turn on miR-21 following transfer of wild-type 
Tregs into Bcl6-deficient mice will provide useful insights into the upstream 
factors that regulate this miRNA in Th2 disease settings. Specifically, we have 
noted increased miR-21 expression in epithelial cells in our Th2 model following 
transfer of Bcl6-deficient Tregs. Thus, testing if epithelial cell-derived cytokines 
(particularly, thymic stromal lymphopoetin, TSLP) induce miR-21 in Th2 disease 
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settings will expand our understanding of the signaling networks in allergic 
diseases. 
 
Assess if the counter-regulation of miR-21 by Bcl6 and Stat3 is a critical 
node in Th2 differentiation program  
Stat3 positively regulates the miR-21 gene and the Stat3 DNA binding site 
is similar to a Bcl6 binding site (Shaffer et al., 2000). Further, we have identified 
miR-21 as a novel Bcl6 gene target in T cells. Reporter assays demonstrate that 
Bcl6 and Stat3 oppose each other in the regulation of miR-21 by IL-6. Stat3 is 
required for complete Th2 differentiation, thus reduced Th2 differentiation of 
Stat3-deficient T cells could be due to their failure to induce miR-21. Thus, Bcl6 
and Stat3 may counter-regulate Th2 differentiation via miR-21; with Bcl6 
repressing miR-21 and thus inhibiting Th2 differentiation and Stat3 activating 
miR-21 and thus augmenting Th2 responses. Mating T cell-specific Stat3 
conditional KO with miR-21 Tg mice and assessing if increased miR-21 can 
rescue the defective Th2 differentiation of Stat3-deficient T cells can test this 
hypothesis. Similarly, mating T cell-specific Bcl6 conditional KO to miR-21 KO 
mice will determine if deleting miR-21 can reduce the increased Th2 responses 
promoted by Bcl6-deficient T cells. Alternatively, these experiments can also be 
performed using miR-21 expressing retroviruses (miR-21 RV) in Stat3-deficient T 
cells and miR-21 inhibitors (antagomiR-21) in Bcl6-deficient T cells to assess the 
effect on Th2 differentiation. 
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Assess if miR-21 is specifically increased in Th2 pathologies in mice and 
human 
Here we will address the specificity of miR-21 expression in different types 
of inflammation. We will induce Th1-type and Th2-type lung inflammation in mice 
by LPS titration in our airway inflammation model. High dose LPS favors a Th1 
response and low dose LPS promotes Th2 response (Eisenbarth et al., 2002). 
We expect that miR-21 will be expressed higher in the lungs of mice in the Th2 
airway inflammation than in the Th1 model. We could also analyze miR-21 
expression in mouse models of Th17 inflammation. Our results on human 
patients with eosinophilic esophagitis and asthma have demonstrated elevated 
miR-21 in these human Th2 diseases. Similarly, we have also noted increased 
circulating miR-21 in these Th2 pathologies, thus indicating that miR-21 can 
serve as a non-invasive biomarker for human Th2 diseases. It will be interesting 
to extend these findings in other human Th2 conditions – allergic rhinitis, food 
allergies and atopic dermatitis. These studies will provide information on the 
association of miR-21 with atopy. In addition, while we did not detect miR-21 
induction in biopsies of human patients with Crohn’s disease (CD) associated 
with Th1 inflammation, it will also be important to assess miR-21 levels in the 
sera of the CD patients. These experiments in additional Th1 and Th2 disease 
models and human pathologies will provide extensive validation on using miR-21 
as a clinical biomarker for Th2 diseases.  
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Assess the relevance of Treg defects to the myocarditis and pulmonary 
vasculitis that develops in Bcl6-deficient mice 
Bcl6-deficient mice develop spontaneous autoimmune disease in the heart 
and lungs. Considering that the disease is T cell-dependent, spontaneous and 
resembles the inflammation in mice with Treg defects, we proposed that 
defective Treg suppressor function in the absence of Bcl6 contributes to the 
pathology noted in Bcl6-deficient mice. While we do note Tregs with a Th2 bias in 
the heart and lungs of Bcl6-deficient mice which can offset the regulatory balance 
in these organs and mediate the development of Th2 inflammation, we were 
unable to address whether Bcl6-expressing Tregs traffic to these organs due to 
lack of appropriate tools. More recently, two different groups have developed 
Bcl6 reporter mouse strains (Kitano et al., 2011; Liu et al., 2012). It would be 
interesting to mate these Bcl6 reporter mice on the wild-type Foxp3gfp knock-in 
background, thus enabling tracking of the Bcl6-expressing Tregs to the inflamed 
heart and lungs following induction of experimental myocarditis (to assess 
recruitment to heart) or allergic inflammation (to assess recruitment to lungs). 
Further, this Treg-specific Bcl6 reporter mouse strain can also help to definitively 
assess the proportion of Tregs expressing Bcl6 in the total Treg subset and could 
be useful to determine if functionally distinct Treg subsets exist, such that Bcl6hi 
Tregs are the ‘Tfr’ Tregs that control the GC response and Bcl6int/low Tregs are 
involved in control of Th1, Th2 and Th17 cell responses, respectively.  
 
	   218 
Assess the importance of Tfr cells in the control of allergic inflammation  
 T follicular regulatory T cells develop in a Bcl6-dependent manner in 
response to T-dependent antigens, to limit the size of Tfh and GC B cells in an 
immune response. Published literature assessing the functional relevance of 
these cells in regulating the quality and quantity of humoral immunity have relied 
on indirect means, such as fetal liver chimeras or adoptive transfer experiments 
(Chung et al., 2011; Linterman et al., 2011). We have generated the Treg-
specific Bcl6 conditional knockout mice. These mice will be ideal tool to assess 
the importance of Tfr cells in control of allergic responses, Allergic reactions are 
caused by the exacerbations associated with uncontrolled IgE and the 
subsequent triggering of inflammatory mediators from mast cells and basophils, 
that mediate vasodilation, smooth muscle contraction and in some cases, IgE-
mediated hypersensitivity. Thus, Tfr cells may play a cardinal role in controlling 
the IgE responses by limiting the GC reaction in the local lymphoid organs. Thus, 
allergic airway inflammation can be induced in cohorts of Bcl6fl/flCre+ and 
Bcl6fl/flCre- mice and development of Tfh, GC B and plasma cell responses in the 
lung mediastinal lymph nodes can be assessed. This system will also be ideal to 
assess the Foxp3+ Treg phenotype and function in the allergic immunity setting. 
Thus, these studies can provide information about the relative contributions of 
Foxp3+ Tregs in control of Th2 immune responses and Bcl6+Foxp3+Tregs in 
regulation of the germinal center reaction and subsequent humoral immunity.  
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Assess the importance of Tfr cells in the control of flu infections  
 Understanding the regulation afforded by Tfr cells is particularly important in 
the context of viral infections that can lead to the identification of useful strategies 
for effective vaccine development. Increased HIV GAG-specific Tfh cells, GC B 
cells and dysregulated antibody response (increased IgG1 subtype) has been 
reported in chronic HIV infections (Lindqvist et al., 2012). Increased IFNγ-
producing Tfh cells have been reported following flu infection (Boyden et al., 
2012). The Treg-specific Bcl6 conditional mutant mice will serve as ideal tools to 
assess the importance of Tfr cells in regulating the Tfh and GC B response in 
viral infections. Here again, cohorts of Bcl6fl/flCre+and Bcl6fl/flCre- mice will be 
immunized with sublethal doses of influenza PR8 virus and we would assess the 
kinetic development of germinal centers, TFH responses, anti-flu IgM, anti-flu 
IgG, anti-flu IgA and anti-flu AFC. In addition, the ability of Bcl6fl/flCre+ mice to 
resist secondary infection with flu virus and mount produce protective Ab 
responses can also be analyzed. 
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Assess the effect of Bcl6 in the Treg transcriptional landscape conferred by 
Foxp3-Gata3 interactions 
 Treg cells express higher levels of Gata3 than conventional T cells and 
recent reports have identified that Gata3 expression in Tregs is important for 
Treg homeostasis and suppressor function (Wang et al., 2011; Wohlfert et al., 
2011). Gata3 has been mapped as a Foxp3-interacting partner in Treg cells, with 
each factor augmenting the expression of the other factor (Rudra et al., 2012). In 
addition, a subset of Foxp3-occupied genes in Tregs are co-bound by Gata3 
(Rudra et al., 2012). Thus, in the absence of Foxp3-Gata3 regulatory circuitry in 
Tregs, Gata3fl/flFoxp3-YFP-Cre mice develop intestinal pathology and dermatitis 
accompanied with increase in IL-4+, IL-5+, IL-13+ and Gata3+ Th2 cells. Thus, the 
Gata3-Foxp3 complex in Tregs is critical for Treg control of Th2 responses 
(Rudra et al., 2012). Bcl6 represses Gata3 expression and function and in the 
absence of Bcl6, Tregs fail to suppress Th2 inflammation. In addition, we have 
noted increased Foxp3 and Treg suppressor genes in Bcl6-deficient Tregs. Thus, 
it will be interesting to assess the effect of Bcl6 in the Foxp3-Gata3 subsection of 
the Treg transcriptome. Thus, we could perform biochemical analysis on Foxp3-
Gata3 protein complexes isolated from Bcl6fl/flCre+and Bcl6fl/flCre- Tregs. This 
study may provide a comprehensive analysis of the regulation of Treg 
transcriptional landscape by Gata3 and Bcl6 that are both involved in Treg 
control of Th2 responses. 
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